[{"id": 248001, "ingredient1": "Buprenorphine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293177/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248002, "ingredient1": "Butabarbital", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293178/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248003, "ingredient1": "Butalbital", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293179/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248004, "ingredient1": "Cabozantinib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293180/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248005, "ingredient1": "Carbamazepine", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293181/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248006, "ingredient1": "Carvedilol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293182/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Acebutolol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Atenolol, Felodipine, Amlodipine, Nifedipine, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248007, "ingredient1": "Frangula purshiana bark", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293183/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248008, "ingredient1": "Castor oil", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293184/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, Linaclotide, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248009, "ingredient1": "Cenobamate", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293185/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248010, "ingredient1": "Ceritinib", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293186/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248011, "ingredient1": "Ceritinib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293187/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248012, "ingredient1": "Cevimeline", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of cevimeline, which is metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Dosage adjustments and clinical monitoring may be appropriate whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy.  Patients should be advised to notify their physician if they experience excessive adverse cholinergic effects of cevimeline such as nausea, vomiting, diarrhea, sweating, salivation, urinary frequency, visual disturbance, confusion, tremor, palpitations, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments and clinical monitoring may be appropriate whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293188/", "reference_text": "[1] \"Product Information. Evoxac (cevimeline).\" Daiichi Pharmaceuticals  (2001):", "alternatives_a": "Bethanechol, Neostigmine, Pyridostigmine, Ambenonium, Pilocarpine", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248013, "ingredient1": "Chloroquine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other antimalarial agents that can prolong the QT interval (e.g., quinine, quinidine, halofantrine, chloroquine) may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should be avoided.  Moreover, artemether-lumefantrine should generally not be used in combination with other antimalarial agents due to limited safety data.  Caution and close monitoring of the ECG are advised when QT-prolonging antimalarial agents are used following treatment with artemether-lumefantrine because of the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293189/", "reference_text": "[1] Lefevre G, Carpenter P, Souppart C, et al. \"Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects.\" J Clin Pharmacol 42 (2002):  1147-58[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248014, "ingredient1": "Chlorpromazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293190/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248015, "ingredient1": "Cilostazol", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293191/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Ticagrelor, Betrixaban, Clopidogrel, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248016, "ingredient1": "Ciprofloxacin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293192/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Tetracycline, Polymyxin B, Chloramphenicol, Gentamicin, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248017, "ingredient1": "Cisapride", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Cisapride can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293193/", "reference_text": "[1] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceuticals  (2001):[2] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999):  251[3] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000):  49-75[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Metoclopramide", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248018, "ingredient1": "Citalopram", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.  Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.  However, if treatment with citalopram is required in these patients, the labeling recommends that the dosage not exceed 40 mg/day, as higher dosages may have an excessive effect on the QT interval and confer no additional benefit in the treatment of depression.  A maximum dosage of 20 mg/day is recommended for patients with hepatic impairment, those greater than 60 years of age, and poor metabolizers of CYP450 2C19.  Patients at risk for significant electrolyte disturbances should have serum potassium and magnesium assessed at baseline and periodically during treatment.  If hypokalemia or hypomagnesemia is found, it should be corrected prior to initiation of treatment.  Regular ECG monitoring is also recommended, and persistent QTc measurements greater than 500 msec should prompt discontinuation of the medication.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.  When citalopram is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293194/", "reference_text": "[1] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide).  http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm\"   (2011):[6] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses.  http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm\"   (2012):[7] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248019, "ingredient1": "Clarithromycin", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293195/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248020, "ingredient1": "Clarithromycin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293196/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248021, "ingredient1": "Clofazimine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293197/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Dapsone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248022, "ingredient1": "Clomipramine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293198/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248023, "ingredient1": "Clozapine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293199/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248024, "ingredient1": "Cobicistat", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293200/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248025, "ingredient1": "Codeine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine.  The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.", "source": "DDInter", "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6.  An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.  In addition, it should be noted that rolapitant, a moderate CYP450 2D6 inhibitor, may interfere with the analgesic effects of codeine for at least 28 days after administration of rolapitant.", "mechanism_text": "Metabolism", "recommendation": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293201/", "reference_text": "[1] Desmeules J, Dayer P, Gascon MP, Magistris M \"Impact of genetic and environmental factors on codeine analgesia.\" Clin Pharmacol Ther 45 (1989):  122[2] Sindrup SH, Arendt-Nielsen L, Brosen K, et al. \"The effect of quinidine on the analgesic effect of codeine.\" Eur J Clin Pharmacol 42 (1992):  587-92[3] Sindrup SH, Hofmann U, Asmussen J, Mikus G, Brosen K, Nielsen F, Ingwersen SH, Broen Christensen C \"Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake.\" Eur J Clin Pharmacol 49 (1996):  503-9[4] Sindrup SH, Brosen K, Bjerring P, et al. \"Codeine increases pain threshold to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.\" Clin Pharmacol Ther 49 (1991):  686-93[5] Poulsen L, Brosen K, Srendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH \"Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.\" Eur J Clin Pharmacol 51 (1996):  289-95[6] Desmeules J, Gascon MP, Dayer P, Magistris M \"Impact of environmental and genetic factors on codeine analgesia.\" Eur J Clin Pharmacol 41 (1991):  23-6[7] Caraco Y, Sheller J, Wood JJ \"Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.\" J Pharmacol Exp Ther 278 (1996):  1165-74[8] Caraco Y, Sheller J, Wood AJJ \"Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects.\" J Pharmacol Exp Ther 290 (1999):  413-22[9] Hersh EV, Moore PA \"Drug interactions in dentistry: the importance of knowing your CYPs.\" J Am Dent Assoc 135 (2004):  298-311[10] Vevelstad M, Pettersen S, Tallaksen C, Brors O \"O-demethylation of codeine to morphine inhibited by low-dose levomepromazine.\" Eur J Clin Pharmacol 65 (2009):  795-801[11] Thorn CF, Klein TE, Altman RB \"Codeine and morphine pathway.\" Pharmacogenet Genomics 19 (2009):  556-8[12] Zhou SF \"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.\" Clin Pharmacokinet 48 (2009):  761-804[13] \"Product Information. Varubi (rolapitant).\" Tesaro Inc.  (2015):", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, Opium, Ibuprofen, More", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248026, "ingredient1": "Conivaptan", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293202/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Tolvaptan", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248027, "ingredient1": "Crizotinib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293203/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248028, "ingredient1": "Dabrafenib", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293204/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248029, "ingredient1": "Dabrafenib", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9.  Dabrafenib has been found in vitro to be an inducer of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy.  Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants.  Alternatives to these medications should be considered if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293205/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline  (2013):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248030, "ingredient1": "Darifenacin", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes.", "source": "DDInter", "management_text": "Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary.  Patients should be advised to contact their physician if they experience undue adverse effects of darifenacin such as severe abdominal pain or constipation for 3 or more days.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293206/", "reference_text": "[1] \"Product Information. Enablex (darifenacin).\" Novartis Pharmaceuticals  (2005):[2] \"Product Information. Qelbree (viloxazine).\" Supernus Pharmaceuticals Inc  (2021):", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248031, "ingredient1": "Darunavir", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293207/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248032, "ingredient1": "Dasatinib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293208/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248033, "ingredient1": "Daunorubicin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293209/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248034, "ingredient1": "Doxorubicin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293210/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248035, "ingredient1": "Deferasirox", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism may involve induction of CYP450 3A4 activity by deferasirox, although in vitro, the drug has been shown to inhibit CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever deferasirox is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293211/", "reference_text": "[1] \"Product Information. Exjade (deferasirox).\" Novartis Pharmaceuticals  (2005):[2] Skerjanec A, Wang J, Maren K, Rojkjaer L \"Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.\" J Clin Pharmacol 50 (2010):  205-13", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248036, "ingredient1": "Degarelix", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293212/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248037, "ingredient1": "Delavirdine", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293213/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248038, "ingredient1": "Desipramine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293214/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248039, "ingredient1": "Deutetrabenazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293215/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248040, "ingredient1": "Dexamethasone", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293216/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248041, "ingredient1": "Dextromethorphan", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293217/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Benzonatate, Clofedanol, Hydrocodone, Pentoxyverine, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248042, "ingredient1": "Disopyramide", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293218/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248043, "ingredient1": "Dofetilide", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293219/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248044, "ingredient1": "Dolasetron", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293220/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Nabilone, Scopolamine, Rolapitant, Aprepitant, Dronabinol", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248045, "ingredient1": "Donepezil", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293221/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248046, "ingredient1": "Doxepin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293222/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248047, "ingredient1": "Doxepin (topical)", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293223/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Quinine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248048, "ingredient1": "Dronedarone", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Dronedarone may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of dronedarone with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of dronedarone with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293224/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Multaq (dronedarone).\" sanofi-aventis  (2009):", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248049, "ingredient1": "Droperidol", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293225/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248050, "ingredient1": "Drospirenone", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with artemether may decrease the plasma concentrations of contraceptive hormones.  The proposed mechanism is artemether induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine.  Alternative or additional methods of birth control should be used.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293226/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol, Progesterone, Megestrol acetate, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 248051, "ingredient1": "Duloxetine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of duloxetine, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if duloxetine is used in combination with CYP450 2D6 inhibitors, particularly potent ones like paroxetine, fluoxetine, or quinidine.  Pharmacologic response to duloxetine should be monitored more closely whenever a CYP450 2D6 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if duloxetine is used in combination with CYP450 2D6 inhibitors, particularly potent ones like paroxetine, fluoxetine, or quinidine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293227/", "reference_text": "[1] Skinner MH, Kuan HY, Pan A, et al. \"Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.\" Clin Pharmacol Ther 73 (2003):  170-7[2] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248052, "ingredient1": "Duvelisib", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with duvelisib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  The mechanism is reduced clearance due to inhibition of CYP450 3A4 by duvelisib.", "source": "DDInter", "management_text": "Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vinca alkaloids).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever duvelisib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293228/", "reference_text": "[1] \"Product Information. Copiktra (duvelisib).\" Verastem, Inc.  (2018):[2] \"Product Information. Copiktra (duvelisib).\" Verastem, Inc.  (2021):", "alternatives_a": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248053, "ingredient1": "Duvelisib", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with duvelisib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  The mechanism is reduced clearance due to inhibition of CYP450 3A4 by duvelisib.", "source": "DDInter", "management_text": "Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vinca alkaloids).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever duvelisib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293229/", "reference_text": "[1] \"Product Information. Copiktra (duvelisib).\" Verastem, Inc.  (2018):[2] \"Product Information. Copiktra (duvelisib).\" Verastem, Inc.  (2021):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248054, "ingredient1": "Echinacea", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4.  Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea.  In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.  If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered.  Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293230/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004):  89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248055, "ingredient1": "Echinacea", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4.  Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea.  In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.  If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered.  Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293231/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004):  89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248056, "ingredient1": "Efavirenz", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration of artemether-lumefantrine with the nonnucleoside reverse transcriptase inhibitors efavirenz, etravirine, or nevirapine may result in decreased plasma concentrations of one or both drugs.  These drugs are all primarily metabolized by CYP450 3A4 but are also inducers of the isoenzyme.", "source": "DDInter", "management_text": "Patients should be closely monitored for reduced antimalarial efficacy if artemether-lumefantrine must be used in combination with a nonnucleoside reverse transcriptase inhibitor.  Food consumption should be encouraged at dosing times to compensate for the decrease in artemether-lumefantrine bioavailability.  Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, close clinical and laboratory monitoring of antiretroviral response is also recommended.", "mechanism_text": "Metabolism", "recommendation": "Patients should be closely monitored for reduced antimalarial efficacy if artemether-lumefantrine must be used in combination with a nonnucleoside reverse transcriptase inhibitor.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293232/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Artesunate, Tafenoquine, Primaquine", "updated_at": 1767369485}, {"id": 248057, "ingredient1": "Efavirenz", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293233/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More", "alternatives_b": "Artesunate, Tafenoquine, Primaquine", "updated_at": 1767369485}, {"id": 248058, "ingredient1": "Elagolix", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293234/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248059, "ingredient1": "Encorafenib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293235/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248060, "ingredient1": "Entrectinib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293236/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248061, "ingredient1": "Enzalutamide", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293237/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Sulfadoxine, Atovaquone", "updated_at": 1767369485}, {"id": 248062, "ingredient1": "Enzalutamide", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293238/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Pyrimethamine, Tafenoquine, Sulfadoxine, Atovaquone", "updated_at": 1767369485}, {"id": 248063, "ingredient1": "Epirubicin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293239/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "updated_at": 1767369485}, {"id": 248064, "ingredient1": "Eribulin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293240/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248065, "ingredient1": "Erythromycin", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293241/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin, Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248066, "ingredient1": "Erythromycin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293242/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Dirithromycin, Lincomycin, Troleandomycin, Clindamycin, Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248067, "ingredient1": "Escitalopram", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293243/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248068, "ingredient1": "Eslicarbazepine", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293244/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248069, "ingredient1": "Ethinylestradiol", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with artemether may decrease the plasma concentrations of contraceptive hormones.  The proposed mechanism is artemether induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine.  Alternative or additional methods of birth control should be used.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293245/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol, Diethylstilbestrol, Histrelin, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, Chloroquine", "updated_at": 1767369485}, {"id": 248070, "ingredient1": "Etonogestrel", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with artemether may decrease the plasma concentrations of contraceptive hormones.  The proposed mechanism is artemether induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine.  Alternative or additional methods of birth control should be used.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293246/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 248071, "ingredient1": "Etravirine", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration of artemether-lumefantrine with the nonnucleoside reverse transcriptase inhibitors efavirenz, etravirine, or nevirapine may result in decreased plasma concentrations of one or both drugs.  These drugs are all primarily metabolized by CYP450 3A4 but are also inducers of the isoenzyme.", "source": "DDInter", "management_text": "Patients should be closely monitored for reduced antimalarial efficacy if artemether-lumefantrine must be used in combination with a nonnucleoside reverse transcriptase inhibitor.  Food consumption should be encouraged at dosing times to compensate for the decrease in artemether-lumefantrine bioavailability.  Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, close clinical and laboratory monitoring of antiretroviral response is also recommended.", "mechanism_text": "Metabolism", "recommendation": "Patients should be closely monitored for reduced antimalarial efficacy if artemether-lumefantrine must be used in combination with a nonnucleoside reverse transcriptase inhibitor.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293247/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248072, "ingredient1": "Ezogabine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293248/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248073, "ingredient1": "Famotidine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Famotidine may cause QTc prolongation.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if famotidine is used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if famotidine is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293249/", "reference_text": "[1] \"Product Information. Pepcid (famotidine).\" Merck & Co., Inc  (2002):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248074, "ingredient1": "Fedratinib", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with fedratinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4, 2C19, and/or 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, and/or 2D6.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, and/or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293250/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation  (2019):", "alternatives_a": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Sulfadoxine", "updated_at": 1767369485}, {"id": 248075, "ingredient1": "Fedratinib", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with fedratinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4, 2C19, and/or 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, and/or 2D6.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, and/or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293251/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation  (2019):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Sulfadoxine", "updated_at": 1767369485}, {"id": 248076, "ingredient1": "Felbamate", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293252/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248077, "ingredient1": "Fesoterodine", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No initial dosing adjustments are recommended when fesoterodine is used in combination with CYP450 2D6 inhibitors.  Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.", "mechanism_text": "Metabolism", "recommendation": "No initial dosing adjustments are recommended when fesoterodine is used in combination with CYP450 2D6 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293253/", "reference_text": "[1] \"Product Information. Toviaz (fesoterodine).\" Pfizer U.S. Pharmaceuticals Group  (2008):", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248078, "ingredient1": "Fingolimod", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of fingolimod treatment in patients receiving drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval.  Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, close monitoring is recommended during initiation of fingolimod treatment in patients receiving concomitant drugs that can prolong the QT interval, patients with significant QT prolongation (QTc >470 msec in females or >450 msec in males), or patients with relevant risk factors for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital QT prolongation).  Overnight continuous ECG monitoring after the first dose is recommended in accordance with the product labeling.  Fingolimod should not be given if baseline QTc interval is 500 msec or greater.  The same precautions are applicable if, after the first month of treatment, fingolimod is discontinued for more than two weeks and then restarted, since the effects on heart rate and AV conduction may recur on reintroduction of fingolimod.  Within the first 2 weeks of treatment, first-dose procedures are also recommended after interruption of one day or more; during week 3 and 4 of treatment, first-dose procedures are recommended after treatment interruption of more than 7 days.", "mechanism_text": "Synergism", "recommendation": "Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293256/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals  (2010):[5] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod).  http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm#data\"   (2012):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248079, "ingredient1": "Flecainide", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293257/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248080, "ingredient1": "Fluconazole", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293258/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Caspofungin, Micafungin, Amphotericin B, Itraconazole, More", "alternatives_b": "Artesunate, Artemether, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248081, "ingredient1": "Fluoxetine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293259/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248082, "ingredient1": "Fluphenazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293260/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248083, "ingredient1": "Flutamide", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293261/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248084, "ingredient1": "Fluvoxamine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293262/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248085, "ingredient1": "Formoterol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293263/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248086, "ingredient1": "Fosamprenavir", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293264/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248087, "ingredient1": "Foscarnet", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293265/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248088, "ingredient1": "Fosphenytoin", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293266/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil", "updated_at": 1767369485}, {"id": 248089, "ingredient1": "Fostamatinib", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.", "source": "DDInter", "management_text": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293267/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals  (2018):", "alternatives_a": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248090, "ingredient1": "Fostamatinib", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.", "source": "DDInter", "management_text": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293268/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals  (2018):", "alternatives_a": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248091, "ingredient1": "Fostemsavir", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293269/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248092, "ingredient1": "Galantamine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293270/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248093, "ingredient1": "Gatifloxacin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293271/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248094, "ingredient1": "Gemifloxacin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293272/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248095, "ingredient1": "Gilteritinib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293273/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248096, "ingredient1": "Glasdegib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293274/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248097, "ingredient1": "Glycerin", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293275/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, Linaclotide, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248098, "ingredient1": "Goserelin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293276/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248099, "ingredient1": "Granisetron", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293277/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Nabilone, Scopolamine, Rolapitant, Aprepitant, Dronabinol", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248100, "ingredient1": "Grepafloxacin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Grepafloxacin can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293278/", "reference_text": "[1] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996):  77-81[2] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[3] Lode H, Vogel F, Elies W \"Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance.\" Clin Ther 21 (1999):  61-74[4] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000):  557-9[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248101, "ingredient1": "Griseofulvin", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293279/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Terbinafine, Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Terbinafine, Econazole, Flucytosine, Tioconazole, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248102, "ingredient1": "Halofantrine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Halofantrine and artemether-lumefantrine may have additive prolonging effects on the QT interval.  Theoretically, coadministration may increase the risk of ventricular arrhythmias including ventricular tachycardia and torsade de pointes, which can lead to cardiac arrest and sudden death in some cases.", "source": "DDInter", "management_text": "Halofantrine and lumefantrine should not be administered within one month of each other due to their long elimination half-lives (6 to 10 days for halofantrine and 3 to 6 days for lumefantrine).", "mechanism_text": "Synergism", "recommendation": "Halofantrine and lumefantrine should not be administered within one month of each other due to their long elimination half-lives (6 to 10 days for halofantrine and 3 to 6 days for lumefantrine).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293280/", "reference_text": "[1] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline  (2003):[2] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Proguanil", "updated_at": 1767369485}, {"id": 248103, "ingredient1": "Haloperidol", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293281/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248104, "ingredient1": "Halothane", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293282/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, Enflurane, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248105, "ingredient1": "Histrelin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293283/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248106, "ingredient1": "Hydroxychloroquine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293284/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248107, "ingredient1": "Hydroxychloroquine", "ingredient2": "Artemether", "severity": "Moderate", "effect": "There are limited data on the safety and efficacy of artemether-lumefantrine in combination with other antimalarial agents.", "source": "DDInter", "management_text": "The manufacturer recommends that the concurrent use of artemether-lumefantrine with other antimalarials be avoided", "mechanism_text": "Others", "recommendation": "The manufacturer recommends that the concurrent use of artemether-lumefantrine with other antimalarials be avoided", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293285/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Tafenoquine, Atovaquone, Halofantrine, Quinine, Sulfadoxine, Chloroquine", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248108, "ingredient1": "Hydroxyzine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293286/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Clobazam, Meprobamate, Alprazolam, Lorazepam, Chlordiazepoxide, Halazepam, Clorazepic acid, Buspirone, Diazepam, Oxazepam", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248109, "ingredient1": "Ibutilide", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293287/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248110, "ingredient1": "Idarubicin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293288/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248111, "ingredient1": "Idelalisib", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293289/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Primaquine, Proguanil", "updated_at": 1767369485}, {"id": 248112, "ingredient1": "Iloperidone", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293290/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248113, "ingredient1": "Imipramine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293291/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248114, "ingredient1": "Indacaterol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293292/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248115, "ingredient1": "Indinavir", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293293/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Mefloquine, Lumefantrine, Tafenoquine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248116, "ingredient1": "Inotuzumab ozogamicin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293294/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248117, "ingredient1": "Isoetharine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293295/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248118, "ingredient1": "Isoprenaline", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.  It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293296/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248119, "ingredient1": "Itraconazole", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293297/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Tafenoquine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248120, "ingredient1": "Ivabradine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Coadministration of ivabradine with drugs that can prolong the QT interval should generally be avoided.  Caution and cardiac monitoring are recommended if concomitant use is required.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of ivabradine with drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293298/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Mittal SR \"Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine.\" J Assoc Physicians India 62 (2014):  426-7[3] \"Product Information. Corlanor (ivabradine).\" Amgen USA  (2015):", "alternatives_a": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Regadenoson, Felodipine, Amlodipine, Nifedipine, Bisoprolol, Acetylsalicylic acid, Atenolol", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248121, "ingredient1": "Ivacaftor", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter.  The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.  The interaction has been studied with midazolam and digoxin, probe substrates for CYP450 3A4 ad P-gp, respectively.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293299/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals  (2012):", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Quinine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248122, "ingredient1": "Lumefantrine", "ingredient2": "Ivosidenib", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293300/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248123, "ingredient1": "Artemether", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293301/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248124, "ingredient1": "Artemether", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293302/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More", "alternatives_b": "Pyrimethamine, Artesunate, Tafenoquine, Proguanil", "updated_at": 1767369485}, {"id": 248125, "ingredient1": "Lumefantrine", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293303/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Pyrimethamine, Artesunate, Tafenoquine, Proguanil", "updated_at": 1767369485}, {"id": 248126, "ingredient1": "Lumefantrine", "ingredient2": "Labetalol", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293304/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Acebutolol, Nadolol, Bisoprolol, Atenolol, Penbutolol, Atenolol, Acebutolol, Nadolol, Esmolol, Betaxolol, Penbutolol, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248127, "ingredient1": "Lumefantrine", "ingredient2": "Lactitol", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293305/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, Linaclotide, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248128, "ingredient1": "Lumefantrine", "ingredient2": "Lactulose", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293306/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, Linaclotide, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248129, "ingredient1": "Lumefantrine", "ingredient2": "Lapatinib", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293307/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248130, "ingredient1": "Artemether", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever larotrectinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  Some authorities recommend avoiding concomitant use of larotrectinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.  These drugs include, but are not limited to:  alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293308/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc  (2018):", "alternatives_a": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248131, "ingredient1": "Lumefantrine", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever larotrectinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  Some authorities recommend avoiding concomitant use of larotrectinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.  These drugs include, but are not limited to:  alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293309/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc  (2018):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248132, "ingredient1": "Lumefantrine", "ingredient2": "Lefamulin", "severity": "Major", "effect": "When administered orally, lefamulin may significantly increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.  Increased exposure to sensitive CYP450 3A4 substrates that can prolong the QT interval may increase the risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of oral (but not intravenous) lefamulin with sensitive CYP450 3A4 substrates that can prolong the QT interval is considered contraindicated.  However, because lefamulin itself can also cause QT prolongation regardless of the route of administration, concomitant use with other drugs that can prolong the QT interval should generally be avoided even when lefamulin is administered intravenously.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of oral (but not intravenous) lefamulin with sensitive CYP450 3A4 substrates that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293310/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248133, "ingredient1": "Artemether", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293311/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248134, "ingredient1": "Lumefantrine", "ingredient2": "Lenvatinib", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293314/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248135, "ingredient1": "Artemether", "ingredient2": "Lesinurad", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293315/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Pegloticase, Febuxostat, Colchicine, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 248136, "ingredient1": "Lumefantrine", "ingredient2": "Leuprolide", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293316/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248137, "ingredient1": "Lumefantrine", "ingredient2": "Levosalbutamol", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293317/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248138, "ingredient1": "Lumefantrine", "ingredient2": "Levofloxacin", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293318/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248139, "ingredient1": "Lumefantrine", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Levomethadyl acetate may cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293321/", "reference_text": "[1] \"Product Information. Orlaam (levomethadyl acetate).\" Roxane Laboratories Inc  (2001):[2] Deamer RL, Wilson DR, Clark DS, Prichard JG \"Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).\" J Addict Dis 20 (2001):  7-14[3] Krantz MJ, Mehler PS \"Synthetic opioids and QT prolongation.\" Arch Intern Med 163 (2003):  1615; author reply 1615[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248140, "ingredient1": "Artemether", "ingredient2": "Levonorgestrel", "severity": "Moderate", "effect": "Coadministration with artemether may decrease the plasma concentrations of contraceptive hormones.  The proposed mechanism is artemether induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine.  Alternative or additional methods of birth control should be used.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293322/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol, Progesterone, Megestrol acetate, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 248141, "ingredient1": "Lumefantrine", "ingredient2": "Lisdexamfetamine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293323/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Amphetamine, Pemoline, Metamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248142, "ingredient1": "Lumefantrine", "ingredient2": "Lithium carbonate", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293324/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248143, "ingredient1": "Lumefantrine", "ingredient2": "Lofexidine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293325/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248144, "ingredient1": "Lumefantrine", "ingredient2": "Lomefloxacin", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293326/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248145, "ingredient1": "Artemether", "ingredient2": "Lonafarnib", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293327/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248146, "ingredient1": "Lumefantrine", "ingredient2": "Loperamide", "severity": "Moderate", "effect": "The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse events, including syncope, cardiac arrest, and arrhythmia related to prolongation of the QT interval.  Under such circumstances, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval.  Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.  If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes.  Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.  In many of the reported cases of loperamide-induced cardiotoxicity, standard antiarrhythmic drugs were ineffective, and electrical pacing or cardioversion was necessary.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if loperamide is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293330/", "reference_text": "[1] Eggleston W, Clark KH, Marraffa JM \"Loperamide abuse associated with cardiac dysrhythmia and death.\" Ann Emerg Med 69 (2017):  83-6[2] US Food and Drug Administration \"FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM505108.pdf\"   (2016):", "alternatives_a": "Opium, Eluxadoline, Diphenoxylate, Difenoxin", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248147, "ingredient1": "Lumefantrine", "ingredient2": "Loratadine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293331/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248148, "ingredient1": "Artemether", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293332/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248149, "ingredient1": "Lumefantrine", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is increased clearance due to lorlatinib-mediated induction of CYP450 3A4 metabolism.  The interaction has been studied with midazolam, a sensitive substrate of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when lorlatinib is used concomitantly with drugs that are substrates of CYP450 3A4.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lorlatinib is added to or withdrawn from therapy.  Avoid concomitant use with lorlatinib where minimal decreases in concentration of the CYP450 3A4 substrate may lead to serious therapeutic failure.  If coadministration is required, the CYP450 3A4 substrate dosage should be increased in accordance with approved product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lorlatinib is used concomitantly with drugs that are substrates of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293333/", "reference_text": "[1] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group  (2018):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248150, "ingredient1": "Macimorelin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Macimorelin can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided.  A sufficient washout period following discontinuation of these drugs is recommended prior to macimorelin administration.  Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293334/", "reference_text": "[1] \"Product Information. Macrilen (macimorelin).\" Aeterna Zentaris  (2018):", "alternatives_a": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Methacholine, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248151, "ingredient1": "Magnesium citrate", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293335/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Sorbitol, Sulfamethizole, Sodium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Magnesium gluconate, Sodium sulfate, Zinc sulfate, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248152, "ingredient1": "Magnesium hydroxide", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293336/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "alternatives_b": "Artesunate, Artemether, Tafenoquine, Atovaquone, Sulfadoxine", "updated_at": 1767369485}, {"id": 248153, "ingredient1": "Maprotiline", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293337/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248154, "ingredient1": "Artemether", "ingredient2": "Medroxyprogesterone acetate", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of medroxyprogesterone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to medroxyprogesterone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.  When administered as the depot formulation for contraception, no dosage adjustment for medroxyprogesterone is currently recommended during coadministration with CYP450 3A4 inducers.  However, consideration may be given to decreasing the dosing interval (e.g., from one injection every 12 weeks to every 10 weeks) if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to medroxyprogesterone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293340/", "reference_text": "[1] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[2] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[3] \"Product Information. Depo-Provera (medroxyprogesterone).\" Pharmacia and Upjohn  (2001):[4] \"Product Information. Provera (medroxyprogesterone).\" Pharmacia and Upjohn  (2001):[5] Kobayashi K, Mimura N, Fujii H, et al. \"Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate.\" Clin Cancer Res 6 (2000):  3297-303[6] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[7] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22", "alternatives_a": "Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol, Megestrol acetate, Dienogest, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 248155, "ingredient1": "Mefloquine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine and mefloquine may have additive prolonging effects on the QT interval.  Theoretically, coadministration may increase the risk of ventricular arrhythmias including ventricular tachycardia and torsade de pointes, which can lead to cardiac arrest and sudden death in some cases.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should be avoided.  Moreover, artemether-lumefantrine should generally not be used in combination with other antimalarial agents due to limited safety data.  Caution and close monitoring of the ECG are advised when QT-prolonging antimalarial agents are used following treatment with artemether-lumefantrine because of the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be monitored for reduced antimalarial efficacy if artemether-lumefantrine is prescribed immediately after mefloquine treatment, and food consumption should be encouraged at dosing times to compensate for the decrease in lumefantrine bioavailability.  Patients should also be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293341/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248156, "ingredient1": "Artemether", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293342/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248157, "ingredient1": "Mesoridazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Mesoridazine can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293343/", "reference_text": "[1] \"Product Information. Serentil (mesoridazine).\" Boehringer-Ingelheim  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248158, "ingredient1": "Orciprenaline", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.  It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293344/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248159, "ingredient1": "Methadone", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293345/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248160, "ingredient1": "Methotrimeprazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293346/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248161, "ingredient1": "Metoprolol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293347/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Bisoprolol, Acetylsalicylic acid, Atenolol, Acebutolol, Nadolol, Esmolol, Betaxolol, Penbutolol, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248162, "ingredient1": "Metronidazole", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "QT prolongation has been reported with metronidazole, particularly when administered with drugs that have the potential for prolonging the QT interval.  This may increase the risk of ventricular arrhythmias associated with QT prolongation including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended when metronidazole is used concomitantly with agents known to cause QT prolongation.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when metronidazole is used concomitantly with agents known to cause QT prolongation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293348/", "reference_text": "[1] \"Product Information. Flagyl (metronidazole).\" Searle  (2001):[2] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005):  472-3[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Pylera (bismuth subcitrate potassium/metronidazo/TCN).\" Aptalis Pharma  (2022):", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248163, "ingredient1": "Mexiletine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293349/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248164, "ingredient1": "Miconazole", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme.  No formal drug interaction studies have been conducted with miconazole buccal tablets.  Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293351/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa  Pharmaceuticals, a Division of Par Pharmaceuticals, Inc.  (2010):", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248165, "ingredient1": "Midostaurin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293352/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248166, "ingredient1": "Mifepristone", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293353/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248167, "ingredient1": "Mifepristone", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Mifepristone may prolong the QTc interval in a dose-related manner.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, coadministration with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended if no alternatives exist and concomitant use is required.  Serum potassium should be assessed prior to starting mifepristone and 1 to 2 weeks following initiation of therapy or an increase in dosage, and periodically as needed.  Hypokalemia must be corrected prior to initiation of mifepristone.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heart rhythm.  Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).", "mechanism_text": "Synergism", "recommendation": "When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, coadministration with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293354/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated  (2012):", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248168, "ingredient1": "Mineral oil", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293355/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, Linaclotide, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248169, "ingredient1": "Mirtazapine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293356/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248170, "ingredient1": "Mitotane", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293358/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248171, "ingredient1": "Modafinil", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293361/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248172, "ingredient1": "Morphine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293362/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Opium, Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, More", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248173, "ingredient1": "Moxifloxacin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293363/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248174, "ingredient1": "Nafcillin", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293364/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248175, "ingredient1": "Nebivolol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293365/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Bisoprolol, Acetylsalicylic acid, Atenolol, Amlodipine, Valsartan, Irbesartan, Hydrochlorothiazide, Losartan, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248176, "ingredient1": "Nefazodone", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293366/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248177, "ingredient1": "Nelfinavir", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293367/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248178, "ingredient1": "Nevirapine", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration of artemether-lumefantrine with the nonnucleoside reverse transcriptase inhibitors efavirenz, etravirine, or nevirapine may result in decreased plasma concentrations of one or both drugs.  These drugs are all primarily metabolized by CYP450 3A4 but are also inducers of the isoenzyme.", "source": "DDInter", "management_text": "Patients should be closely monitored for reduced antimalarial efficacy if artemether-lumefantrine must be used in combination with a nonnucleoside reverse transcriptase inhibitor.  Food consumption should be encouraged at dosing times to compensate for the decrease in artemether-lumefantrine bioavailability.  Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, close clinical and laboratory monitoring of antiretroviral response is also recommended.", "mechanism_text": "Metabolism", "recommendation": "Patients should be closely monitored for reduced antimalarial efficacy if artemether-lumefantrine must be used in combination with a nonnucleoside reverse transcriptase inhibitor.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293368/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248179, "ingredient1": "Nevirapine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with nevirapine may decrease the plasma concentrations and therapeutic efficacy of drugs that are substrates of CYP450 3A4.  The proposed mechanism is increased clearance due to nevirapine-mediated induction of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if nevirapine is used concomitantly with drugs that are CYP450 3A4 substrates.  Dosage adjustments as well as clinical and laboratory monitoring of coadministered drugs should be considered whenever nevirapine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nevirapine is used concomitantly with drugs that are CYP450 3A4 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293369/", "reference_text": "[1] \"Product Information. Viramune (nevirapine).\" Boehringer-Ingelheim  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Viramune XR (nevirapine).\" Boehringer Ingelheim  (2017):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248180, "ingredient1": "Nilotinib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293370/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248181, "ingredient1": "Nilutamide", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293371/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248182, "ingredient1": "Norethisterone", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with artemether may decrease the plasma concentrations of contraceptive hormones.  The proposed mechanism is artemether induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine.  Alternative or additional methods of birth control should be used.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293372/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Relugolix, Lanreotide, Gonadorelin, Ulipristal, Norelgestromin, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 248183, "ingredient1": "Norfloxacin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293373/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, Acyclovir, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248184, "ingredient1": "Norgestrel", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with artemether may decrease the plasma concentrations of contraceptive hormones.  The proposed mechanism is artemether induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine.  Alternative or additional methods of birth control should be used.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with artemether-lumefantrine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293374/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Progesterone, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 248185, "ingredient1": "Nortriptyline", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293375/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248186, "ingredient1": "Ofloxacin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293376/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, Tinidazole, Tetracycline, Cefepime, Cefuroxime, Secnidazole, Cefixime, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248187, "ingredient1": "Olanzapine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293377/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248188, "ingredient1": "Oliceridine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293378/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, Opium, Ibuprofen, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248189, "ingredient1": "Olodaterol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293379/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248190, "ingredient1": "Ondansetron", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293384/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Nabilone, Scopolamine, Rolapitant, Aprepitant, Dronabinol", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248191, "ingredient1": "Osilodrostat", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293385/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248192, "ingredient1": "Osilodrostat", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293386/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248193, "ingredient1": "Osimertinib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293387/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248194, "ingredient1": "Oxaliplatin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293388/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248195, "ingredient1": "Oxcarbazepine", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293389/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248196, "ingredient1": "Oxycodone", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293390/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, Opium, Ibuprofen, More", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248197, "ingredient1": "Oxytocin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293391/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Methylergometrine, Misoprostol, Ergometrine, Dinoprostone, Terlipressin, Desmopressin", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248198, "ingredient1": "Ozanimod", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293392/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248199, "ingredient1": "Paliperidone", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293395/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248200, "ingredient1": "Palonosetron", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293396/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Nabilone, Scopolamine, Rolapitant, Aprepitant, Dronabinol", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248201, "ingredient1": "Panobinostat", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293397/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248202, "ingredient1": "Papaverine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Intracoronary administration of papaverine has been associated with QT interval prolongation and torsade de pointes (TdP) arrhythmia.  The risk may theoretically increase in patients receiving concomitant medications that can also prolong the QT interval or cause bradycardia.  The precise mechanism of papaverine-induced ventricular tachyarrhythmias has not been delineated, but may involve inhibition of potassium currents and prolongation of the action potential duration.", "source": "DDInter", "management_text": "Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293398/", "reference_text": "[1] Nakayama M, Tanaka N, Sakoda K, et al. \"Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve study of patients with moderate coronary artery disease.\" Circ J 79 (2015):  530-6[2] Goto M, Sato M, Kitzazawa H, et al. \"Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation.\" Intern Med 53 (2014):  1629-31[3] Nakayama M, Saito A, Kitazawa H, et al. \"Papaverine-induced polymorphic ventricular tachycardia in relation to QTU and giant T-U waves in four cases.\" Intern Med 51 (2012):  351-6[4] Inoue T, Asahi S, Takayanagi K, Morooka S, Takabatake Y \"QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine.\" Cardiology 84 (1994):  9-13[5] Vrolix M, Piessens J, De Geest H \"Torsades de pointes after intracoronary papaverine.\" Eur Heart J 12 (1991):  273-6[6] Kern MJ, Deligonul U, Serota H, Gudipati C, Buckingham T \"Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve.\" Cathet Cardiovasc Diagn 19 (1990):  229-36[7] Talman CL, Winniford MD, Rossen JD, Simonetti I, Kienzle MG, Marcus ML \"Polymorphous ventricular tachycardia: a side effect of intracoronary papaverine.\" J Am Coll Cardiol 15 (1990):  275-8[8] Jain A, Jenkins MG \"Intracoronary electrocardiogram during torsade des pointes secondary to intracoronary papaverine.\" Cathet Cardiovasc Diagn 18 (1989):  255-7", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248203, "ingredient1": "Paroxetine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293399/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248204, "ingredient1": "Pasireotide", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293400/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248205, "ingredient1": "Pazopanib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293401/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248206, "ingredient1": "Pentamidine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293402/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Miltefosine, Nifurtimox, Benznidazole", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248207, "ingredient1": "Pentobarbital", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293403/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248208, "ingredient1": "Perflutren", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Perflutren lipid microsphere suspension (Definity) has been reported to cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of perflutren lipid microsphere suspension with other agents that can prolong the QT interval may be considered contraindicated in some cases.  Please refer to the prescribing information for these drugs for more information.  No data are available regarding the effect of perflutren protein-type A microsphere suspension (Optison) on the QT interval of the electrocardiogram.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of perflutren lipid microsphere suspension with other agents that can prolong the QT interval may be considered contraindicated in some cases.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293404/", "reference_text": "[1] \"Product Information. Definity (perflutren).\" Lantheus Medical Imaging Inc  (2015):[2] \"Product Information. Optison (perflutren).\" Mallinckrodt Medical Inc  (2015):", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248209, "ingredient1": "Perphenazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293405/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248210, "ingredient1": "Pexidartinib", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293406/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Hydroxychloroquine, Primaquine, Proguanil, Chloroquine", "updated_at": 1767369485}, {"id": 248211, "ingredient1": "Pexidartinib", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with pexidartinib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4.  The proposed mechanism is increased clearance due to pexidartinib-mediated induction of CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Concomitant administration of pexidartinib with drugs that are substrates of CYP450 3A4 should generally be avoided, particularly those with a narrow therapeutic range.  The potential for diminished therapeutic effects should be considered when pexidartinib is prescribed in combination with drugs that are substrates of CYP450 3A4.  Dosage adjustments as well as clinical and laboratory monitoring of the CYP450 3A4 substrate drug should be considered whenever pexidartinib is added to or withdrawn from therapy with these drugs.", "mechanism_text": "Metabolism", "recommendation": "Concomitant administration of pexidartinib with drugs that are substrates of CYP450 3A4 should generally be avoided, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293407/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc.  (2019):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Hydroxychloroquine, Primaquine, Proguanil, Chloroquine", "updated_at": 1767369485}, {"id": 248212, "ingredient1": "Phenobarbital", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293408/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248213, "ingredient1": "Phenolphthalein", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293409/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, Linaclotide, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248214, "ingredient1": "Phenylbutazone", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293410/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Acetylsalicylic acid, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248215, "ingredient1": "Phenytoin", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293411/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil", "updated_at": 1767369485}, {"id": 248216, "ingredient1": "Pimavanserin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293412/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248217, "ingredient1": "Pimozide", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Pimozide can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of pimozide with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of pimozide with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293413/", "reference_text": "[1] \"Product Information. Orap (pimozide).\" Gate Pharmaceuticals[2] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001):  1774-82[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248218, "ingredient1": "Pindolol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293414/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Penbutolol, Atenolol, Acebutolol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Atenolol", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248219, "ingredient1": "Pirbuterol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293415/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Ephedrine, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248220, "ingredient1": "Pirfenidone", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 may increase the plasma concentrations of pirfenidone, especially when used in addition to a moderate or potent CYP450 1A2 inhibitor.", "source": "DDInter", "management_text": "Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.g., certain fluoroquinolones, oral contraceptives, deferasirox, methoxsalen, mexiletine, thiabendazole, ticlopidine, zileuton) should be avoided.  No particular precaution is necessary if pirfenidone and CYP450 2C9, 2C19, 2D6, and/or 2E1 inhibitors are coadministered without a moderate or potent CYP450 1A2 inhibitor.  However, a prolonged duration of monitoring for adverse effects may be required depending on the elimination half-life of the concomitant drug.  For example, it should be noted that rolapitant, a moderate CYP450 2D6 inhibitor, may increase plasma concentrations and the risk of adverse effects of pirfenidone for at least 28 days after administration of rolapitant.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of pirfenidone with moderate or potent inhibitors of CYP450 2C9, 2C19, 2D6, and/or 2E1 in addition to a moderate or potent inhibitor of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293416/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Esbriet (pirfenidone).\" Intermune Inc  (2013):[3] \"Product Information. Varubi (rolapitant).\" Tesaro Inc.  (2015):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248221, "ingredient1": "Pitolisant", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293419/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Quinine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248222, "ingredient1": "Polyethylene glycol (3350)", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293420/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248223, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293421/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Artemether, Tafenoquine, Atovaquone, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248224, "ingredient1": "Posaconazole", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293423/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248225, "ingredient1": "Posaconazole", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293424/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248226, "ingredient1": "Pralsetinib", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293425/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248227, "ingredient1": "Pralsetinib", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293426/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248228, "ingredient1": "Primaquine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293427/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248229, "ingredient1": "Primaquine", "ingredient2": "Artemether", "severity": "Moderate", "effect": "There are limited data on the safety and efficacy of artemether-lumefantrine in combination with other antimalarial agents.", "source": "DDInter", "management_text": "The manufacturer recommends that the concurrent use of artemether-lumefantrine with other antimalarials be avoided", "mechanism_text": "Others", "recommendation": "The manufacturer recommends that the concurrent use of artemether-lumefantrine with other antimalarials be avoided", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293428/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Tafenoquine, Atovaquone, Halofantrine, Quinine, Sulfadoxine, Chloroquine", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248230, "ingredient1": "Primidone", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293429/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248231, "ingredient1": "Probucol", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293430/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248232, "ingredient1": "Procainamide", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293431/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248233, "ingredient1": "Prochlorperazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293432/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248234, "ingredient1": "Promazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293434/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248235, "ingredient1": "Promethazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293435/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248236, "ingredient1": "Propafenone", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293436/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248237, "ingredient1": "Propofol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including TdP and sudden death.", "source": "DDInter", "management_text": "Caution and clinical monitoring is recommended if propofol is used concomitantly with other agents associated with QT interval prolongation.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring is recommended if propofol is used concomitantly with other agents associated with QT interval prolongation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293437/", "reference_text": "[1] Whyte SD, Booker PD, Buckley DG \"The Effects of Propofol and Sevoflurane on the QT Interval and Transmural Dispersion of Repolarization in Children.\" Anesth Analg 100 (2005):  71-77[2] Staikou C, Stamelos M, Stavroulakis E \"Impact of anaesthetic drugs and adjuvants on ECG markers of torsadogenicity.\" Br J Anaesth 112 (2014):  217-30[3] Toyoda T, Terao Y, Oji M, Okada M, Fukusaki M, Sumikawa K \"The interaction of antiemetic dose of droperidol with propofol on QT interval during anesthetic induction.\" J Anesth 27 (2013):  885-9[4] Wutzler A, De Asmundis C, Matsuda H, et al. \"Effects of propofol on ventricular repolarization and incidence of malignant arrhythmias in adults.\" J Electrocardiol 51 (2018):  170-4[5] Kim DH, Kweon TD, Nam SB, Han DW, Cho WY, Lee JS \"Effects of target concentration infusion of propofol and tracheal intubation on QTc interval.\" Anaesthesia 63 (2008):  1061-4[6] Scalese MJ, Herring HR, Rathburn RC, Skrepnek GH, Ripley TL \"Propofol-associated QTc prolongation.\" Ther Adv Drug Saf 7 (2016):  68-78[7] Hanci V, Aydin M, Yurtlu BS, et al. \"Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals.\" Kaohsiung J Med Sci 26 (2010):  470-7[8] Kleinsasser A, Kuenszberg E, Loeckinger A, et al. \"Sevoflurane, but not propofol, significantly prolongs the Q-T interval.\" Anesth Analg 90 (2000):  25-7[9] Paventi S, Santevecchi A, Ranieri R \"Effects of sevoflurane versus propofol on QT interval.\" Minerva Anestesiol 67 (2001):  637-40[10] Kleinsasser A, Loeckinger A, Lindner KH, Keller C, Boehler M, Puehringer F \"Reversing sevoflurane-associated Q-Tc prolongation by changing to propofol.\" Anaesthesia 56 (2001):  248-50", "alternatives_a": "Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, Enflurane, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248238, "ingredient1": "Dextropropoxyphene", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293438/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, Opium, Ibuprofen, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248239, "ingredient1": "Propranolol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293439/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Bisoprolol, Acetylsalicylic acid, Atenolol, Acebutolol, Nadolol, Esmolol, Betaxolol, Penbutolol, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248240, "ingredient1": "Protriptyline", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293440/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248241, "ingredient1": "Quetiapine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293442/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248242, "ingredient1": "Quinidine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other antimalarial agents that can prolong the QT interval (e.g., quinine, quinidine, halofantrine, chloroquine) may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should be avoided.  Moreover, artemether-lumefantrine should generally not be used in combination with other antimalarial agents due to limited safety data.  Caution and close monitoring of the ECG are advised when QT-prolonging antimalarial agents are used following treatment with artemether-lumefantrine because of the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293444/", "reference_text": "[1] Lefevre G, Carpenter P, Souppart C, et al. \"Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects.\" J Clin Pharmacol 42 (2002):  1147-58[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lidocaine, Moricizine, Bretylium, Tocainide", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248243, "ingredient1": "Quinine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other antimalarial agents that can prolong the QT interval (e.g., quinine, quinidine, halofantrine, chloroquine) may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should be avoided.  Moreover, artemether-lumefantrine should generally not be used in combination with other antimalarial agents due to limited safety data.  Caution and close monitoring of the ECG are advised when QT-prolonging antimalarial agents are used following treatment with artemether-lumefantrine because of the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293445/", "reference_text": "[1] Lefevre G, Carpenter P, Souppart C, et al. \"Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects.\" J Clin Pharmacol 42 (2002):  1147-58[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Quinine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248244, "ingredient1": "Ranolazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293446/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Regadenoson", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248245, "ingredient1": "Relugolix", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293447/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248246, "ingredient1": "Ribociclib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293448/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248247, "ingredient1": "Ribociclib", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of CYP450 3A4.  The proposed mechanism is decreased clearance due to ribociclib-mediated inhibition of CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Caution is advised when ribociclib is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ribociclib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ribociclib is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293449/", "reference_text": "[1] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993):  853-61[2] Trivier JM, Libersa C, Belloc C, Lhermitte M \"Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report).\" Life Sci 52 (1993):  pl91-6[3] Rawden HC, Kokwaro GO, Ward SA, Edwards G \"Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes.\" Br J Clin Pharmacol 49 (2000):  313-22[4] DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM \"Effect of alosetron on the pharmacokinetics of alprazolam.\" J Clin Pharmacol 41 (2001):  452-4[5] Katoh M, Nakajima M, Yamazaki H, Yokoi T \"Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.\" Eur J Pharm Sci 12 (2001):  505-13[6] Kane GC, Lipsky JJ \"Drug-grapefruit juice interactions.\" Mayo Clin Proc 75 (2000):  933-42[7] Yu DK \"The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.\" J Clin Pharmacol 39 (1999):  1203-11[8] Nagy J, Schipper HG, Koopmans RP, Butter JJ, van Boxtel CJ, Kager PA \"Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability.\" Am J Trop Med Hyg 66 (2002):  260-3[9] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals  (2017):", "alternatives_a": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248248, "ingredient1": "Rifabutin", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293450/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248249, "ingredient1": "Rifampicin", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293451/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Lumefantrine, Pyrimethamine, Tafenoquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248250, "ingredient1": "Rifapentine", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293452/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248251, "ingredient1": "Rifapentine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with rifapentine may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C8, 2C9, and/or 3A4 isoenzymes.  The mechanism is accelerated clearance due to induction of these isoenzymes by rifapentine.", "source": "DDInter", "management_text": "The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever rifapentine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293453/", "reference_text": "[1] \"Product Information. Priftin (rifapentine).\" Hoechst Marion Roussel  (2001):[2] Thijssen HH, Flin ois JP, Beaune PH \"Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.\" Drug Metab Dispos 28 (2000):  1284-90", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248252, "ingredient1": "Rilpivirine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293454/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248253, "ingredient1": "Risperidone", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293455/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248254, "ingredient1": "Ritodrine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.  It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293456/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5", "alternatives_a": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248255, "ingredient1": "Ritonavir", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293457/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Tafenoquine, Lumefantrine, Sulfadoxine", "updated_at": 1767369485}, {"id": 248256, "ingredient1": "Rivastigmine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%).", "source": "DDInter", "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.  Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293458/", "reference_text": "[1] \"Product Information. Aricept (donepezil).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Exelon (rivastigmine).\" Novartis Pharmaceuticals  (2001):[3] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc  (2005):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248257, "ingredient1": "Romidepsin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293459/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248258, "ingredient1": "Ropivacaine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293460/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lidocaine, Chloroprocaine, Bupivacaine, Levobupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248259, "ingredient1": "Rucaparib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293461/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248260, "ingredient1": "Rucaparib", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 3A4.  The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293462/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248261, "ingredient1": "Rufinamide", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293463/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248262, "ingredient1": "Salmeterol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293464/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5[28] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[29] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[30] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248263, "ingredient1": "Saquinavir", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293465/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248264, "ingredient1": "Saquinavir", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293466/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248265, "ingredient1": "Secobarbital", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293467/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248266, "ingredient1": "Selpercatinib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293468/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248267, "ingredient1": "Selpercatinib", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with selpercatinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  The mechanism is reduced clearance due to inhibition of CYP450 3A4 by selpercatinib.  The interaction may be particularly important for sensitive substrates or those that demonstrate a narrow therapeutic index.", "source": "DDInter", "management_text": "Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever selpercatinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293469/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company  (2020):", "alternatives_a": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248268, "ingredient1": "Sertraline", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293471/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248269, "ingredient1": "Sevoflurane", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293472/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, Enflurane, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248270, "ingredient1": "Siponimod", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of siponimod treatment in patients receiving drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Siponimod has not been studied in patients receiving drugs that can prolong the QT interval.  Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with siponimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.  Advice from a cardiologist should be sought if treatment with siponimod is considered in patients on concurrent therapy with QT prolonging drugs with a known risk of torsades de pointes or drugs that slow heart rate or AV conduction.", "mechanism_text": "Synergism", "recommendation": "Siponimod has not been studied in patients receiving drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293473/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248271, "ingredient1": "Iodide I-123", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.", "source": "DDInter", "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.  Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week.  Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.", "mechanism_text": "Others", "recommendation": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293474/", "reference_text": "[1] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare  (2022):", "alternatives_a": "Artesunate, Tafenoquine, Lumefantrine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248272, "ingredient1": "Iodide I-131", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.", "source": "DDInter", "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.  Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week.  Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.", "mechanism_text": "Others", "recommendation": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293475/", "reference_text": "[1] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare  (2022):", "alternatives_a": "Ibritumomab tiuxetan, Tositumomab", "alternatives_b": "Artesunate, Tafenoquine", "updated_at": 1767369485}, {"id": 248273, "ingredient1": "Iodide I-131", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.", "source": "DDInter", "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.  Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week.  Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.", "mechanism_text": "Others", "recommendation": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293476/", "reference_text": "[1] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare  (2022):", "alternatives_a": "Iodide I-123, Ibritumomab tiuxetan, Tositumomab", "alternatives_b": "Artesunate, Tafenoquine", "updated_at": 1767369485}, {"id": 248274, "ingredient1": "Solifenacin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293477/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248275, "ingredient1": "Somapacitan", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293478/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 248276, "ingredient1": "Somapacitan", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293479/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 248277, "ingredient1": "Somatrem", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293480/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248278, "ingredient1": "Somatrem", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293481/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248279, "ingredient1": "Somatotropin", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293482/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248280, "ingredient1": "Somatotropin", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293483/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248281, "ingredient1": "Sorafenib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293484/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248282, "ingredient1": "Sotalol", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293485/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Acebutolol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Atenolol, Acebutolol, Nadolol, Bisoprolol, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248283, "ingredient1": "Sparfloxacin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Sparfloxacin may cause dose-related prolongation of the QT interval in some patients.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293488/", "reference_text": "[1] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996):  77-81[2] Jaillon P, Morganroth J, Brumpt I, Talbot G \"Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.\" J Antimicrob Chemother 37(suppl a) (1996):  161-7[3] Zix JA, GeerdesFenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997):  1668-72[4] \"Product Information. Zagam (sparfloxacin).\" Rhone Poulenc Rorer  (2001):[5] Demolis JL, Charransol A, Funck-Brentano C, Jaillon P \"Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers.\" Br J Clin Pharmacol 41 (1996):  499-503[6] Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B \"Torsades de pointe probably related to sparfloxacin.\" Eur J Clin Microbiol Infect Dis 15 (1996):  350-1[7] Lipsky BA, Dorr MB, Magner DJ, Talbot GH \"Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.\" Clin Ther 21 (1999):  148-59[8] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001):  301-19[9] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs.\" BMJ 322 (2001):  46-7[10] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000):  557-9[11] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001):  122-6[12] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002):  455-64[13] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002):  663-8; discussion 668-72[14] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002):  121-8[15] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004):  1091-124[16] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003):  2317-20[17] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002):  269-77[18] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[19] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[20] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007):  374-9[21] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248284, "ingredient1": "St. John's Wort", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293489/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Sulfadoxine", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "updated_at": 1767369485}, {"id": 248285, "ingredient1": "Stiripentol", "ingredient2": "Artemether", "severity": "Moderate", "effect": "The concomitant administration of stiripentol may significantly increase plasma concentrations, pharmacologic effects, and toxicities of drugs that are substrates of CYP450 2C19, 3A4, and/or 2D6.  The mechanism is inhibition of cytochrome P-450 metabolism by stiripentol.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use.  Dosage adjustments may be required if increased plasma levels or effects are observed.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293490/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248286, "ingredient1": "Stiripentol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "The concomitant administration of stiripentol may significantly increase plasma concentrations, pharmacologic effects, and toxicities of drugs that are substrates of CYP450 2C19, 3A4, and/or 2D6.  The mechanism is inhibition of cytochrome P-450 metabolism by stiripentol.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use.  Dosage adjustments may be required if increased plasma levels or effects are observed.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293491/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):", "alternatives_a": "Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248287, "ingredient1": "Sulfamethoxazole", "ingredient2": "Lumefantrine", "severity": "Minor", "effect": "Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia).  In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293492/", "reference_text": "[1] Wiener I, Rubin D, Martinez E, et al. \"QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration.\" Mt Sinai J Med 48 (1981):  53-5[2] Crouch MA, Limon L, Cassano AT \"Clinical relevance and management of drug-related QT interval prolongation.\" Pharmacotherapy 23 (2003):  881-908[3] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T \"QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole.\" Am J Cardiol 59 (1987):  376-7[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Darpo B \"Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes.\" Eur Heart J Suppl 3(Suppl K) (2001):  K70-80", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More", "alternatives_b": "Artesunate, Artemether, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248288, "ingredient1": "Sulfinpyrazone", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293493/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Pegloticase, Febuxostat, Colchicine, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248289, "ingredient1": "Sunitinib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293494/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248290, "ingredient1": "Tacrine", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%).", "source": "DDInter", "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.  Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293495/", "reference_text": "[1] \"Product Information. Aricept (donepezil).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Exelon (rivastigmine).\" Novartis Pharmaceuticals  (2001):[3] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc  (2005):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248291, "ingredient1": "Tacrolimus", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293496/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248292, "ingredient1": "Tamoxifen", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293497/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248293, "ingredient1": "Tazemetostat", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with tazemetostat may decrease the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  The proposed mechanism is increased clearance due to induction of CYP450 3A4 by tazemetostat.", "source": "DDInter", "management_text": "Caution is advised when tazemetostat is used concomitantly with drugs that undergo metabolism by CYP450 3A4.  Dose adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever tazemetostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when tazemetostat is used concomitantly with drugs that undergo metabolism by CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293498/", "reference_text": "[1] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc  (2020):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248294, "ingredient1": "Telaprevir", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293501/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248295, "ingredient1": "Telavancin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293502/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248296, "ingredient1": "Telithromycin", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293503/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248297, "ingredient1": "Telithromycin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293504/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Dirithromycin, Lincomycin, Troleandomycin, Clindamycin", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248298, "ingredient1": "Telotristat ethyl", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes.  The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293505/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc.  (2017):", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248299, "ingredient1": "Telotristat ethyl", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes.  The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293506/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc.  (2017):", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248300, "ingredient1": "Terbutaline", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.  It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293507/", "reference_text": "[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978):  767-9[4] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977):  174-9[13] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990):  259-61[15] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[16] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998):  145-7[21] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[22] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006):  582-90[25] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998):  1400-5", "alternatives_a": "Ephedrine, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248301, "ingredient1": "Terfenadine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293508/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248302, "ingredient1": "Tetrabenazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293509/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248303, "ingredient1": "Thalidomide", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Thalidomide can cause bradycardia and may have additive effects with other drugs that decrease heart rate.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia.  Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.  A dose reduction of thalidomide or discontinuation may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293510/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248304, "ingredient1": "Thioridazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, all of which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The use of thioridazine with drugs that inhibit CYP450 2D6 is considered contraindicated.  Depending on the elimination half-life of these drugs, a considerable waiting period may be appropriate following their discontinuation before thioridazine is initiated.  For example, the manufacturer of fluoxetine recommends that thioridazine not be administered within 5 weeks after discontinuing fluoxetine because of the drug's long half-life.  In addition, the prolonged duration of CYP450 2D6 inhibition by the moderate CYP450 2D6 inhibitor rolapitant of at least 28 days after its administration should also be taken into account.", "mechanism_text": "Metabolism", "recommendation": "The use of thioridazine with drugs that inhibit CYP450 2D6 is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293511/", "reference_text": "[1] Silver JM, Yudofsky SC, Kogan M, Katz BL \"Elevation of thioridazine plasma levels by propranolol.\" Am J Psychiatry 143 (1986):  1290-2[2] Greendyke RM, Kanter DR \"Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations.\" J Clin Psychopharmacol 7 (1987):  178-82[3] Greendyke RM, Gulya A \"Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital.\" J Clin Psychiatry 49 (1988):  105-7[4] Abernethy DR, Greenblatt DJ, Steel K, Shader RI \"Impairment of hepatic drug oxidation by propoxyphene.\" Ann Intern Med 97 (1982):  223-4[5] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[6] Fletcher GF, Kazamias TM \"Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias.\" Am Heart J 78 (1969):  135-8[7] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[8] \"Product Information. Mellaril (thioridazine).\" Sandoz Pharmaceuticals Corporation  (2001):[9] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996):  77-81[10] Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL \"Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans.\" Clin Pharmacol Ther 60 (1996):  543-53[11] Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J \"Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.\" J Clin Psychopharmacol 19 (1999):  494-9[12] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001):  1774-82[13] \"Product Information. Varubi (rolapitant).\" Tesaro Inc.  (2015):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248305, "ingredient1": "Timolol", "ingredient2": "Lumefantrine", "severity": "Moderate", "effect": "Coadministration with lumefantrine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumefantrine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lumefantrine is used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293512/", "reference_text": "[1] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Acebutolol, Nadolol, Esmolol, Betaxolol, Penbutolol, Bisoprolol, Carteolol, Atenolol, Neostigmine, Brimonidine, Levobunolol, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248306, "ingredient1": "Tizanidine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293513/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Cyclobenzaprine, Methocarbamol, Chlormezanone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248307, "ingredient1": "Tolterodine", "ingredient2": "Lumefantrine", "severity": "Minor", "effect": "Coadministration with drugs that are inhibitors of CYP450 2D6 may increase the plasma concentrations of tolterodine, which is primarily metabolized by this isoenzyme in patients that are extensive metabolizers, or EMs (approximately 93% of Caucasians and more than 98% of Asians and individuals of African descent).", "source": "DDInter", "management_text": "This interaction is unlikely to produce clinically significant effects because of metabolic shunting to CYP450 3A4 in 2D6-deficient states.  Moreover, since the active 5-hydroxymethyl metabolite (5-HM) generated by CYP450 2D6 is equipotent compared with tolterodine, and the sum of unbound serum concentrations of tolterodine and 5-HM are only 25% higher during the interaction, little alteration in the overall pharmacologic activity would be expected.  Thus, dosage reductions should not be necessary.  However, a prolonged duration of monitoring for adverse effects may be required depending on the elimination half-life of the concomitant drug.  For example, it should be noted that rolapitant, a moderate CYP450 2D6 inhibitor, can increase plasma concentrations and the risk of adverse effects of tolterodine for at least 28 days after administration of rolapitant.", "mechanism_text": "Metabolism", "recommendation": "This interaction is unlikely to produce clinically significant effects because of metabolic shunting to CYP450 3A4 in 2D6-deficient states.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293514/", "reference_text": "[1] \"Product Information. Detrol (tolterodine).\" Pharmacia and Upjohn  (2001):[2] Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L \"Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance.\" Br J Clin Pharmacol 48 (1999):  553-63[3] \"Product Information. Varubi (rolapitant).\" Tesaro Inc.  (2015):", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "alternatives_b": "Artesunate, Mefloquine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248308, "ingredient1": "Toremifene", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293515/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248309, "ingredient1": "Tramadol", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine and tramadol may each cause prolongation of the QT interval.  Theoretically, coadministration of multiple agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with tramadol should generally be avoided.  If concomitant use is required, careful consideration of the effects on tramadol and M1 is recommended.  Patients should be monitored for opioid withdrawal, seizures, and serotonin syndrome, and care should be exercised in patients suspected to be at an increased risk of torsade de pointes.  If artemether-lumefantrine is discontinued, consider reducing the tramadol dose (taking into account the elimination half-life of lumefantrine [3 to 6 days]) until stable drug effects are achieved and monitor for respiratory depression and sedation.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with tramadol should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293516/", "reference_text": "[1] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):[6] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[7] Saarikoski T, Saari TI, Hagelberg NM, et al. \"Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.\" Eur J Clin Pharmacol 71 (2015):  321-7", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, Opium, Ibuprofen, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248310, "ingredient1": "Trazodone", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293517/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248311, "ingredient1": "Triclabendazole", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293518/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Praziquantel, Oxamniquine", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248312, "ingredient1": "Trifluoperazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293519/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248313, "ingredient1": "Triflupromazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293520/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248314, "ingredient1": "Alimemazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293521/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248315, "ingredient1": "Trimipramine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293522/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248316, "ingredient1": "Triptorelin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293523/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248317, "ingredient1": "Troglitazone", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293526/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine", "updated_at": 1767369485}, {"id": 248318, "ingredient1": "Troleandomycin", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293527/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248319, "ingredient1": "Tucatinib", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293528/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248320, "ingredient1": "Valbenazine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293529/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248321, "ingredient1": "Vandetanib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Vandetanib can cause concentration-dependent prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided.  Should treatment with other QT-prolonging drugs be required, the manufacturer recommends more frequent monitoring of the ECG as well as serum potassium, magnesium, and calcium levels.  Given vandetanib's half-life of 19 days, ECGs and serum electrolytes should typically be obtained at baseline, at 2 to 4 weeks and 8 to 12 weeks after starting treatment, and every 3 months thereafter.  Vandetanib should not be started if baseline QTcF is greater than 450 ms, and treatment should be interrupted if QTcF is greater than 500 ms.  Treatment may resume when QTcF returns to less than 450 ms, but at a reduced dosage.  In addition, hypokalemia, hypomagnesemia, and/or hypocalcemia must be corrected prior to vandetanib administration.  Since diarrhea is a common side effect of vandetanib and may cause electrolyte imbalances, ECG and electrolyte levels should also be monitored more frequently when diarrhea develops.  Vandetanib treatment should be stopped in the presence of severe diarrhea.  Treatment may resume when diarrhea improves, but at a reduced dosage.  Following any dosage reduction, or any interruption of treatment greater than 2 weeks, QT assessment and serum electrolytes should be conducted as described previously.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.  Because of the drug's long half-life, adverse reactions including a prolonged QT interval may not resolve quickly, thus appropriate monitoring is necessary.", "mechanism_text": "Synergism", "recommendation": "Coadministration of vandetanib with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293530/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Vandetanib (vandetanib).\" Astra-Zeneca Pharmaceuticals  (2011):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More", "alternatives_b": "Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248322, "ingredient1": "Vardenafil", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293531/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248323, "ingredient1": "Vasopressin", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293532/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248324, "ingredient1": "Vemurafenib", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293533/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248325, "ingredient1": "Vemurafenib", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.  Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293534/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More", "alternatives_b": "Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248326, "ingredient1": "Venlafaxine", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293535/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248327, "ingredient1": "Voriconazole", "ingredient2": "Artemether", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.  However, caution is advised due to increased risk of QT interval prolongation.  Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.  Patients should also be monitored for reduced effects or potential loss of efficacy of the concomitant drug(s), especially antiretroviral agents.", "mechanism_text": "Metabolism", "recommendation": "No dose adjustment of artemether-lumefantrine is necessary when administered in combination with potent CYP450 3A4 inhibitors such as azole antifungal agents, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293537/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248328, "ingredient1": "Voriconazole", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Artemether-lumefantrine may cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.  Caution is recommended when these drugs are used following treatment with artemether-lumefantrine due to the long elimination half-life of lumefantrine (3 to 6 days).  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of artemether-lumefantrine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293538/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Coartem (artemether-lumefantrine).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248329, "ingredient1": "Voxelotor", "ingredient2": "Artemether", "severity": "Moderate", "effect": "Coadministration with voxelotor may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  The mechanism is reduced clearance due to inhibition of CYP450 3A4 by voxelotor.  The interaction may be significant for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index.", "source": "DDInter", "management_text": "Caution is advised when voxelotor is used concomitantly with drugs that undergo metabolism by CYP450 3A4.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever voxelotor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when voxelotor is used concomitantly with drugs that undergo metabolism by CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293539/", "reference_text": "[1] \"Product Information. Oxbryta (voxelotor).\" Global Blood Therapeutics, Inc.  (2019):", "alternatives_a": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Pyrimethamine, Tafenoquine, Atovaquone, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248330, "ingredient1": "Ziprasidone", "ingredient2": "Lumefantrine", "severity": "Major", "effect": "Ziprasidone can cause dose-related prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of ziprasidone with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293540/", "reference_text": "[1] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[2] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001):  1774-82[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 248331, "ingredient1": "Diclofenac", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293542/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Fluocinolone acetonide, Fluorometholone, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248332, "ingredient1": "Diclofenac", "ingredient2": "Brentuximab vedotin", "severity": "Moderate", "effect": "Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293543/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Salicylic acid, Fluocinolone acetonide, Cortisone, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 248333, "ingredient1": "Dimethyl fumarate", "ingredient2": "Diclofenac", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293545/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Indomethacin, Fluocinolone acetonide, Fluorometholone, Ketorolac, Indomethacin, Fluocinolone acetonide, Piroxicam, Flurbiprofen, Fluorometholone, Bromfenac, Rabeprazole, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Siponimod, More", "updated_at": 1767369485}, {"id": 248334, "ingredient1": "Diroximel fumarate", "ingredient2": "Diclofenac", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293546/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Indomethacin, Fluocinolone acetonide, Fluorometholone, Ketorolac, Indomethacin, Fluocinolone acetonide, Piroxicam, Flurbiprofen, Fluorometholone, Bromfenac, Rabeprazole, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Siponimod, More", "updated_at": 1767369485}, {"id": 248335, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Diclofenac", "severity": "Major", "effect": "Coadministration of radiolabeled ibritumomab tiuxetan and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.", "source": "DDInter", "management_text": "Caution is advised if radiolabeled ibritumomab tiuxetan is used in combination with drugs that interfere with platelet function or coagulation.  Close clinical and laboratory observation for bleeding complications is recommended during and after treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if radiolabeled ibritumomab tiuxetan is used in combination with drugs that interfere with platelet function or coagulation.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293547/", "reference_text": "[1] \"Product Information. In-111 Zevalin (ibritumomab tiuxetan).\" IDEC Pharmaceuticals Corporation", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Salicylic acid, Fluocinolone acetonide, Cortisone, More", "alternatives_b": "Iodide I-131", "updated_at": 1767369485}, {"id": 248336, "ingredient1": "Diclofenac", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293548/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Indomethacin, Fluocinolone acetonide, Fluorometholone, Ketorolac, Indomethacin, Fluocinolone acetonide, Piroxicam, Flurbiprofen, Fluorometholone, Bromfenac, Rabeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248337, "ingredient1": "Diclofenac", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293551/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Indomethacin, Fluocinolone acetonide, Fluorometholone, Salicylic acid, Ketorolac, Indomethacin, Fluocinolone acetonide, Piroxicam, Flurbiprofen, Fluorometholone, Bromfenac, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 248338, "ingredient1": "Diclofenac", "ingredient2": "Tafasitamab", "severity": "Moderate", "effect": "Coadministration of tafasitamab with drugs that can affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextrans, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of bleeding.", "source": "DDInter", "management_text": "When possible, consideration should be given to withholding concomitant medications that may increase bleeding risk in patients treated with tafasitamab.  Close clinical and laboratory monitoring for bleeding complications is recommended if concomitant use is unavoidable.  Refer to the product labeling for guidance on frequency of laboratory monitoring and dose modifications or withholding recommendations for platelet counts below 50,000/mcL.  Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "When possible, consideration should be given to withholding concomitant medications that may increase bleeding risk in patients treated with tafasitamab.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293552/", "reference_text": "[1] \"Product Information. Monjuvi (tafasitamab).\" Morphosys US  (2020):[2] \"Product Information. Minjuvi (tafasitamab).\" Incyte Biosciences UK Ltd  (2022):[3] \"Product Information. Minjuvi (tafasitamab).\" Incyte Corporation  (2021):", "alternatives_a": "Fludrocortisone, Indomethacin, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Salicylic acid, Ketorolac, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 248339, "ingredient1": "Diclofenac", "ingredient2": "Upadacitinib", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293554/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Indomethacin, Fluocinolone acetonide, Fluorometholone, Ketorolac, Indomethacin, Fluocinolone acetonide, Piroxicam, Flurbiprofen, Fluorometholone, Bromfenac, Rabeprazole, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Siponimod, More", "updated_at": 1767369485}, {"id": 248340, "ingredient1": "Alfentanil", "ingredient2": "Articaine", "severity": "Minor", "effect": "Concomitant use of lidocaine theoretically may decrease the clearance and increase the elimination half-life of alfentanil.  The mechanism is thought to be inhibition of the cytochrome P-450 isoenzyme 3A3/4.", "source": "DDInter", "management_text": "If lidocaine is used in a patient who has been receiving alfentanil for an extended period of time, the patient should be monitored more closely for excessive alfentanil effects (i.e., central nervous system depression, respiratory depression).  Other amide-type local anesthetics may interact with alfentanil in a similar manner.", "mechanism_text": "Metabolism", "recommendation": "If lidocaine is used in a patient who has been receiving alfentanil for an extended period of time, the patient should be monitored more closely for excessive alfentanil effects (i.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293555/", "reference_text": "[1] Yun CH, Wood M, Wood AJ, Guengerich FP \"Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance.\" Anesthesiology 77 (1992):  467-74[2] Kharasch ED, Thummel KE \"Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance?\" Anesth Analg 76 (1993):  1033-9[3] Koehntop DE, Noormohamed SE, Fletcher CV \"Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation.\" Pharmacotherapy 14 (1994):  592-9", "alternatives_a": "Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Fentanyl, Desflurane, Sufentanil, Propofol, Enflurane, More", "alternatives_b": "Chloroprocaine, Tetracaine, Meloxicam, Procaine, Prilocaine", "updated_at": 1767369485}, {"id": 248341, "ingredient1": "Alprazolam", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293556/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248342, "ingredient1": "Aminosalicylic acid", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293557/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248343, "ingredient1": "Amiodarone", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Amide-type local anesthetics may have additive cardiac effects (e.g., bradycardia, chest pain, heart block, arrhythmias, ECG abnormalities, cardiac arrest) with class III antiarrhythmic agents.", "source": "DDInter", "management_text": "Patients treated with class III antiarrhythmic agents (e.g., amiodarone, dofetilide, ibutilide, sotalol) should be under close surveillance during administration of amide-type local anesthetics.  ECG monitoring should be considered.", "mechanism_text": "Synergism", "recommendation": "Patients treated with class III antiarrhythmic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293558/", "reference_text": "[1] Keidar S, Grenadier E, Palant A \"Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration.\" Am Heart J 104 (1982):  1384-5[2] \"Product Information. Naropin (ropivacaine).\" Astra-Zeneca Pharmaceuticals  (2001):", "alternatives_a": "Quinidine, Lidocaine, Dronedarone, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Moricizine", "alternatives_b": "Procaine, Chloroprocaine, Tetracaine", "updated_at": 1767369485}, {"id": 248344, "ingredient1": "Amyl Nitrite", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293559/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Promethazine, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248345, "ingredient1": "Oxybuprocaine (ophthalmic)", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293560/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Prilocaine, Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248346, "ingredient1": "Benzocaine (topical)", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293561/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248347, "ingredient1": "Bretylium", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Amide-type local anesthetics may have additive cardiac effects (e.g., bradycardia, chest pain, heart block, arrhythmias, ECG abnormalities, cardiac arrest) with class III antiarrhythmic agents.", "source": "DDInter", "management_text": "Patients treated with class III antiarrhythmic agents (e.g., amiodarone, dofetilide, ibutilide, sotalol) should be under close surveillance during administration of amide-type local anesthetics.  ECG monitoring should be considered.", "mechanism_text": "Synergism", "recommendation": "Patients treated with class III antiarrhythmic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293562/", "reference_text": "[1] Keidar S, Grenadier E, Palant A \"Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration.\" Am Heart J 104 (1982):  1384-5[2] \"Product Information. Naropin (ropivacaine).\" Astra-Zeneca Pharmaceuticals  (2001):", "alternatives_a": "Quinidine, Lidocaine, Dronedarone, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Moricizine", "alternatives_b": "Procaine, Chloroprocaine, Tetracaine, Meloxicam", "updated_at": 1767369485}, {"id": 248348, "ingredient1": "Bupivacaine", "ingredient2": "Articaine", "severity": "Major", "effect": "Additive toxicities may occur when bupivacaine is coadministered with other local anesthetics.  The potential for increased risk of systemic toxicities such as methemoglobinemia and central nervous system and cardiovascular adverse reactions should be recognized.", "source": "DDInter", "management_text": "Additional use of local anesthetics should generally be avoided within 96 hours following administration of bupivacaine.  If coadministration cannot be avoided, overall local anesthetic exposure through 72 hours must be considered in addition to monitoring for the development of methemoglobinemia as well as central nervous system and cardiovascular adverse reactions.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Early warning signs of central nervous system toxicity may include restlessness, anxiety, incoherent speech, dizziness, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, blurred vision, tremors, twitching, depression, and drowsiness.  Cardiovascular toxicity may include atrioventricular block, ventricular arrhythmias, cardiac arrest, and decreased cardiac output and arterial blood pressure due to depressed cardiac conductivity, excitability, and myocardial contractility.  Patients should have cardiovascular and respiratory vital signs and state of consciousness constantly monitored while under treatment.", "mechanism_text": "Synergism", "recommendation": "Additional use of local anesthetics should generally be avoided within 96 hours following administration of bupivacaine.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293563/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Lidocaine, Chloroprocaine, Levobupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Bupivacaine", "updated_at": 1767369485}, {"id": 248349, "ingredient1": "Bupivacaine (liposome)", "ingredient2": "Articaine", "severity": "Major", "effect": "Administration of bupivacaine liposome suspension together with other local anesthetics, either simultaneously in the same syringe or sequentially to the same site, may impact the pharmacokinetic and/or physicochemical properties of bupivacaine liposome.", "source": "DDInter", "management_text": "Bupivacaine liposome suspension should not be admixed with other, non-bupivacaine based local anesthetics.  It may be admixed with bupivacaine hydrochloride as long as the ratio of the milligram dose of bupivacaine HCl to bupivacaine liposome does not exceed 1:2.  Additional use of local anesthetics should generally be avoided within 96 hours following administration of bupivacaine liposome suspension.  According to the manufacturer, bupivacaine liposome may be locally administered after at least 20 minutes following the local administration of lidocaine.  However, there are no data to support administration of other local, non-bupivacaine based anesthetics prior to administration of bupivacaine liposome.  Because the toxic effects of these medications are additive, caution and close observation for development of methemoglobinemia as well as central nervous system and cardiovascular adverse reactions are advised during concomitant use.  Early warning signs of central nervous system toxicity may include restlessness, anxiety, incoherent speech, dizziness, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, blurred vision, tremors, twitching, depression, and drowsiness.  Cardiovascular toxicity include atrioventricular block, ventricular arrhythmias, cardiac arrest, and decreased cardiac output and arterial blood pressure due to depressed cardiac conductivity, excitability, and myocardial contractility.  Patients should have cardiovascular and respiratory vital signs and state of consciousness constantly monitored while under treatment.", "mechanism_text": "Others", "recommendation": "Bupivacaine liposome suspension should not be admixed with other, non-bupivacaine based local anesthetics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293564/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Exparel (BUPivacaine liposome).\" Pacira Pharmaceuticals Inc  (2011):[3] Kharitonov V \"A review of the compatibility of liposome bupivacaine with other drug products and commonly used implant materials.\" Postgrad Med 126 (2014):  129-38", "alternatives_a": "Lidocaine, Chloroprocaine, Levobupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248350, "ingredient1": "Chlordiazepoxide", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293565/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248351, "ingredient1": "Chloroquine", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293567/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Sulfadoxine", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248352, "ingredient1": "Clobazam", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293568/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248353, "ingredient1": "Clonazepam", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293569/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248354, "ingredient1": "Clorazepic acid", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293570/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248355, "ingredient1": "Cocaine (nasal)", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293571/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Prilocaine, Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248356, "ingredient1": "Cocaine (topical)", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293572/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Prilocaine, Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248357, "ingredient1": "Cyclophosphamide", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293573/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248358, "ingredient1": "Dapsone", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293574/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Methylprednisolone, Azelaic acid, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248359, "ingredient1": "Dapsone (topical)", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293575/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Methylprednisolone, Azelaic acid, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248360, "ingredient1": "Diazepam", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293576/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248361, "ingredient1": "Cinchocaine (topical)", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293577/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248362, "ingredient1": "Dofetilide", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Amide-type local anesthetics may have additive cardiac effects (e.g., bradycardia, chest pain, heart block, arrhythmias, ECG abnormalities, cardiac arrest) with class III antiarrhythmic agents.", "source": "DDInter", "management_text": "Patients treated with class III antiarrhythmic agents (e.g., amiodarone, dofetilide, ibutilide, sotalol) should be under close surveillance during administration of amide-type local anesthetics.  ECG monitoring should be considered.", "mechanism_text": "Synergism", "recommendation": "Patients treated with class III antiarrhythmic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293578/", "reference_text": "[1] Keidar S, Grenadier E, Palant A \"Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration.\" Am Heart J 104 (1982):  1384-5[2] \"Product Information. Naropin (ropivacaine).\" Astra-Zeneca Pharmaceuticals  (2001):", "alternatives_a": "Quinidine, Lidocaine, Dronedarone, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Moricizine", "alternatives_b": "Procaine, Chloroprocaine, Tetracaine, Meloxicam", "updated_at": 1767369485}, {"id": 248363, "ingredient1": "Estazolam", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293579/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248364, "ingredient1": "Flurazepam", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293580/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248365, "ingredient1": "Flutamide", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293581/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Enzalutamide, Relugolix, Bicalutamide, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248366, "ingredient1": "Halazepam", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293582/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "Etidocaine, Levobupivacaine, Meloxicam", "updated_at": 1767369485}, {"id": 248367, "ingredient1": "Hyaluronidase", "ingredient2": "Articaine", "severity": "Minor", "effect": "When hyaluronidase is added to a local anesthetic, the local anesthetic solution undergoes increased absorption, resulting in a shorter duration of action and possible increased frequency of systemic reactions.", "source": "DDInter", "management_text": "When hyaluronidase is added to a local anesthetic, the local anesthetic solution undergoes increased absorption, resulting in a shorter duration of action and possible increased frequency of systemic reactions.  The clinical significance is unknown.  It may be advisable to monitor the patient for altered anesthetic efficacy and side effects.", "mechanism_text": "Absorption", "recommendation": "When hyaluronidase is added to a local anesthetic, the local anesthetic solution undergoes increased absorption, resulting in a shorter duration of action and possible increased frequency of systemic reactions.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293583/", "reference_text": "[1] \"Product Information. Vitrase (hyaluronidase).\" Bausch and Lomb Americas, Inc.  (2004):", "alternatives_a": "Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Streptokinase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248368, "ingredient1": "Hydroxyurea", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293584/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248369, "ingredient1": "Ibutilide", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Amide-type local anesthetics may have additive cardiac effects (e.g., bradycardia, chest pain, heart block, arrhythmias, ECG abnormalities, cardiac arrest) with class III antiarrhythmic agents.", "source": "DDInter", "management_text": "Patients treated with class III antiarrhythmic agents (e.g., amiodarone, dofetilide, ibutilide, sotalol) should be under close surveillance during administration of amide-type local anesthetics.  ECG monitoring should be considered.", "mechanism_text": "Synergism", "recommendation": "Patients treated with class III antiarrhythmic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293585/", "reference_text": "[1] Keidar S, Grenadier E, Palant A \"Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration.\" Am Heart J 104 (1982):  1384-5[2] \"Product Information. Naropin (ropivacaine).\" Astra-Zeneca Pharmaceuticals  (2001):", "alternatives_a": "Quinidine, Lidocaine, Dronedarone, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Moricizine", "alternatives_b": "Procaine, Chloroprocaine, Tetracaine, Meloxicam", "updated_at": 1767369485}, {"id": 248370, "ingredient1": "Ifosfamide", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293586/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More", "alternatives_b": "Etidocaine, Levobupivacaine, Meloxicam", "updated_at": 1767369485}, {"id": 248371, "ingredient1": "Isosorbide", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293587/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Etidocaine, Levobupivacaine, Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248372, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293588/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248373, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293589/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Nesiritide, Vericiguat", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248374, "ingredient1": "Articaine", "ingredient2": "Lidocaine (ophthalmic)", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293590/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Lidocaine, Procaine, Tetracaine, Lidocaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, More", "alternatives_b": "Prilocaine, Meloxicam", "updated_at": 1767369485}, {"id": 248375, "ingredient1": "Articaine", "ingredient2": "Lidocaine (topical)", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293591/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Lidocaine, Procaine, Tetracaine, Lidocaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248376, "ingredient1": "Articaine", "ingredient2": "Lorazepam", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293592/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248377, "ingredient1": "Articaine", "ingredient2": "Meperidine", "severity": "Minor", "effect": "One in vitro study has suggested that meperidine may displace bupivacaine from plasma protein-binding sites.  Theoretically, the risk of toxicity from the local anesthetic could be increased.", "source": "DDInter", "management_text": "For insurance purposes, we do not recommend the concomitant use of Meperidine and bupivacaine in clinical care because anesthetic-induced toxicity is often fatal.", "mechanism_text": "Distribution", "recommendation": "For insurance purposes, we do not recommend the concomitant use of Meperidine and bupivacaine in clinical care because anesthetic-induced toxicity is often fatal.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293593/", "reference_text": "[1] Ghoneim MM, Pandya H \"Plasma protein binding of bupivacaine and its interaction with other drugs in man.\" Br J Anaesth 46 (1974):  435-8", "alternatives_a": "Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Butorphanol, Fentanyl, Ibuprofen, Codeine, More", "alternatives_b": "Ropivacaine, Chloroprocaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Etidocaine", "updated_at": 1767369485}, {"id": 248378, "ingredient1": "Articaine", "ingredient2": "Metoclopramide", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293594/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Cisapride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248379, "ingredient1": "Articaine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293595/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248380, "ingredient1": "Morphine", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Concomitant epidural administration of local anesthetics may affect the release of morphine sulfate from the liposomal formulation.  The mechanism of interaction is unknown.", "source": "DDInter", "management_text": "To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.5%-1:200,000, 3 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 15 minutes after the test dose before administering the morphine.  Following administration of an analgesic dose of bupivacaine (0.25%, 20 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 30 minutes before administering the morphine.  Liposomal morphine should not be mixed with any other medications.  Once it has been administered, no other medication should be administered into the epidural space for at least 48 hours.", "mechanism_text": "Absorption", "recommendation": "To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293596/", "reference_text": "[1] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):", "alternatives_a": "Diphenoxylate, Opium, Eluxadoline, Difenoxin, Loperamide, Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, More", "alternatives_b": "Procaine, Chloroprocaine, Tetracaine", "updated_at": 1767369485}, {"id": 248381, "ingredient1": "Nitric Oxide", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293597/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Doxapram, Ivacaftor, Elexacaftor, Lumacaftor", "alternatives_b": "Etidocaine, Levobupivacaine, Meloxicam", "updated_at": 1767369485}, {"id": 248382, "ingredient1": "Nitrofurantoin", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293598/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248383, "ingredient1": "Nitroglycerin", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293599/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248384, "ingredient1": "Nitroprusside", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293600/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Meloxicam", "alternatives_b": "Minoxidil, Diazoxide, Hydralazine", "updated_at": 1767369485}, {"id": 248385, "ingredient1": "Nitrous oxide", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293601/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Fentanyl, Desflurane, Sufentanil, Propofol, Enflurane, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248386, "ingredient1": "Oxazepam", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293602/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248387, "ingredient1": "Phenazopyridine", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293603/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248388, "ingredient1": "Phenobarbital", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293604/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248389, "ingredient1": "Phenytoin", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293605/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248390, "ingredient1": "Primaquine", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293606/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Sulfadoxine", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248391, "ingredient1": "Proparacaine (ophthalmic)", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293608/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Prilocaine, Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248392, "ingredient1": "Quazepam", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293609/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248393, "ingredient1": "Quinine", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293610/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248394, "ingredient1": "Rasburicase", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293611/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Promethazine, More", "alternatives_b": "Etidocaine, Levobupivacaine, Meloxicam", "updated_at": 1767369485}, {"id": 248395, "ingredient1": "Remimazolam", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293612/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248396, "ingredient1": "Silver nitrate (topical)", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293614/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Etidocaine, Levobupivacaine, Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248397, "ingredient1": "Silver sulfadiazine (topical)", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293615/", "reference_text": "[1] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT \"Acquired methemoglobinemia.\" West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M \"Severe methemoglobinaemia due to benzocaine-containing 'burn cream': two case reports in an adult and in a child.\" Burns 37 (2011):  e63-6[4] Gala HC, Madave A \"An unusual case of neonatal methemoglobinemia.\" Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a \"Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center's four-year experience.\" J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R \"Topical antimicrobial agents for pediatric burns.\" Burns Trauma 5 (2017):  33", "alternatives_a": "Etidocaine, Levobupivacaine, Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248398, "ingredient1": "Nitrous acid", "ingredient2": "Articaine", "severity": "Major", "effect": "Sodium nitrite can cause methemoglobin formation, which diminishes oxygen-carrying capacity of the blood.  Coadministration with other agents that are also associated with methemoglobinemia including local anesthetics (e.g., benzocaine, lidocaine, prilocaine), antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide (primarily in infants), nitrofurantoin (primarily in infants), phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Sodium nitrite should be used with caution in the presence of other methemoglobin-inducing drugs.  Patients should be closely monitored to ensure adequate perfusion and oxygenation during treatment with sodium nitrite.  Methemoglobin levels should be monitored and oxygen administered whenever possible.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, and shock.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10%.  If patient does not respond to administration of oxygen, clinically significant methemoglobinemia should be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 minutes.", "mechanism_text": "Synergism", "recommendation": "Sodium nitrite should be used with caution in the presence of other methemoglobin-inducing drugs.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293616/", "reference_text": "[1] Coleman MD, Coleman NA \"Drug-induced methaemoglobinaemia: treatment issues.\" Drug Saf 14 (1996):  394-405[2] \"Product Information. Sodium Nitrite (sodium nitrite).\" Hope Pharmaceuticals  (2012):[3] Rehman HU \"Methemoglobinemia.\" West J Med 175 (2001):  193-6", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Promethazine, More", "alternatives_b": "Ropivacaine, Levobupivacaine, Bupivacaine, Mepivacaine, Meloxicam, Etidocaine", "updated_at": 1767369485}, {"id": 248399, "ingredient1": "Sotalol", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Amide-type local anesthetics may have additive cardiac effects (e.g., bradycardia, chest pain, heart block, arrhythmias, ECG abnormalities, cardiac arrest) with class III antiarrhythmic agents.", "source": "DDInter", "management_text": "Patients treated with class III antiarrhythmic agents (e.g., amiodarone, dofetilide, ibutilide, sotalol) should be under close surveillance during administration of amide-type local anesthetics.  ECG monitoring should be considered.", "mechanism_text": "Synergism", "recommendation": "Patients treated with class III antiarrhythmic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293617/", "reference_text": "[1] Keidar S, Grenadier E, Palant A \"Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration.\" Am Heart J 104 (1982):  1384-5[2] \"Product Information. Naropin (ropivacaine).\" Astra-Zeneca Pharmaceuticals  (2001):", "alternatives_a": "Acebutolol, Labetalol, Nadolol, Propranolol, Metoprolol, Carvedilol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, More", "alternatives_b": "Procaine, Chloroprocaine, Tetracaine", "updated_at": 1767369485}, {"id": 248400, "ingredient1": "Sulfadiazine", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293618/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248401, "ingredient1": "Sulfamethizole", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293619/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Sorbitol, Sodium citrate, Magnesium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Tamsulosin, Tinidazole, Ascorbic acid, More", "alternatives_b": "Etidocaine, Levobupivacaine, Meloxicam", "updated_at": 1767369485}, {"id": 248402, "ingredient1": "Sulfamethoxazole", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293620/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248403, "ingredient1": "Sulfasalazine", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293621/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248404, "ingredient1": "Sulfisoxazole", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293622/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248405, "ingredient1": "Tafenoquine", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293623/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Sulfadoxine", "alternatives_b": "Etidocaine, Levobupivacaine, Meloxicam", "updated_at": 1767369485}, {"id": 248406, "ingredient1": "Temazepam", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293624/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248407, "ingredient1": "Tetracaine (ophthalmic)", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293625/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More", "alternatives_b": "Prilocaine, Meloxicam", "updated_at": 1767369485}, {"id": 248408, "ingredient1": "Tetracaine (topical)", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293626/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More", "alternatives_b": "Meloxicam", "updated_at": 1767369485}, {"id": 248409, "ingredient1": "Tilmanocept", "ingredient2": "Articaine", "severity": "Moderate", "effect": "Locally injected anesthetics have been reported to reduce lymphatic flow of Technetium Tc 99m tilmanocept in animal studies.", "source": "DDInter", "management_text": "Co-injection (mixture) of local anesthetics with Technetium Tc 99m tilmanocept is not recommended due to potential impairment of lymph nodal mapping.", "mechanism_text": "Others", "recommendation": "Co-injection (mixture) of local anesthetics with Technetium Tc 99m tilmanocept is not recommended due to potential impairment of lymph nodal mapping.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293627/", "reference_text": "[1] \"Product Information. Lymphoseek (tilmanocept).\" Navidea Biopharmaceuticals, Dublin, OH.", "alternatives_a": "Etidocaine, Levobupivacaine, Meloxicam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248410, "ingredient1": "Triazolam", "ingredient2": "Articaine", "severity": "Moderate", "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects.  Both types of drugs are CNS depressants.", "source": "DDInter", "management_text": "Caution is advised during concurrent use.  Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects.  Dosage adjustments may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293628/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248411, "ingredient1": "Trimethoprim", "ingredient2": "Articaine", "severity": "Major", "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293629/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Marcaine HCl (bupivacaine).\" Hospira Inc  (2008):[3] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[5] \"Product Information. Zynrelef (bupivacaine-meloxicam).\" Heron Therapeutics  (2021):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248412, "ingredient1": "Anisindione", "ingredient2": "Ascorbic acid", "severity": "Minor", "effect": "The use of ascorbic acid has been implicated in causing warfarin resistance.", "source": "DDInter", "management_text": "When ascorbic acid and warfarin are used concomitantly, we recommend close monitoring of the patient's INR and timely adjustment of warfarin dosage according to the INR to ensure the effectiveness of anticoagulation.", "mechanism_text": "Antagonism", "recommendation": "When ascorbic acid and warfarin are used concomitantly, we recommend close monitoring of the patient's INR and timely adjustment of warfarin dosage according to the INR to ensure the effectiveness of anticoagulation.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293631/", "reference_text": "[1] Feetam CL, Leach RH, Meynell MJ \"Lack of a clinically important interaction between warfarin and ascorbic acid.\" Toxicol Appl Pharmacol 31 (1975):  544-7[2] Rosenthal G \"Interaction of ascorbic acid and warfarin.\" JAMA 215 (1971):  1671[3] Hume R, Johnstone JM, Weyers E \"Interaction of ascorbic acid and warfarin.\" JAMA 219 (1972):  1479[4] Smith EC, Skalski RJ, Johnson GC, Rossi GV \"Interaction of ascorbic acid and warfarin.\" JAMA 221 (1972):  1166[5] Weintraub M, Griner PF \"Warfarin and ascorbic acid: lack of evidence for a drug interaction.\" Toxicol Appl Pharmacol 28 (1974):  53-6", "alternatives_a": "Tamsulosin, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Vemurafenib, Probenecid, Tioconazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248413, "ingredient1": "Dicoumarol", "ingredient2": "Ascorbic acid", "severity": "Minor", "effect": "The use of ascorbic acid has been implicated in causing warfarin resistance.", "source": "DDInter", "management_text": "When ascorbic acid and warfarin are used concomitantly, we recommend close monitoring of the patient's INR and timely adjustment of warfarin dosage according to the INR to ensure the effectiveness of anticoagulation.", "mechanism_text": "Antagonism", "recommendation": "When ascorbic acid and warfarin are used concomitantly, we recommend close monitoring of the patient's INR and timely adjustment of warfarin dosage according to the INR to ensure the effectiveness of anticoagulation.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293632/", "reference_text": "[1] Feetam CL, Leach RH, Meynell MJ \"Lack of a clinically important interaction between warfarin and ascorbic acid.\" Toxicol Appl Pharmacol 31 (1975):  544-7[2] Rosenthal G \"Interaction of ascorbic acid and warfarin.\" JAMA 215 (1971):  1671[3] Hume R, Johnstone JM, Weyers E \"Interaction of ascorbic acid and warfarin.\" JAMA 219 (1972):  1479[4] Smith EC, Skalski RJ, Johnson GC, Rossi GV \"Interaction of ascorbic acid and warfarin.\" JAMA 221 (1972):  1166[5] Weintraub M, Griner PF \"Warfarin and ascorbic acid: lack of evidence for a drug interaction.\" Toxicol Appl Pharmacol 28 (1974):  53-6", "alternatives_a": "Tamsulosin, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, Vemurafenib, Probenecid, Tioconazole, More", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "updated_at": 1767369485}, {"id": 248414, "ingredient1": "Iron", "ingredient2": "St. John's Wort", "severity": "Minor", "effect": "The tannic acid present in some herbs like St. John's wort and saw palmetto may inhibit the absorption of iron.", "source": "DDInter", "management_text": "The administration of these herbs and iron-containing supplements should be separated by several hours.", "mechanism_text": "Absorption", "recommendation": "The administration of these herbs and iron-containing supplements should be separated by several hours.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293635/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "updated_at": 1767369485}, {"id": 248415, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293636/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Biperiden, Trihexyphenidyl, Benzatropine, Procyclidine", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248416, "ingredient1": "Bendroflumethiazide", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293637/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Trichlormethiazide, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Chlorzoxazone, Cyclobenzaprine, Chlormezanone", "updated_at": 1767369485}, {"id": 248417, "ingredient1": "Benzthiazide", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293638/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, More", "alternatives_b": "Chlorzoxazone, Cyclobenzaprine, Chlormezanone", "updated_at": 1767369485}, {"id": 248418, "ingredient1": "Chlorothiazide", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293640/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Chlorzoxazone, Chlormezanone", "updated_at": 1767369485}, {"id": 248419, "ingredient1": "Chlorthalidone", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293641/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248420, "ingredient1": "Felodipine", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293642/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Ivabradine", "alternatives_b": "Chlorzoxazone, Chlormezanone, Biperiden, Trihexyphenidyl, Benzatropine, Procyclidine", "updated_at": 1767369485}, {"id": 248421, "ingredient1": "Glycopyrronium (topical)", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293643/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "Carisoprodol, Chlorzoxazone, Tizanidine, Baclofen, Methocarbamol, Chlormezanone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248422, "ingredient1": "Diamorphine", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293644/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlormezanone", "alternatives_b": "Acamprosate, Naltrexone, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 248423, "ingredient1": "Hydroflumethiazide", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293645/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Chlorzoxazone, Cyclobenzaprine, Chlormezanone", "updated_at": 1767369485}, {"id": 248424, "ingredient1": "Indapamide", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293646/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, Ciclopirox, More", "alternatives_b": "Chlorzoxazone, Cyclobenzaprine, Chlormezanone", "updated_at": 1767369485}, {"id": 248425, "ingredient1": "Isradipine", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293647/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlorzoxazone, Chlormezanone, Biperiden, Trihexyphenidyl, Benzatropine, Procyclidine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248426, "ingredient1": "Orphenadrine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293648/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More", "alternatives_b": "Chlorzoxazone, Chlormezanone", "updated_at": 1767369485}, {"id": 248427, "ingredient1": "Orphenadrine", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293649/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlorzoxazone, Cyclobenzaprine, Chlormezanone, Biperiden, Trihexyphenidyl, Benzatropine, Procyclidine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248428, "ingredient1": "Orphenadrine", "ingredient2": "Nifedipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293650/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Ivabradine", "alternatives_b": "Chlorzoxazone, Chlormezanone, Biperiden, Procyclidine, Benzatropine", "updated_at": 1767369485}, {"id": 248429, "ingredient1": "Orphenadrine", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293651/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlorzoxazone, Chlormezanone, Biperiden, Trihexyphenidyl, Benzatropine, Procyclidine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248430, "ingredient1": "Orphenadrine", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293652/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlorzoxazone, Cyclobenzaprine, Chlormezanone, Biperiden, Trihexyphenidyl, Benzatropine, Procyclidine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248431, "ingredient1": "Polythiazide", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293653/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlorzoxazone, Cyclobenzaprine, Chlormezanone", "alternatives_b": "Trichlormethiazide, Methyclothiazide, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "updated_at": 1767369485}, {"id": 248432, "ingredient1": "St. John's Wort", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293654/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Biperiden, Trihexyphenidyl, Procyclidine", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 248433, "ingredient1": "Carisoprodol", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293655/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248434, "ingredient1": "Diamorphine", "ingredient2": "Carisoprodol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293656/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlormezanone", "alternatives_b": "Nalmefene, Disulfiram, Acamprosate, Naltrexone", "updated_at": 1767369485}, {"id": 248435, "ingredient1": "Isradipine", "ingredient2": "Carisoprodol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293657/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlorzoxazone, Chlormezanone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248436, "ingredient1": "Carisoprodol", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293658/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlorzoxazone, Cyclobenzaprine, Chlormezanone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248437, "ingredient1": "Carisoprodol", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293659/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlorzoxazone, Chlormezanone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248438, "ingredient1": "Carisoprodol", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293660/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlorzoxazone, Cyclobenzaprine, Chlormezanone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248439, "ingredient1": "Carisoprodol", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293661/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248440, "ingredient1": "Brentuximab vedotin", "ingredient2": "Atazanavir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of brentuximab vedotin.", "source": "DDInter", "management_text": "Caution is advised when brentuximab vedotin is used concomitantly with potent CYP450 3A4 inhibitors.  Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, hepatotoxicity, pulmonary toxicity and hyperglycemia is recommended, and the dosing of brentuximab vedotin adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when brentuximab vedotin is used concomitantly with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293674/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):[3] Han TH, Gopal AK, Ramchandren R, et al. \"CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.\" J Clin Pharmacol 53 (2013):  866-77", "alternatives_a": "Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 248441, "ingredient1": "Cobicistat", "ingredient2": "Brentuximab vedotin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of brentuximab vedotin.", "source": "DDInter", "management_text": "Caution is advised when brentuximab vedotin is used concomitantly with potent CYP450 3A4 inhibitors.  Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, hepatotoxicity, pulmonary toxicity and hyperglycemia is recommended, and the dosing of brentuximab vedotin adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when brentuximab vedotin is used concomitantly with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293675/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):[3] Han TH, Gopal AK, Ramchandren R, et al. \"CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.\" J Clin Pharmacol 53 (2013):  866-77", "alternatives_a": "Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 248442, "ingredient1": "Somapacitan", "ingredient2": "Atazanavir", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.  Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended.  Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293680/", "reference_text": "[1] \"Product Information. Invirase (saquinavir).\" Roche Laboratories  (2001):[2] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[3] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[4] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997):  87,90[5] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997):  194-209[6] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[7] Acosta EP, Henry K, Baken L, Page LM, Fletcher CV \"Indinavir concentrations and antiviral effect.\" Pharmacotherapy 19 (1999):  708-12[8] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999):  s29-40[9] Hugen PWH, Burger DM, Brinkman K, terHofstede HJM, Schuurman R, Koopmans PP, Hekster YA \"Carbamazepine-indinavir interaction causes antiretroviral therapy failure.\" Ann Pharmacother 34 (2000):  465-70[10] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000):  1333-9[11] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[12] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[13] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[14] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004):  482-9[15] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim  (2005):[16] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[17] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 248443, "ingredient1": "Cobicistat", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with moderate or weak inducers of CYP450 3A4 may reduce the plasma concentrations of cobicistat, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of antiretroviral regimens containing cobicistat with these inducers should be avoided.  Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.  If concomitant use is required, close clinical and laboratory monitoring of antiretroviral response is recommended.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of antiretroviral regimens containing cobicistat with these inducers should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293681/", "reference_text": "[1] Smith DS, Fujimoto JM \"Alterations produced by novobiocin during biliary excretion of morphine, morphine-3-glucuronide and other compounds.\" J Pharmacol Exp Ther 188 (1974):  504-15[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[4] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Tybost (cobicistat).\" Gilead Sciences  (2014):[7] \"Product Information. Genvoya (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences  (2015):", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 248444, "ingredient1": "St. John's Wort", "ingredient2": "Atazanavir", "severity": "Major", "effect": "Coadministration with St. John's wort may significantly reduce the plasma concentrations of HIV protease inhibitors and result in a potential loss of virologic response.  The mechanism is induction of CYP450 3A4 metabolism by constituents of St. John's wort.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of HIV protease inhibitors with St. John's wort is considered contraindicated.  The enzyme induction may last for up to 2 weeks after the last dose of St. John's wort.  Patients should be advised to consult with their caregivers before using any herbal or alternative medicines.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of HIV protease inhibitors with St.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293682/", "reference_text": "[1] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, More", "alternatives_b": "Phenelzine, Desipramine, Tranylcypromine, Desvenlafaxine, Maprotiline, Fluoxetine, Isocarboxazid, Oxitriptan, Milnacipran, Vortioxetine, Nortriptyline, More", "updated_at": 1767369485}, {"id": 248445, "ingredient1": "Cobicistat", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cobicistat, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of antiretroviral regimens containing cobicistat with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of antiretroviral regimens containing cobicistat with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293683/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[5] \"Product Information. Tybost (cobicistat).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Bupropion, Esketamine", "updated_at": 1767369485}, {"id": 248446, "ingredient1": "Telotristat ethyl", "ingredient2": "Atazanavir", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes.  The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293685/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc.  (2017):", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Cobicistat, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248447, "ingredient1": "Amobarbital", "ingredient2": "Atenolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293688/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Pentobarbital, Melatonin, Valerian", "alternatives_b": "Pindolol, Pindolol, Betaxolol, Carteolol, Sotalol, Acetylsalicylic acid, Sotalol, Sotalol", "updated_at": 1767369485}, {"id": 248448, "ingredient1": "Amobarbital", "ingredient2": "Chlorthalidone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293689/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Estazolam, Tasimelteon, Melatonin, Primidone, Valerian", "alternatives_b": "Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "updated_at": 1767369485}, {"id": 248449, "ingredient1": "Chlorthalidone", "ingredient2": "Chlorphenesin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293690/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, Flucytosine, More", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 248450, "ingredient1": "Chlorzoxazone", "ingredient2": "Chlorthalidone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293691/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248451, "ingredient1": "Dimethyl fumarate", "ingredient2": "Chlorthalidone", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293692/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 248452, "ingredient1": "Diroximel fumarate", "ingredient2": "Chlorthalidone", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293693/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 248453, "ingredient1": "Eravacycline", "ingredient2": "Chlorthalidone", "severity": "Minor", "effect": "The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN).", "source": "DDInter", "management_text": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.  If renal function deteriorates, discontinuation of one or both agents may be necessary.", "mechanism_text": "Synergism", "recommendation": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293694/", "reference_text": "[1] Jick H, Slone D, Shapiro S, et al. \"Tetracycline and drug-attributed rises in blood urea nitrogen: a report from the Boston Collaborative Drug Surveillance Program.\" JAMA 220 (1972):  377-9[2] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980):  203-7[3] Tannenberg AM \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713[4] Alexander MR \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713-4", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Sarecycline", "updated_at": 1767369485}, {"id": 248454, "ingredient1": "Gadoxetic acid", "ingredient2": "Atenolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293695/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Ferumoxsil", "updated_at": 1767369485}, {"id": 248455, "ingredient1": "Diamorphine", "ingredient2": "Atenolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293696/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Carteolol, Acetylsalicylic acid, Ivabradine", "alternatives_b": "Acamprosate, Naltrexone, Disulfiram, Levacetylmethadol, Nalmefene", "updated_at": 1767369485}, {"id": 248456, "ingredient1": "Diamorphine", "ingredient2": "Chlorthalidone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293697/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 248457, "ingredient1": "Atenolol", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293698/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Pindolol, Acebutolol, Betaxolol, Pindolol, Sotalol, Felodipine, Ivabradine, Sotalol, Acebutolol, Sotalol", "alternatives_b": "Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Pentobarbital, Melatonin, Valerian", "updated_at": 1767369485}, {"id": 248458, "ingredient1": "Chlorthalidone", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293699/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248459, "ingredient1": "Chlorthalidone", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293700/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Ciclopirox, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 248460, "ingredient1": "Chlorthalidone", "ingredient2": "Omadacycline", "severity": "Minor", "effect": "The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN).", "source": "DDInter", "management_text": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.  If renal function deteriorates, discontinuation of one or both agents may be necessary.", "mechanism_text": "Synergism", "recommendation": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293701/", "reference_text": "[1] Jick H, Slone D, Shapiro S, et al. \"Tetracycline and drug-attributed rises in blood urea nitrogen: a report from the Boston Collaborative Drug Surveillance Program.\" JAMA 220 (1972):  377-9[2] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980):  203-7[3] Tannenberg AM \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713[4] Alexander MR \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713-4", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Sarecycline", "updated_at": 1767369485}, {"id": 248461, "ingredient1": "Chlorthalidone", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293703/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 248462, "ingredient1": "Remifentanil", "ingredient2": "Atenolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293704/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Pindolol, Penbutolol, Acebutolol, Carvedilol, Esmolol, Betaxolol, Penbutolol, Carteolol, Sotalol, Pindolol, Felodipine, More", "alternatives_b": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 248463, "ingredient1": "Chlorthalidone", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293705/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 248464, "ingredient1": "Chlorthalidone", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293706/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 248465, "ingredient1": "Chlorthalidone", "ingredient2": "Tigecycline", "severity": "Minor", "effect": "The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN).", "source": "DDInter", "management_text": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.  If renal function deteriorates, discontinuation of one or both agents may be necessary.", "mechanism_text": "Synergism", "recommendation": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293708/", "reference_text": "[1] Jick H, Slone D, Shapiro S, et al. \"Tetracycline and drug-attributed rises in blood urea nitrogen: a report from the Boston Collaborative Drug Surveillance Program.\" JAMA 220 (1972):  377-9[2] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980):  203-7[3] Tannenberg AM \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713[4] Alexander MR \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713-4", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Sarecycline", "updated_at": 1767369485}, {"id": 248466, "ingredient1": "Chlorthalidone", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293709/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Tioconazole, More", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Estazolam, Tasimelteon, Melatonin, Primidone, Valerian", "updated_at": 1767369485}, {"id": 248467, "ingredient1": "Brentuximab vedotin", "ingredient2": "Atovaquone", "severity": "Moderate", "effect": "Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293713/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Furazolidone, Quinacrine, Nitazoxanide, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Halofantrine, Primaquine, Proguanil", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 248468, "ingredient1": "Atovaquone", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Use of hepatotoxic drugs together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.  Patients treated with levoketoconazole or ketoconazole should have liver tests performed prior to and during treatment.  Levoketoconazole manufacturer recommends interrupting treatment immediately if signs of hepatotoxicity occur.  Refer to levoketoconazole labeling for specific instructions on management of hepatotoxicity.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293714/", "reference_text": "[1] \"Product Information. Ketoconazole (ketoconazole).\" Mylan Pharmaceuticals Inc  (2019):[2] \"Product Information. Recorlev (levoketoconazole).\" Xeris Pharmaceuticals Inc  (2022):[3] Auchus R, Pivonello R, Fleseriu M, et al. \"Levoketoconazole: a novel treatment for endogenous Cushing's syndrome.  https://www.tandfonline.com/doi/pdf/10.1080/17446651.2021.1945440\"   (2022):", "alternatives_a": "Tinidazole, Quinacrine, Secnidazole, Furazolidone, Nitazoxanide, Pyrimethamine, Artesunate, Tafenoquine, Proguanil", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 248469, "ingredient1": "Efavirenz", "ingredient2": "Brentuximab vedotin", "severity": "Moderate", "effect": "Coadministration of efavirenz with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when efavirenz is used in combination with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; other HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Monitoring of liver function tests should occur before and during treatment, especially in patients with underlying hepatic disease (including hepatitis B or C coinfection) or marked transaminase elevations.  The benefit of continued therapy with efavirenz should be considered against the unknown risks of significant liver toxicity in patients who develop persistent elevations of serum transaminases greater than five times the upper limit of normal.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when efavirenz is used in combination with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293715/", "reference_text": "[1] \"Product Information. Sustiva (efavirenz).\" DuPont Pharmaceuticals  (2001):[2] Elsharkawy AM, Schwab U, McCarron B, et al. \"Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser.\" J Clin Virol 58 (2013):  331-3", "alternatives_a": "Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 248470, "ingredient1": "Gemtuzumab ozogamicin", "ingredient2": "Efavirenz", "severity": "Moderate", "effect": "Coadministration of efavirenz with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when efavirenz is used in combination with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; other HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Monitoring of liver function tests should occur before and during treatment, especially in patients with underlying hepatic disease (including hepatitis B or C coinfection) or marked transaminase elevations.  The benefit of continued therapy with efavirenz should be considered against the unknown risks of significant liver toxicity in patients who develop persistent elevations of serum transaminases greater than five times the upper limit of normal.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when efavirenz is used in combination with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293716/", "reference_text": "[1] \"Product Information. Sustiva (efavirenz).\" DuPont Pharmaceuticals  (2001):[2] Elsharkawy AM, Schwab U, McCarron B, et al. \"Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser.\" J Clin Virol 58 (2013):  331-3", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 248471, "ingredient1": "Efavirenz", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of efavirenz, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if efavirenz is prescribed in combination with CYP450 3A4 inducers.  Close clinical and laboratory monitoring of antiretroviral response is recommended.  Alternative treatment that do not affect efavirenz metabolism should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if efavirenz is prescribed in combination with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293719/", "reference_text": "[1] \"Product Information. Sustiva (efavirenz).\" DuPont Pharmaceuticals  (2001):[2] Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T \"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.\" Aids 15 (2001):  71-5", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 248472, "ingredient1": "Efavirenz", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Coadministration with St. John's wort may significantly reduce the plasma concentrations of certain antiretroviral agents such as nonnucleoside reverse transcriptase inhibitors (NNRTIs), and CCR5 coreceptor antagonists.  The mechanism is induction of CYP450 3A4 metabolism by constituents of St. John's wort.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, patients treated with antiretroviral agents should avoid using St. John's wort.  Patients should be advised to consult with their caregivers before using any herbal or alternative medicines.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, patients treated with antiretroviral agents should avoid using St.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293720/", "reference_text": "[1] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[2] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[3] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[4] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[5] Acosta EP, Henry K, Baken L, Page LM, Fletcher CV \"Indinavir concentrations and antiviral effect.\" Pharmacotherapy 19 (1999):  708-12[6] FDA \"FDA public health advisory on risk of drug interactions with St John's wort and indinavir and other drugs.  URL: http://www.fda.gov/cder/drug/advisory/sjwort.htm\"   (2001):[7] Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J \"Indinavir concentrations and St John's wort.\" Lancet 355 (2000):  547-8[8] Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH \"St John's Wort: Effect on CYP3A4 activity.\" Clin Pharmacol Ther 67 (2000):  451-7[9] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000):  1333-9[10] \"Product Information. Kaletra (lopinavir-ritonavir).\" Abbott Pharmaceutical  (2001):[11] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[12] de Maat MM, Hoetelmans RM, Mathot RA, et al. \"Drug interaction between St John's wort and nevirapine.\" AIDS 15 (2001):  420-1[13] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[14] Veldkamp AI, Weverling GJ, Lange JM, et al. \"High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.\" AIDS 15 (2001):  1089-95[15] Mangum EM, Graham KK \"Lopinavir-Ritonavir: a new protease inhibitor.\" Pharmacotherapy 21 (2001):  1352-63[16] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[17] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[18] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[19] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim  (2005):[20] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[21] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group  (2007):", "alternatives_a": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Tryptophan, Levomilnacipran, Esketamine", "updated_at": 1767369485}, {"id": 248473, "ingredient1": "Efavirenz", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes.  The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293722/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc.  (2017):", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Cobicistat, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248474, "ingredient1": "Diphenoxylate", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293725/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248475, "ingredient1": "Diphenoxylate", "ingredient2": "Alfentanil", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293726/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "Loperamide", "updated_at": 1767369485}, {"id": 248476, "ingredient1": "Diphenoxylate", "ingredient2": "Asenapine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293728/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248477, "ingredient1": "Diphenoxylate", "ingredient2": "Baclofen", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293729/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cyclobenzaprine, Methocarbamol, Chlormezanone", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248478, "ingredient1": "Diphenoxylate", "ingredient2": "Benzatropine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293730/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248479, "ingredient1": "Diphenoxylate", "ingredient2": "Biperiden", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293731/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248480, "ingredient1": "Diphenoxylate", "ingredient2": "Brexanolone", "severity": "Moderate", "effect": "Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.  Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring.  During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation.  After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate.  If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia.  Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.  Patients must be accompanied during interactions with their child(ren) while receiving brexanolone because of the potential for excessive sedation and sudden loss of consciousness.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293732/", "reference_text": "[1] \"Product Information. Zulresso (brexanolone).\" Sage Therapeutics, Inc.  (2019):", "alternatives_a": "Eluxadoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248481, "ingredient1": "Diphenoxylate", "ingredient2": "Brexpiprazole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293733/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248482, "ingredient1": "Diphenoxylate", "ingredient2": "Brimonidine (ophthalmic)", "severity": "Moderate", "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.  Additive hypotensive effects and orthostasis may also occur with some CNS depressants and other agents that have these effects, particularly during initial dosing and/or parenteral administration.", "source": "DDInter", "management_text": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293734/", "reference_text": "[1] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[2] \"Product Information. Alphagan (brimonidine ophthalmic).\" Allergan Inc  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Pekdemir M, Yanturali S, Karakus G \"More than just an ocular solution.\" Emerg Med J 22 (2005):  753-4[5] \"Product Information. Mirvaso (brimonidine topical).\" Galderma Laboratories Inc  (2013):", "alternatives_a": "Tacrolimus, Minoxidil, Deoxycholic acid, Magnesium sulfate, Glycopyrronium, Calcium gluconate, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248483, "ingredient1": "Diphenoxylate", "ingredient2": "Brimonidine (topical)", "severity": "Moderate", "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.  Additive hypotensive effects and orthostasis may also occur with some CNS depressants and other agents that have these effects, particularly during initial dosing and/or parenteral administration.", "source": "DDInter", "management_text": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293735/", "reference_text": "[1] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[2] \"Product Information. Alphagan (brimonidine ophthalmic).\" Allergan Inc  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Pekdemir M, Yanturali S, Karakus G \"More than just an ocular solution.\" Emerg Med J 22 (2005):  753-4[5] \"Product Information. Mirvaso (brimonidine topical).\" Galderma Laboratories Inc  (2013):", "alternatives_a": "Tacrolimus, Minoxidil, Deoxycholic acid, Magnesium sulfate, Glycopyrronium, Calcium gluconate, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248484, "ingredient1": "Diphenoxylate", "ingredient2": "Brivaracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293736/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248485, "ingredient1": "Diphenoxylate", "ingredient2": "Bromocriptine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293737/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Tolcapone, Amantadine, Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248486, "ingredient1": "Diphenoxylate", "ingredient2": "Brompheniramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293738/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 248487, "ingredient1": "Diphenoxylate", "ingredient2": "Buprenorphine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293739/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248488, "ingredient1": "Diphenoxylate", "ingredient2": "Butorphanol", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293740/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248489, "ingredient1": "Diphenoxylate", "ingredient2": "Cannabidiol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293741/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248490, "ingredient1": "Diphenoxylate", "ingredient2": "Carbamazepine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293743/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248491, "ingredient1": "Diphenoxylate", "ingredient2": "Pentoxyverine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293744/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Benzonatate", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248492, "ingredient1": "Diphenoxylate", "ingredient2": "Carbinoxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293745/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248493, "ingredient1": "Diphenoxylate", "ingredient2": "Cariprazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293746/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248494, "ingredient1": "Diphenoxylate", "ingredient2": "Carisoprodol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293747/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cyclobenzaprine, Methocarbamol, Chlormezanone", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248495, "ingredient1": "Diphenoxylate", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293748/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248496, "ingredient1": "Diphenoxylate", "ingredient2": "Cetirizine", "severity": "Moderate", "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293749/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Xyzal (levocetirizine).\" UCB Pharma Inc  (2007):", "alternatives_a": "Ketotifen, Olopatadine, Cromoglicic acid, Nedocromil, Phenylephrine, Azelastine, Brimonidine, Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248497, "ingredient1": "Diphenoxylate", "ingredient2": "Clofedanol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293750/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Benzonatate", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248498, "ingredient1": "Diphenoxylate", "ingredient2": "Chloral hydrate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293751/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248499, "ingredient1": "Diphenoxylate", "ingredient2": "Chlordiazepoxide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293752/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Meprobamate, Alprazolam, Diazepam, Lorazepam, Halazepam, Buspirone, Hydroxyzine, Oxazepam", "alternatives_b": "Loperamide, Eluxadoline, Difenoxin", "updated_at": 1767369485}, {"id": 248500, "ingredient1": "Diphenoxylate", "ingredient2": "Chlorphenesin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293753/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More", "alternatives_b": "Loperamide, Eluxadoline, Difenoxin", "updated_at": 1767369485}, {"id": 248501, "ingredient1": "Diphenoxylate", "ingredient2": "Chlorpheniramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293754/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248502, "ingredient1": "Diphenoxylate", "ingredient2": "Chlorzoxazone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293755/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cyclobenzaprine, Methocarbamol, Chlormezanone", "alternatives_b": "Loperamide, Eluxadoline, Difenoxin", "updated_at": 1767369485}, {"id": 248503, "ingredient1": "Diphenoxylate", "ingredient2": "Citalopram", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293756/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Viloxazine, Amoxapine, Imipramine, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248504, "ingredient1": "Diphenoxylate", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293757/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Tripelennamine, Doxepin, Promethazine, Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248505, "ingredient1": "Diphenoxylate", "ingredient2": "Clobazam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293758/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Meprobamate, Alprazolam, Diazepam, Lorazepam, Halazepam, Buspirone, Hydroxyzine, Oxazepam", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248506, "ingredient1": "Diphenoxylate", "ingredient2": "Clorazepic acid", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293759/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Meprobamate, Alprazolam, Diazepam, Lorazepam, Halazepam, Buspirone, Hydroxyzine, Oxazepam", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248507, "ingredient1": "Diphenoxylate", "ingredient2": "Clozapine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293760/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 248508, "ingredient1": "Diphenoxylate", "ingredient2": "Codeine", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293761/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone, Benzonatate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248509, "ingredient1": "Diphenoxylate", "ingredient2": "Cyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293762/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 248510, "ingredient1": "Diphenoxylate", "ingredient2": "Cyproheptadine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293763/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248511, "ingredient1": "Diphenoxylate", "ingredient2": "Dantrolene", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293764/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Loperamide, Eluxadoline, Difenoxin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248512, "ingredient1": "Diphenoxylate", "ingredient2": "Desvenlafaxine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293766/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Viloxazine, Amoxapine, Imipramine, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248513, "ingredient1": "Diphenoxylate", "ingredient2": "Deutetrabenazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293767/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248514, "ingredient1": "Diphenoxylate", "ingredient2": "Dexbrompheniramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293768/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248515, "ingredient1": "Diphenoxylate", "ingredient2": "Dexmedetomidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293769/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Loperamide, Eluxadoline, Difenoxin", "updated_at": 1767369485}, {"id": 248516, "ingredient1": "Diphenoxylate", "ingredient2": "Dextromethorphan", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293770/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Benzonatate, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248517, "ingredient1": "Diphenoxylate", "ingredient2": "Dezocine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293771/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "Loperamide", "updated_at": 1767369485}, {"id": 248518, "ingredient1": "Diphenoxylate", "ingredient2": "Dimenhydrinate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293773/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248519, "ingredient1": "Diphenoxylate", "ingredient2": "Diphenhydramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293774/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Tripelennamine, Doxepin, Promethazine, Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248520, "ingredient1": "Diphenoxylate", "ingredient2": "Valproic acid", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293775/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248521, "ingredient1": "Doxylamine", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293776/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248522, "ingredient1": "Dronabinol", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293777/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248523, "ingredient1": "Droperidol", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293778/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248524, "ingredient1": "Duloxetine", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293779/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Viloxazine, Amoxapine, Imipramine, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248525, "ingredient1": "Eluxadoline", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.  Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs.  Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293780/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc.  (2015):", "alternatives_a": "Loperamide, Diphenoxylate, Difenoxin", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248526, "ingredient1": "Entacapone", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293781/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Tolcapone, Amantadine", "alternatives_b": "Loperamide, Eluxadoline, Difenoxin", "updated_at": 1767369485}, {"id": 248527, "ingredient1": "Esketamine", "ingredient2": "Diphenoxylate", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293782/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Viloxazine, Amoxapine, Imipramine, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248528, "ingredient1": "Eslicarbazepine", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293783/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248529, "ingredient1": "Estazolam", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293784/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Eluxadoline, Difenoxin", "updated_at": 1767369485}, {"id": 248530, "ingredient1": "Eszopiclone", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293785/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248531, "ingredient1": "Ethanol", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.", "source": "DDInter", "management_text": "Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293786/", "reference_text": "[1] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986):  31-7[2] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Promethazine, Deferoxamine, Levoleucovorin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248532, "ingredient1": "Ethosuximide", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293787/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Loperamide, Eluxadoline, Difenoxin", "updated_at": 1767369485}, {"id": 248533, "ingredient1": "Ezogabine", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293788/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248534, "ingredient1": "Felbamate", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293789/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Loperamide, Eluxadoline, Difenoxin", "updated_at": 1767369485}, {"id": 248535, "ingredient1": "Fenfluramine", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293790/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Tiagabine, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248536, "ingredient1": "Fentanyl", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293791/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Naltrexone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248537, "ingredient1": "Flibanserin", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "The central nervous system (CNS) effects of flibanserin such as somnolence and fatigue may be potentiated by concomitant use of other agents with CNS depressant effects.", "source": "DDInter", "management_text": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue.  Patients should not drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking flibanserin and until they know how the medication affects them.", "mechanism_text": "Synergism", "recommendation": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293792/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals  (2015):", "alternatives_a": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248538, "ingredient1": "Fluphenazine", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293793/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 248539, "ingredient1": "Gabapentin", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293794/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248540, "ingredient1": "Diphenoxylate", "ingredient2": "Diamorphine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293796/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Loperamide, Eluxadoline", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 248541, "ingredient1": "Hydrocodone", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293797/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Benzonatate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248542, "ingredient1": "Hydromorphone", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293798/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248543, "ingredient1": "Iloperidone", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293799/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248544, "ingredient1": "Isocarboxazid", "ingredient2": "Diphenoxylate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293800/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Viloxazine, Amoxapine, Imipramine, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248545, "ingredient1": "Diphenoxylate", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293801/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Loperamide, Eluxadoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248546, "ingredient1": "Diphenoxylate", "ingredient2": "Ketamine", "severity": "Major", "effect": "Coadministration of ketamine with opioid analgesics, benzodiazepines, or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.  Concomitant use of ketamine with other CNS depressants can potentiate CNS depression and/or increase the risk of developing respiratory depression.  In addition, opioid analgesics, barbiturates, and benzodiazepines may prolong the time to complete recovery from anesthesia.", "source": "DDInter", "management_text": "During concomitant use of ketamine with opioid analgesics, benzodiazepines, or other central nervous system (CNS) depressants, including alcohol, close monitoring of neurologic status and respiratory parameters, including respiratory rate and pulse oximetry, is recommended.  Dosage adjustments should be considered according to the patient's clinical situation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of ketamine with opioid analgesics, benzodiazepines, or other central nervous system (CNS) depressants, including alcohol, close monitoring of neurologic status and respiratory parameters, including respiratory rate and pulse oximetry, is recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293802/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "Loperamide, Eluxadoline, Difenoxin", "updated_at": 1767369485}, {"id": 248547, "ingredient1": "Diphenoxylate", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with alcohol or other central nervous system (CNS) depressants may enhance the sedative effects of lasmiditan and increase the likelihood and/or severity of cognitive and/or neuropsychiatric adverse reactions.", "source": "DDInter", "management_text": "Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation.  Patients should be advised against driving and other activities that require complete mental alertness for at least 8 hours after lasmiditan is administered.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293803/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company  (2019):", "alternatives_a": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Clonidine, Naratriptan, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248548, "ingredient1": "Diphenoxylate", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293804/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248549, "ingredient1": "Diphenoxylate", "ingredient2": "Levocetirizine", "severity": "Moderate", "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293805/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Xyzal (levocetirizine).\" UCB Pharma Inc  (2007):", "alternatives_a": "Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, Promethazine, Fexofenadine, Meclizine, Azatadine, Alimemazine, Loratadine, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248550, "ingredient1": "Diphenoxylate", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293806/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Tolcapone, Amantadine", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248551, "ingredient1": "Diphenoxylate", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293807/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248552, "ingredient1": "Diphenoxylate", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293808/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248553, "ingredient1": "Diphenoxylate", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293809/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248554, "ingredient1": "Diphenoxylate", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293810/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248555, "ingredient1": "Diphenoxylate", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293811/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248556, "ingredient1": "Diphenoxylate", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293812/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248557, "ingredient1": "Diphenoxylate", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293813/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248558, "ingredient1": "Diphenoxylate", "ingredient2": "Methadone", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293814/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248559, "ingredient1": "Diphenoxylate", "ingredient2": "Methohexital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293815/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Opium, Eluxadoline, Loperamide", "updated_at": 1767369485}, {"id": 248560, "ingredient1": "Diphenoxylate", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293816/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248561, "ingredient1": "Diphenoxylate", "ingredient2": "Morphine", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293817/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Loperamide, Diphenoxylate, Difenoxin, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "Morphine", "updated_at": 1767369485}, {"id": 248562, "ingredient1": "Diphenoxylate", "ingredient2": "Nabilone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293818/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248563, "ingredient1": "Diphenoxylate", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293819/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248564, "ingredient1": "Diphenoxylate", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293820/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248565, "ingredient1": "Diphenoxylate", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293821/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248566, "ingredient1": "Diphenoxylate", "ingredient2": "Olopatadine (nasal)", "severity": "Moderate", "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293822/", "reference_text": "[1] \"Product Information. Patanase (olopatadine nasal).\" Alcon Laboratories Inc  (2008):[2] \"Product Information. Ryaltris (mometasone-olopatadine nasal).\" Hikma Americas, Inc  (2022):", "alternatives_a": "Eluxadoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248567, "ingredient1": "Diphenoxylate", "ingredient2": "Opicapone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293823/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Tolcapone, Amantadine", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248568, "ingredient1": "Diphenoxylate", "ingredient2": "Opium", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293824/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Loperamide, Diphenoxylate, Difenoxin, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "Opium", "updated_at": 1767369485}, {"id": 248569, "ingredient1": "Diphenoxylate", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293825/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cyclobenzaprine, Methocarbamol, Chlormezanone", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 248570, "ingredient1": "Diphenoxylate", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293826/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248571, "ingredient1": "Diphenoxylate", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293827/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248572, "ingredient1": "Diphenoxylate", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293828/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248573, "ingredient1": "Diphenoxylate", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293829/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248574, "ingredient1": "Diphenoxylate", "ingredient2": "Pentazocine", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293830/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248575, "ingredient1": "Diphenoxylate", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293831/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248576, "ingredient1": "Diphenoxylate", "ingredient2": "Pergolide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293832/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Tolcapone, Amantadine", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248577, "ingredient1": "Diphenoxylate", "ingredient2": "Phenobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293833/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248578, "ingredient1": "Diphenoxylate", "ingredient2": "Pimozide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293834/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 248579, "ingredient1": "Diphenoxylate", "ingredient2": "Pramipexole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293835/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Tolcapone, Amantadine", "alternatives_b": "Eluxadoline, Difenoxin", "updated_at": 1767369485}, {"id": 248580, "ingredient1": "Diphenoxylate", "ingredient2": "Pregabalin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293836/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248581, "ingredient1": "Diphenoxylate", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293837/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248582, "ingredient1": "Diphenoxylate", "ingredient2": "Prochlorperazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293838/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Chlorpromazine, Quetiapine, Mesoridazine, Promazine, Haloperidol, Methotrimeprazine, Perphenazine, Thiothixene, Thioridazine, Pimavanserin, Ziprasidone, More", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 248583, "ingredient1": "Diphenoxylate", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293839/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248584, "ingredient1": "Diphenoxylate", "ingredient2": "Dextropropoxyphene", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293840/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248585, "ingredient1": "Diphenoxylate", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293841/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Viloxazine, Amoxapine, Imipramine, More", "alternatives_b": "Difenoxin", "updated_at": 1767369485}, {"id": 248586, "ingredient1": "Diphenoxylate", "ingredient2": "Mepyramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293842/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Tripelennamine, Doxepin, Promethazine, Ketotifen, Chlorcyclizine, Triprolidine, Tripelennamine, Azelastine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248587, "ingredient1": "Diphenoxylate", "ingredient2": "Ramelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293843/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248588, "ingredient1": "Diphenoxylate", "ingredient2": "Rasagiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293844/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Tolcapone, Amantadine", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248589, "ingredient1": "Diphenoxylate", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293845/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "Loperamide", "updated_at": 1767369485}, {"id": 248590, "ingredient1": "Diphenoxylate", "ingredient2": "Remimazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293846/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248591, "ingredient1": "Diphenoxylate", "ingredient2": "Rotigotine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293847/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Tolcapone, Amantadine", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248592, "ingredient1": "Diphenoxylate", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293848/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248593, "ingredient1": "Diphenoxylate", "ingredient2": "Safinamide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293849/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Tolcapone, Amantadine", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248594, "ingredient1": "Diphenoxylate", "ingredient2": "Scopolamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293850/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248595, "ingredient1": "Diphenoxylate", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293851/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248596, "ingredient1": "Diphenoxylate", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293852/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Apomorphine, Ropinirole, Cabergoline, Tolcapone, Amantadine", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248597, "ingredient1": "Diphenoxylate", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293853/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Loperamide", "updated_at": 1767369485}, {"id": 248598, "ingredient1": "Diphenoxylate", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293854/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Halothane, Thiopental, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "Loperamide", "updated_at": 1767369485}, {"id": 248599, "ingredient1": "Diphenoxylate", "ingredient2": "Suvorexant", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293855/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248600, "ingredient1": "Diphenoxylate", "ingredient2": "Tapentadol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293856/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "Loperamide", "updated_at": 1767369485}, {"id": 248601, "ingredient1": "Diphenoxylate", "ingredient2": "Tasimelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293857/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248602, "ingredient1": "Diphenoxylate", "ingredient2": "Tetrabenazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293858/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248603, "ingredient1": "Diphenoxylate", "ingredient2": "Tizanidine", "severity": "Moderate", "effect": "The sedative effect of tizanidine may be potentiated by concomitant use of other agents with central nervous system (CNS) depressant effects.  In addition, tizanidine and many of these agents (e.g., alcohol, anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, muscle relaxants) also can exhibit hypotensive effects, which may be additive during coadministration and may increase the risk of symptomatic hypotension and orthostasis, particularly during initiation of therapy or dose escalation.", "source": "DDInter", "management_text": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to avoid rising abruptly from a sitting or recumbent position.  Patients should contact their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or excessive CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293859/", "reference_text": "[1] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics  (2001):", "alternatives_a": "Cyclobenzaprine, Methocarbamol, Chlormezanone", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248604, "ingredient1": "Diphenoxylate", "ingredient2": "Tramadol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293860/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248605, "ingredient1": "Diphenoxylate", "ingredient2": "Trihexyphenidyl", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293861/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248606, "ingredient1": "Diphenoxylate", "ingredient2": "Valbenazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293862/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Pitolisant, Amifampridine, Tafamidis", "alternatives_b": "Eluxadoline", "updated_at": 1767369485}, {"id": 248607, "ingredient1": "Diphenoxylate", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293863/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Triazolam, Flurazepam, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Temazepam, Butabarbital, Quazepam, Paraldehyde, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248608, "ingredient1": "Diphenoxylate", "ingredient2": "Vigabatrin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293864/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248609, "ingredient1": "Diphenoxylate", "ingredient2": "Ziconotide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293865/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Methoxyflurane, Salsalate, Acetylsalicylic acid", "alternatives_b": "Loperamide, Eluxadoline", "updated_at": 1767369485}, {"id": 248610, "ingredient1": "Diphenoxylate", "ingredient2": "Zonisamide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293866/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Ethotoin, Clonazepam, Topiramate, Paramethadione, Mephenytoin, Methsuximide, Phensuximide, Lamotrigine, Fosphenytoin, Methylphenobarbital, More", "alternatives_b": "Eluxadoline, Difenoxin", "updated_at": 1767369485}, {"id": 248611, "ingredient1": "Abciximab", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due to the additive inhibitory effects of salicylates on platelet function.  Arterial puncture sites may be most problematic.", "source": "DDInter", "management_text": "It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.  Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites.  Therapy should be discontinued immediately if serious or uncontrollable bleeding or thrombocytopenia occurs.", "mechanism_text": "Synergism", "recommendation": "It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293867/", "reference_text": "[1] \"Product Information. ReoPro (abciximab).\" Lilly, Eli and Company  (2001):[2] \"Product Information. Integrilin (eptifibatide).\" Schering Corporation  (2001):[3] Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S \"Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.\" Clin Pharmacol Ther 67 (2000):  305-13[4] Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians \"The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians.\" Chest 119(1 Suppl) (2001):  1S-2S", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248612, "ingredient1": "Acetohexamide", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293868/", "reference_text": "[1] Petitpierre B, Perrin L, Rudhardt M, et al. \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972):  120-4[2] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[3] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[4] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[5] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984):  470-2[6] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[7] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[8] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[9] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967):  889-94[10] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[11] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[12] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[13] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[14] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[15] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[16] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[17] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[18] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[19] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[20] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[21] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[22] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[23] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990):  s30-4[24] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[25] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[26] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[27] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976):  58-63[28] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[29] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[30] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[31] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[32] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[33] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[34] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985):  482-5[35] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[36] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[37] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987):  245-7[38] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992):  317-9[39] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974):  344[40] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[41] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971):  1092-3[42] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[43] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977):  573-9[44] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[45] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971):  29-30[46] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[47] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[48] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[49] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn  (2002):[50] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[51] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[52] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[53] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[54] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[55] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[56] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[57] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[58] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[59] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[60] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[61] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[62] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[63] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[64] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[65] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[66] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[67] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994):  163-76[68] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994):  997-1002[69] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[70] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[71] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[72] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[73] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[74] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[75] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[76] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[77] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990):  245-52[78] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[79] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982):  123-6[80] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[81] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[82] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[83] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[84] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[85] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[86] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[87] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[88] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001):  194-200[89] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[90] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[91] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002):  1772-8[92] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[93] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997):  31-36[94] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[95] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[96] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001):  344[97] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001):  1845-6[98] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[99] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[100] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[101] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[102] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248613, "ingredient1": "Alendronic acid", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa.  Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.  Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools.  Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.  Serum creatinine should be assessed prior to each treatment, and treatment should be withheld in the presence of renal deterioration.  In patients treated for bone metastases, treatment should not be resumed until renal function returns to baseline.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293869/", "reference_text": "[1] \"Product Information. Didronel I.V. (etidronate).\" MGI Pharma Inc  (2022):[2] \"Product Information. Didronel (etidronate).\" Procter and Gamble Pharmaceuticals  (2022):[3] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Fosamax (alendronate).\" Merck & Co., Inc  (2001):[5] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals  (2001):[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals  (2001):[7] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001):  107-10[8] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001):  1862[9] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc  (2001):[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories  (2005):[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 248614, "ingredient1": "Aliskiren", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of aliskiren.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving aliskiren who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving aliskiren who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293870/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Hydrochlorothiazide, Hydrochlorothiazide, Sacubitril, Nebivolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "updated_at": 1767369485}, {"id": 248615, "ingredient1": "Alteplase", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.", "source": "DDInter", "management_text": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.  Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment.", "mechanism_text": "Synergism", "recommendation": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293871/", "reference_text": "[1] \"Product Information. Ticlid (ticlopidine).\" Syntex Laboratories Inc  (2001):[2] \"Product Information. Abbokinase (urokinase).\" Abbott Pharmaceutical  (2001):[3] \"Product Information. Activase (alteplase).\" Genentech  (2001):[4] \"Product Information. Streptase (streptokinase).\" Astra-Zeneca Pharmaceuticals  (2001):[5] \"Product Information. Retavase (reteplase).\" Boehringer Mannheim  (2001):[6] \"Product Information. TNKase (tenecteplase).\" Genentech  (2001):[7] Harder S, Klinkhardt U \"Thrombolytics: drug interactions of clinical significance.\" Drug Saf 23 (2000):  391-9[8] Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians \"The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians.\" Chest 119(1 Suppl) (2001):  1S-2S", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248616, "ingredient1": "Aluminum hydroxide", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance", "source": "DDInter", "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293873/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987):  607-17[2] Gaspari F, Vigano G, Locatelli M, Remuzzi G \"Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis.\" Am J Kidney Dis 11 (1988):  338-42[3] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988):  58-62[4] Miners JO \"Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.\" Clin Pharmacokinet 17 (1989):  327-44[5] Levy G, Lampman T, Kamath BL, Garrettson LK \"Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid.\" N Engl J Med 293 (1975):  323-5[6] Shastri RA \"Effect of antacids on salicylate kinetics.\" Int J Clin Pharmacol Ther Toxicol 23 (1985):  480-4[7] Covington TR, eds., Lawson LC, Young LL \"Handbook of Nonprescription Drugs.\" Washington, DC: American Pharmaceutical Association  (1993):[8] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248617, "ingredient1": "Amikacin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods.", "source": "DDInter", "management_text": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.  During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293874/", "reference_text": "[1] Zarfin Y, Koren G, Maresky D, et al. \"Clinical and laboratory observations: possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 106 (1985):  511-3[2] Scott CS, RetschBogart GZ, Henry MM \"Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen.\" Pediat Pulm 31 (2001):  314-6[3] Kovesi TA, Swartz R, MacDonald N \"Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.\" N Engl J Med 338 (1998):  65-6[4] Gagliardi L \"Possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 107 (1985):  991-2[5] Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S \"Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium.\" Clin Sci 91 (1996):  187-91[6] Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M \"Prostaglandins and aminoglycoside nephrotoxicity.\" Toxicol Appl Pharmacol 78 (1985):  386-94", "alternatives_a": "Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248618, "ingredient1": "Amikacin (liposome)", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods.", "source": "DDInter", "management_text": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.  During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293875/", "reference_text": "[1] Zarfin Y, Koren G, Maresky D, et al. \"Clinical and laboratory observations: possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 106 (1985):  511-3[2] Scott CS, RetschBogart GZ, Henry MM \"Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen.\" Pediat Pulm 31 (2001):  314-6[3] Kovesi TA, Swartz R, MacDonald N \"Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.\" N Engl J Med 338 (1998):  65-6[4] Gagliardi L \"Possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 107 (1985):  991-2[5] Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S \"Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium.\" Clin Sci 91 (1996):  187-91[6] Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M \"Prostaglandins and aminoglycoside nephrotoxicity.\" Toxicol Appl Pharmacol 78 (1985):  386-94", "alternatives_a": "Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248619, "ingredient1": "Amlodipine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.", "source": "DDInter", "management_text": "Monitoring for altered blood pressure control is recommended.", "mechanism_text": "Antagonism", "recommendation": "Monitoring for altered blood pressure control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293876/", "reference_text": "[1] Ring ME, Corrigan JJ, Fenster PE \"Effects of oral diltiazem on platelet function: alone and in combination with \"low dose\" aspirin.\" Thromb Res 44 (1986):  391-400[2] Altman R, Scazziota A, Dujovne C \"Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation.\" Clin Pharmacol Ther 44 (1988):  320-5[3] Cremer KF, Pieper JA, Joyal M, Mehta J \"Effects of diltiazem, dipyridamole, and their combination on hemostasis.\" Clin Pharmacol Ther 36 (1984):  641-4[4] Minuz P, Pancera P, Ribul M, et al. \"Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.\" Br J Clin Pharmacol 39 (1995):  45-50[5] Houston MC, Weir M, Gray J, et al. \"The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.\" Arch Intern Med 155 (1995):  1049-54[6] Deleeuw PW \"Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective.\" Drugs 51 (1996):  179-87[7] \"Product Information. DurAct (bromfenac).\" Wyeth-Ayerst Laboratories[8] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle  (2001):[9] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002):  1015-1022", "alternatives_a": "Hydrochlorothiazide, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Pravastatin, Ezetimibe, Bempedoic acid, Indapamide, Fenofibrate, Hydrochlorothiazide, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Magnesium hydroxide, Ammonium chloride, More", "updated_at": 1767369485}, {"id": 248620, "ingredient1": "Anisindione", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293877/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248621, "ingredient1": "Anistreplase", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.", "source": "DDInter", "management_text": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.  Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment.", "mechanism_text": "Synergism", "recommendation": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293878/", "reference_text": "[1] \"Product Information. Ticlid (ticlopidine).\" Syntex Laboratories Inc  (2001):[2] \"Product Information. Abbokinase (urokinase).\" Abbott Pharmaceutical  (2001):[3] \"Product Information. Activase (alteplase).\" Genentech  (2001):[4] \"Product Information. Streptase (streptokinase).\" Astra-Zeneca Pharmaceuticals  (2001):[5] \"Product Information. Retavase (reteplase).\" Boehringer Mannheim  (2001):[6] \"Product Information. TNKase (tenecteplase).\" Genentech  (2001):[7] Harder S, Klinkhardt U \"Thrombolytics: drug interactions of clinical significance.\" Drug Saf 23 (2000):  391-9[8] Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians \"The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians.\" Chest 119(1 Suppl) (2001):  1S-2S", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248622, "ingredient1": "Phenyl salicylate", "ingredient2": "Apixaban", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293879/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248623, "ingredient1": "Phenyl salicylate", "ingredient2": "Ardeparin", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293880/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248624, "ingredient1": "Phenyl salicylate", "ingredient2": "Argatroban", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293881/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248625, "ingredient1": "Acetylsalicylic acid", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding, ulceration) and bruising or bleeding.", "source": "DDInter", "management_text": "Concomitant use of more than one salicylate at a time should generally be avoided.  Patients treated with a salicylate should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of more than one salicylate at a time should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293882/", "reference_text": "[1] \"Product Information. Pepto-Bismol (bismuth subsalicylate).\" Procter and Gamble Pharmaceuticals  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine, More", "alternatives_b": "Apomorphine, Fesoterodine, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, Ammonium chloride, More", "updated_at": 1767369485}, {"id": 248626, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293883/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Sacubitril, Nebivolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "updated_at": 1767369485}, {"id": 248627, "ingredient1": "Baricitinib", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293884/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248628, "ingredient1": "Benazepril", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.", "source": "DDInter", "management_text": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293885/", "reference_text": "[1] Moore TJ, Crantz FR, Hollenberg NK \"Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.\" Hypertension 3 (1981):  168-73[2] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[3] Silberbauer K, Stanek B, Templ H \"Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.\" Br J Clin Pharmacol 14 (1982):  s87-93[4] Ahmad S \"Indomethacin-enalapril interaction: an alert.\" South Med J 84 (1991):  411-2[5] Allon M, Pasque CB, Rodriguez M \"Interaction of captopril and ibuprofen on glomerular and tubular function in humans.\" Am J Physiol 259 (1990):  f233-8[6] Seto S, Aoi W, Iwami K, et al. \"Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension.\" Clin Exp Hypertens 9 (1987):  623-7[7] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[8] Abdel-Haq B, Magagna A, Favilla S, Salvetti A \"Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects.\" J Cardiovasc Pharmacol 18 (1991):  s33-6[9] Morgan T, Anderson A \"Interaction of indomethacin with felodipine and enalapril.\" J Hypertens 11 (1993):  S338-9[10] \"Product Information. Daypro (oxaprozin).\" Searle  (2001):[11] Townend JN, Doran J, Lote CJ, Davies MK \"Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.\" Br Heart J 73 (1995):  434-41[12] Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueiragomes M \"Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients.\" J Hypertens 13 (1995):  925-31[13] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Indapamide, Bisoprolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, More", "updated_at": 1767369485}, {"id": 248629, "ingredient1": "Bepridil", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.", "source": "DDInter", "management_text": "Monitoring for altered blood pressure control is recommended.", "mechanism_text": "Antagonism", "recommendation": "Monitoring for altered blood pressure control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293886/", "reference_text": "[1] Ring ME, Corrigan JJ, Fenster PE \"Effects of oral diltiazem on platelet function: alone and in combination with \"low dose\" aspirin.\" Thromb Res 44 (1986):  391-400[2] Altman R, Scazziota A, Dujovne C \"Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation.\" Clin Pharmacol Ther 44 (1988):  320-5[3] Cremer KF, Pieper JA, Joyal M, Mehta J \"Effects of diltiazem, dipyridamole, and their combination on hemostasis.\" Clin Pharmacol Ther 36 (1984):  641-4[4] Minuz P, Pancera P, Ribul M, et al. \"Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.\" Br J Clin Pharmacol 39 (1995):  45-50[5] Houston MC, Weir M, Gray J, et al. \"The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.\" Arch Intern Med 155 (1995):  1049-54[6] Deleeuw PW \"Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective.\" Drugs 51 (1996):  179-87[7] \"Product Information. DurAct (bromfenac).\" Wyeth-Ayerst Laboratories[8] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle  (2001):[9] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002):  1015-1022", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Tolterodine, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248630, "ingredient1": "Betamethasone", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.", "source": "DDInter", "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293887/", "reference_text": "[1] Baer PA, Shore A, Ikeman RL \"Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis.\" Arthritis Rheum 30 (1987):  345-7[2] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L \"Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis.\" Ther Drug Monit 9 (1987):  177-9[3] Edelman J, Potter JM, Hackett LP \"The effect of intra-articular steroids on plasma salicylate concentrations.\" Br J Clin Pharmacol 21 (1986):  301-7[4] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991):  735-40[5] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD \"Risk of adverse gastrointestinal events from inhaled corticosteroids.\" Pharmacotherapy 28 (2008):  1325-34", "alternatives_a": "Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248631, "ingredient1": "Betrixaban", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293888/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248632, "ingredient1": "Bismuth subsalicylate", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding, ulceration) and bruising or bleeding.", "source": "DDInter", "management_text": "Concomitant use of more than one salicylate at a time should generally be avoided.  Patients treated with a salicylate should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of more than one salicylate at a time should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293889/", "reference_text": "[1] \"Product Information. Pepto-Bismol (bismuth subsalicylate).\" Procter and Gamble Pharmaceuticals  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248633, "ingredient1": "Bivalirudin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293890/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248634, "ingredient1": "Brinzolamide (ophthalmic)", "ingredient2": "Phenyl salicylate", "severity": "Major", "effect": "The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate toxicity.  The mechanism is unknown but may involve salicylate-induced displacement of CAIs from plasma protein-binding sites and reduced renal clearance, or CAI-induced plasma pH changes resulting in increased amounts of unionised salicylates entering the CNS.", "source": "DDInter", "management_text": "In general, concomitant use of antirheumatic doses of salicylates and oral CAIs is not recommended.  If coadministration is necessary, careful monitoring of the patient's mental status and acid base balance is strongly recommended.  Patients should be advised to promptly notify their physicians if they experience symptoms such as lethargy, tinnitus, confusion, nausea, vomiting, or hyperventilation.", "mechanism_text": "Others", "recommendation": "In general, concomitant use of antirheumatic doses of salicylates and oral CAIs is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293891/", "reference_text": "[1] Sweeney KR, Chapron DJ, Kramer PA \"Effect of salicylate on serum protein binding and red blood cell uptake of acetazolamide in vitro.\" J Pharm Sci 77 (1988):  751-6[2] Favre L, Vallotton MB \"Relationship of renal prostaglandins to three diuretics.\" Prostaglandins Leukot Med 14 (1984):  313-9[3] Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM \"Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function.\" Br Med J (Clin Res Ed) 289 (1984):  347-8[4] Sweeney KR, Chapron DJ, Brandt JL, Gomolin IH, Feig PU, Kramer PA \"Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation.\" Clin Pharmacol Ther 40 (1986):  518-24[5] Anderson CJ, Kaufman PL, Sturm RJ \"Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin.\" Am J Ophthalmol 86 (1978):  516-9[6] Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM \"Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function.\" Br Med J (Clin Res Ed) 289 (1984):  347-8[7] Sweeney KR, Chapron DJ, Brandt JL, Gomolin IH, Feig PU, Kramer PA \"Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation.\" Clin Pharmacol Ther 40 (1986):  518-24[8] Sweeney KR, Chapron DJ, Antal EJ, Kramer PA \"Differential effects of flurbiprofen and aspirin on acetazolamide disposition in humans.\" Br J Clin Pharmacol 27 (1989):  866-9[9] Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM \"Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function.\" Br Med J (Clin Res Ed) 289 (1984):  347-8[10] Rousseau P, Fuentevilla-Clifton A \"Acetazolamide and salicylate interaction in the elderly: a case report.\" J Am Geriatr Soc 41 (1993):  868-9[11] \"Product Information. Diamox (acetazolamide).\" Lederle Laboratories  (2001):[12] \"Product Information. Azopt (brinzolamide ophthalmic).\" Alcon Laboratories Inc  (2001):[13] \"Product Information. Trusopt (dorzolamide ophthalmic).\" Merck & Co., Inc  (2001):[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[16] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248635, "ingredient1": "Budesonide", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.", "source": "DDInter", "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293892/", "reference_text": "[1] Baer PA, Shore A, Ikeman RL \"Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis.\" Arthritis Rheum 30 (1987):  345-7[2] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L \"Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis.\" Ther Drug Monit 9 (1987):  177-9[3] Edelman J, Potter JM, Hackett LP \"The effect of intra-articular steroids on plasma salicylate concentrations.\" Br J Clin Pharmacol 21 (1986):  301-7[4] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991):  735-40[5] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD \"Risk of adverse gastrointestinal events from inhaled corticosteroids.\" Pharmacotherapy 28 (2008):  1325-34", "alternatives_a": "Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Terbutaline, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 248636, "ingredient1": "Bumetanide", "ingredient2": "Phenyl salicylate", "severity": "Minor", "effect": "Salicylates in anti-inflammatory dosages may blunt the diuretic and natriuretic response to loop diuretics.  The interaction has been demonstrated in patients with ascites secondary to liver cirrhosis and in normal volunteers.  Investigators theorize that salicylates may inhibit the renal effects of loop diuretics that are mediated by prostaglandins, including increases in sodium excretion, renal blood flow, and plasma renin activity.", "source": "DDInter", "management_text": "Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.  No clinical interventions are generally required, but the possibility of a potential interaction should be considered in patients with ascites treated with a loop diuretic and salicylate or salicylate-related product.", "mechanism_text": "Antagonism", "recommendation": "Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293893/", "reference_text": "[1] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981):  663-7[2] Salerno F, Lorenzano E, Maggi A, Badalamenti S, Minuz P, Degan M, Chinea B, Scotti A \"Effects of imidazole-salicylate on renal function and the diuretic action of furosemide in cirrhotic patients with ascites.\" J Hepatol 19 (1993):  279-84[3] Bartoli E, Arras S, Faedda R, Soggia G, Satta A, Olmeo NA \"Blunting of furosemide diuresis by aspirin in man.\" J Clin Pharmacol 20 (1980):  452-8[4] Tobert MB, Ostaszewski T, Reger B, Meisinger MA, Cook TJ \"Diflunisal-furosemide interaction.\" Clin Pharmacol Ther 27 (1980):  289-90[5] Planas R, Arroyo V, Rimola A, Perez-Ayuso RM, Rodes J \"Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites.\" Gastroenterology 84 (1983):  247-52[6] Wilson TW, McCauley FA, Wells HD \"Effects of low-dose aspirin on responsses to furosemide.\" J Clin Pharmacol 26 (1986):  100-5[7] Valette H, Apoil E \"Interaction between salicylate and two loop diuretics.\" Br J Clin Pharmacol 8 (1979):  592-4", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Mitapivat, Methazolamide, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, More", "updated_at": 1767369485}, {"id": 248637, "ingredient1": "Calcium carbonate", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance", "source": "DDInter", "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293894/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987):  607-17[2] Gaspari F, Vigano G, Locatelli M, Remuzzi G \"Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis.\" Am J Kidney Dis 11 (1988):  338-42[3] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988):  58-62[4] Miners JO \"Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.\" Clin Pharmacokinet 17 (1989):  327-44[5] Levy G, Lampman T, Kamath BL, Garrettson LK \"Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid.\" N Engl J Med 293 (1975):  323-5[6] Shastri RA \"Effect of antacids on salicylate kinetics.\" Int J Clin Pharmacol Ther Toxicol 23 (1985):  480-4[7] Covington TR, eds., Lawson LC, Young LL \"Handbook of Nonprescription Drugs.\" Washington, DC: American Pharmaceutical Association  (1993):[8] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Ascorbic acid, Calcium chloride, Calcium citrate, Calcium acetate, Calcium Phosphate", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248638, "ingredient1": "Captopril", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.", "source": "DDInter", "management_text": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293896/", "reference_text": "[1] Moore TJ, Crantz FR, Hollenberg NK \"Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.\" Hypertension 3 (1981):  168-73[2] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[3] Silberbauer K, Stanek B, Templ H \"Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.\" Br J Clin Pharmacol 14 (1982):  s87-93[4] Ahmad S \"Indomethacin-enalapril interaction: an alert.\" South Med J 84 (1991):  411-2[5] Allon M, Pasque CB, Rodriguez M \"Interaction of captopril and ibuprofen on glomerular and tubular function in humans.\" Am J Physiol 259 (1990):  f233-8[6] Seto S, Aoi W, Iwami K, et al. \"Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension.\" Clin Exp Hypertens 9 (1987):  623-7[7] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[8] Abdel-Haq B, Magagna A, Favilla S, Salvetti A \"Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects.\" J Cardiovasc Pharmacol 18 (1991):  s33-6[9] Morgan T, Anderson A \"Interaction of indomethacin with felodipine and enalapril.\" J Hypertens 11 (1993):  S338-9[10] \"Product Information. Daypro (oxaprozin).\" Searle  (2001):[11] Townend JN, Doran J, Lote CJ, Davies MK \"Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.\" Br Heart J 73 (1995):  434-41[12] Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueiragomes M \"Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients.\" J Hypertens 13 (1995):  925-31[13] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Indapamide, Bisoprolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248639, "ingredient1": "Chlorpropamide", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293897/", "reference_text": "[1] Petitpierre B, Perrin L, Rudhardt M, et al. \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972):  120-4[2] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[3] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[4] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[5] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984):  470-2[6] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[7] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[8] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[9] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967):  889-94[10] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[11] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[12] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[13] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[14] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[15] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[16] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[17] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[18] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[19] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[20] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[21] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[22] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[23] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990):  s30-4[24] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[25] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[26] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[27] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976):  58-63[28] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[29] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[30] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[31] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[32] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[33] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[34] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985):  482-5[35] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[36] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[37] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987):  245-7[38] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992):  317-9[39] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974):  344[40] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[41] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971):  1092-3[42] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[43] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977):  573-9[44] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[45] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971):  29-30[46] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[47] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[48] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[49] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn  (2002):[50] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[51] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[52] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[53] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[54] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[55] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[56] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[57] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[58] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[59] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[60] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[61] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[62] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[63] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[64] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[65] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[66] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[67] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994):  163-76[68] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994):  997-1002[69] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[70] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[71] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[72] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[73] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[74] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[75] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[76] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[77] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990):  245-52[78] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[79] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982):  123-6[80] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[81] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[82] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[83] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[84] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[85] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[86] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[87] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[88] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001):  194-200[89] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[90] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[91] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002):  1772-8[92] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[93] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997):  31-36[94] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[95] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[96] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001):  344[97] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001):  1845-6[98] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[99] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[100] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[101] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[102] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248640, "ingredient1": "Choline salicylate", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding, ulceration) and bruising or bleeding.", "source": "DDInter", "management_text": "Concomitant use of more than one salicylate at a time should generally be avoided.  Patients treated with a salicylate should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of more than one salicylate at a time should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293898/", "reference_text": "[1] \"Product Information. Pepto-Bismol (bismuth subsalicylate).\" Procter and Gamble Pharmaceuticals  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Diflunisal, Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248641, "ingredient1": "Cinoxacin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293899/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248642, "ingredient1": "Ciprofloxacin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293900/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Tetracycline, Polymyxin B, More", "alternatives_b": "Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248643, "ingredient1": "Citalopram", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293901/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248644, "ingredient1": "Clomipramine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293902/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Tadalafil, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248645, "ingredient1": "Clopidogrel", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Clopidogrel has been shown to potentiate the inhibition of platelet aggregation due to aspirin.", "source": "DDInter", "management_text": "Until further data are available, caution is recommended, especially in patients at risk of bleeding (i.e., GI ulceration), if clopidogrel is coadministered on a long-term basis with drugs that may cause GI lesions.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, red or black stools, or bloody or coffee-ground emesis.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, caution is recommended, especially in patients at risk of bleeding (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293903/", "reference_text": "[1] \"Product Information. Plavix (clopidogrel).\" Bristol-Myers Squibb  (2001):[2] Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S \"Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.\" Clin Pharmacol Ther 67 (2000):  305-13", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Apomorphine, Fesoterodine, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, Magnesium hydroxide, More", "updated_at": 1767369485}, {"id": 248646, "ingredient1": "Clove", "ingredient2": "Phenyl salicylate", "severity": "Minor", "effect": "Clove and clove oil may potentiate the effects of anticoagulants and other drugs that may affect hemostasis such as platelet inhibitors, thrombolytic agents, and nonsteroidal anti-inflammatory drugs, possibly increasing the risk of bleeding.  Eugenol, the active constituent of clove and clove oil, has been shown to be an inhibitor of platelet activity.", "source": "DDInter", "management_text": "In patients who have used clove and clove oil extensively prior to receiving treatment with anticoagulants or other drugs that may affect hemostasis, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "In patients who have used clove and clove oil extensively prior to receiving treatment with anticoagulants or other drugs that may affect hemostasis, the potential for an interaction should be considered.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293904/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[2] Srivasta KC \"Antiplatelet principles from a food spice clove (Syzygium aromaticum L) [corrected]\" Prostaglandins Leukot Essent Fatty Acids 48 (1993):  363-72[3] Srivstava KC, Malhotra N \"Acetyl eugenol, a component of oil of cloves (Syzygium aromaticum L.) inhibits aggregation and alters arachidonic acid metabolism in human blood platelets.\" Prostaglandins Leukot Essent Fatty Acids 42 (1991):  73-81[4] Saeed SA, Gilani AH \"Antithrombotic activity of clove oil.\" J Pak Med Assoc 44 (1994):  112-5", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248647, "ingredient1": "Cyclosporine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present.", "source": "DDInter", "management_text": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293906/", "reference_text": "[1] Sesin GP, O'Keefe E, Roberto P \"Sulindac-induced elevation of serum cyclosporine concentration.\" Clin Pharm 8 (1989):  445-6[2] Branthwaite JP, Nicholls A \"Cyclosporin and diclofenac interaction in rheumatoid arthritis.\" Lancet 337 (1991):  252[3] Harris KP, Jenkins D, Walls J \"Nonsteroidal antiinflammatory drugs and cyclosporine.\" Transplantation 46 (1988):  598-9[4] Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A \"Enhancement of cyclosporine A nephrotoxicity by diclofenac.\" Clin Nephrol 27 (1987):  213-4[5] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85[6] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle  (2001):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Avanafil, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248648, "ingredient1": "Dalteparin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293908/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248649, "ingredient1": "Danaparoid", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293909/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248650, "ingredient1": "Deferasirox", "ingredient2": "Phenyl salicylate", "severity": "Major", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal bleeding associated with the use of deferasirox.", "source": "DDInter", "management_text": "Caution is advised if deferasirox is used in combination with NSAIDs.  Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, vomiting blood, anorexia, or black, tarry stools.  Serum creatinine and/or creatinine clearance should be closely monitored (e.g., prior to initiation of deferasirox therapy, then weekly during the first month after initiation or modification of therapy and monthly thereafter), especially in the elderly and patients with preexisting renal impairment, comorbid conditions, dehydration, or severe infections.  Dosage reduction, interruption, or discontinuation should be considered in the presence of creatinine elevations.  A progressive increase in serum creatinine beyond the age-appropriate upper limit of normal may warrant an interruption of therapy.  Once the creatinine has returned to within the normal range, therapy may be reinitiated at a lower dose followed by a gradual dose escalation according to the product labeling, provided the clinical benefit is expected to outweigh potential risks.  In clinical studies, the daily dosage of deferasirox was reduced by 10 mg/kg for increases of serum creatinine on two consecutive measures (i.e., >33% in patients older than 15 years of age, or >33% and greater than the age-appropriate upper limit of normal in patients younger than 15 years of age).  Care should be taken to maintain adequate hydration in patients who develop diarrhea or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if deferasirox is used in combination with NSAIDs.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293910/", "reference_text": "[1] \"Product Information. Exjade (deferasirox).\" Novartis Pharmaceuticals  (2005):[2] Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M \"Fanconi Syndrome Due to Deferasirox.\" Am J Kidney Dis  (2009):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Magnesium hydroxide, More", "updated_at": 1767369485}, {"id": 248651, "ingredient1": "Deflazacort", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.", "source": "DDInter", "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293911/", "reference_text": "[1] Baer PA, Shore A, Ikeman RL \"Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis.\" Arthritis Rheum 30 (1987):  345-7[2] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L \"Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis.\" Ther Drug Monit 9 (1987):  177-9[3] Edelman J, Potter JM, Hackett LP \"The effect of intra-articular steroids on plasma salicylate concentrations.\" Br J Clin Pharmacol 21 (1986):  301-7[4] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991):  735-40[5] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD \"Risk of adverse gastrointestinal events from inhaled corticosteroids.\" Pharmacotherapy 28 (2008):  1325-34", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248652, "ingredient1": "Delafloxacin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293912/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248653, "ingredient1": "Desirudin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293913/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248654, "ingredient1": "Desvenlafaxine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293914/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248655, "ingredient1": "Dexamethasone", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.", "source": "DDInter", "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293915/", "reference_text": "[1] Baer PA, Shore A, Ikeman RL \"Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis.\" Arthritis Rheum 30 (1987):  345-7[2] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L \"Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis.\" Ther Drug Monit 9 (1987):  177-9[3] Edelman J, Potter JM, Hackett LP \"The effect of intra-articular steroids on plasma salicylate concentrations.\" Br J Clin Pharmacol 21 (1986):  301-7[4] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991):  735-40[5] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD \"Risk of adverse gastrointestinal events from inhaled corticosteroids.\" Pharmacotherapy 28 (2008):  1325-34", "alternatives_a": "Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Vardenafil, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248656, "ingredient1": "Dexfenfluramine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293916/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "alternatives_b": "Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248657, "ingredient1": "Dexlansoprazole", "ingredient2": "Phenyl salicylate", "severity": "Minor", "effect": "Coadministration with proton pump inhibitors may decrease the oral bioavailability of aspirin and other salicylates.", "source": "DDInter", "management_text": "In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates. It is only necessary to pay attention to the dosing interval.", "mechanism_text": "Absorption", "recommendation": "In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293917/", "reference_text": "[1] Nefesoglu FZ, Ayanoglu-Dulger G, Ulusoy NB, Imeryuz N \"Interaction of omeprazole with enteric-coated salicylate tablets.\" Int J Clin Pharmacol Ther 36 (1998):  549-53[2] Anand BS, Sanduja SK, Lichetenberger LM \"Effect of omeprazole on the bioavailability of aspirin: a randomized controlled study on healthy volunteers.\" Gastroenterology 116 (1999):  A371[3] Inarrea P, Esteva F, Cornudella R, Lanas A \"Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man.\" Scand J Gastroenterol 35 (2000):  242-6", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Nizatidine, Ranitidine, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248658, "ingredient1": "Dicoumarol", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293918/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248659, "ingredient1": "Didanosine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance", "source": "DDInter", "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293919/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987):  607-17[2] Gaspari F, Vigano G, Locatelli M, Remuzzi G \"Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis.\" Am J Kidney Dis 11 (1988):  338-42[3] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988):  58-62[4] Miners JO \"Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.\" Clin Pharmacokinet 17 (1989):  327-44[5] Levy G, Lampman T, Kamath BL, Garrettson LK \"Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid.\" N Engl J Med 293 (1975):  323-5[6] Shastri RA \"Effect of antacids on salicylate kinetics.\" Int J Clin Pharmacol Ther Toxicol 23 (1985):  480-4[7] Covington TR, eds., Lawson LC, Young LL \"Handbook of Nonprescription Drugs.\" Washington, DC: American Pharmaceutical Association  (1993):[8] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Darifenacin, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 248660, "ingredient1": "Digoxin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase plasma digoxin concentrations and half-life.  The exact mechanism is unknown, but may be related to reduced renal clearance of digoxin.", "source": "DDInter", "management_text": "Patients who require concomitant therapy should be monitored for altered pharmacologic effects of digoxin and for increased plasma levels. The digoxin dosage may require adjustment.  Patients should be advised to notify their physician if they experience nausea, anorexia, visual changes, slow pulse, or irregular heartbeats.", "mechanism_text": "Excretion", "recommendation": "Patients who require concomitant therapy should be monitored for altered pharmacologic effects of digoxin and for increased plasma levels.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293920/", "reference_text": "[1] Rodin SM, Johnson BF \"Pharmacokinetic interactions with digoxin.\" Clin Pharmacokinet 15 (1988):  227-44[2] Jorgensen HS, Christensen HR, Kampmann JP \"Interaction between digoxin and indomethacin or ibuprofen.\" Br J Clin Pharmacol 31 (1991):  108-10[3] Marcus FI \"Pharmacokinetic interactions between digoxin and other drugs.\" J Am Coll Cardiol 5 (1985):  a82-90[4] Finch MB, Johnston GD, Kelly JG, McDevitt DG \"Pharmacokinetics of digoxin alone and in the presence of indomethacin therapy.\" Br J Clin Pharmacol 17 (1984):  353-5[5] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Digitoxin", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248661, "ingredient1": "Diltiazem", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.", "source": "DDInter", "management_text": "Monitoring for altered blood pressure control is recommended.", "mechanism_text": "Antagonism", "recommendation": "Monitoring for altered blood pressure control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293922/", "reference_text": "[1] Ring ME, Corrigan JJ, Fenster PE \"Effects of oral diltiazem on platelet function: alone and in combination with \"low dose\" aspirin.\" Thromb Res 44 (1986):  391-400[2] Altman R, Scazziota A, Dujovne C \"Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation.\" Clin Pharmacol Ther 44 (1988):  320-5[3] Cremer KF, Pieper JA, Joyal M, Mehta J \"Effects of diltiazem, dipyridamole, and their combination on hemostasis.\" Clin Pharmacol Ther 36 (1984):  641-4[4] Minuz P, Pancera P, Ribul M, et al. \"Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.\" Br J Clin Pharmacol 39 (1995):  45-50[5] Houston MC, Weir M, Gray J, et al. \"The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.\" Arch Intern Med 155 (1995):  1049-54[6] Deleeuw PW \"Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective.\" Drugs 51 (1996):  179-87[7] \"Product Information. DurAct (bromfenac).\" Wyeth-Ayerst Laboratories[8] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle  (2001):[9] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002):  1015-1022", "alternatives_a": "Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate, Nitroglycerin", "alternatives_b": "Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248662, "ingredient1": "Dimethyl fumarate", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293923/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248663, "ingredient1": "Diroximel fumarate", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293924/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248664, "ingredient1": "Valproic acid", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Salicylates, particularly aspirin, may displace valproate from protein binding sites and inhibit its clearance.", "source": "DDInter", "management_text": "Small single doses of salicylates are unlikely to cause significant effects.  However, patients who take large doses of salicylates or over a prolonged period of time should be closely monitored for clinical and laboratory evidence of valproate toxicity and hepatotoxicity.  Free fraction of valproate may be particularly helpful in detecting this interaction.  Patients should be advised to notify their physician if they experience possible symptoms of toxicity (e.g., malaise, weakness, lethargy, drowsiness, nausea, vomiting, or abdominal pain).", "mechanism_text": "Distribution", "recommendation": "Small single doses of salicylates are unlikely to cause significant effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293925/", "reference_text": "[1] Orr JM, Abbott FS, Farrell K, Ferguson S, Sheppard I, Godolphin W \"Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects.\" Clin Pharmacol Ther 31 (1982):  642-9[2] Farrell K, Orr JM, Abbott FS, et al. \"The effect of acetylsalicylic acid on serum free valproate concentrations and valproate clearance in children.\" J Pediatr 101 (1982):  142-4[3] Abbott FS, Kassam J, Orr JM, Farrell K \"The effect of aspirin on valproic acid metabolism.\" Clin Pharmacol Ther 40 (1986):  94-100[4] Dasgupta A, Jacques M \"Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera - role of uremic compounds.\" Am J Clin Pathol 101 (1994):  349-53", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Darifenacin, Avanafil, More", "updated_at": 1767369485}, {"id": 248665, "ingredient1": "Donepezil", "ingredient2": "Phenyl salicylate", "severity": "Minor", "effect": "Donepezil may increase gastric acid secretion by increasing cholinergic activity.", "source": "DDInter", "management_text": "Donepezil may increase gastric acid secretion by increasing cholinergic activity.  The risk for gastrointestinal bleeding is, therefore, theoretically increased in patients receiving donepezil in combination with a nonsteroidal anti-inflammatory agent.  Caution is recommended when this combination is used.", "mechanism_text": "Synergism", "recommendation": "Donepezil may increase gastric acid secretion by increasing cholinergic activity.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293926/", "reference_text": "[1] \"Product Information. Aricept (donepezil).\" Pfizer U.S. Pharmaceuticals  (2001):", "alternatives_a": "Rivastigmine, Galantamine, Tacrine, Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248666, "ingredient1": "Dorzolamide (ophthalmic)", "ingredient2": "Phenyl salicylate", "severity": "Major", "effect": "The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate toxicity.  The mechanism is unknown but may involve salicylate-induced displacement of CAIs from plasma protein-binding sites and reduced renal clearance, or CAI-induced plasma pH changes resulting in increased amounts of unionised salicylates entering the CNS.", "source": "DDInter", "management_text": "In general, concomitant use of antirheumatic doses of salicylates and oral CAIs is not recommended.  If coadministration is necessary, careful monitoring of the patient's mental status and acid base balance is strongly recommended.  Patients should be advised to promptly notify their physicians if they experience symptoms such as lethargy, tinnitus, confusion, nausea, vomiting, or hyperventilation.", "mechanism_text": "Others", "recommendation": "In general, concomitant use of antirheumatic doses of salicylates and oral CAIs is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293927/", "reference_text": "[1] Sweeney KR, Chapron DJ, Kramer PA \"Effect of salicylate on serum protein binding and red blood cell uptake of acetazolamide in vitro.\" J Pharm Sci 77 (1988):  751-6[2] Favre L, Vallotton MB \"Relationship of renal prostaglandins to three diuretics.\" Prostaglandins Leukot Med 14 (1984):  313-9[3] Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM \"Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function.\" Br Med J (Clin Res Ed) 289 (1984):  347-8[4] Sweeney KR, Chapron DJ, Brandt JL, Gomolin IH, Feig PU, Kramer PA \"Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation.\" Clin Pharmacol Ther 40 (1986):  518-24[5] Anderson CJ, Kaufman PL, Sturm RJ \"Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin.\" Am J Ophthalmol 86 (1978):  516-9[6] Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM \"Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function.\" Br Med J (Clin Res Ed) 289 (1984):  347-8[7] Sweeney KR, Chapron DJ, Brandt JL, Gomolin IH, Feig PU, Kramer PA \"Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation.\" Clin Pharmacol Ther 40 (1986):  518-24[8] Sweeney KR, Chapron DJ, Antal EJ, Kramer PA \"Differential effects of flurbiprofen and aspirin on acetazolamide disposition in humans.\" Br J Clin Pharmacol 27 (1989):  866-9[9] Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM \"Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function.\" Br Med J (Clin Res Ed) 289 (1984):  347-8[10] Rousseau P, Fuentevilla-Clifton A \"Acetazolamide and salicylate interaction in the elderly: a case report.\" J Am Geriatr Soc 41 (1993):  868-9[11] \"Product Information. Diamox (acetazolamide).\" Lederle Laboratories  (2001):[12] \"Product Information. Azopt (brinzolamide ophthalmic).\" Alcon Laboratories Inc  (2001):[13] \"Product Information. Trusopt (dorzolamide ophthalmic).\" Merck & Co., Inc  (2001):[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[16] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248667, "ingredient1": "Drospirenone", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim.  Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.", "source": "DDInter", "management_text": "Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.  Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.  Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293928/", "reference_text": "[1] Ponce SP, Jennings AE, Madias NE, Harrington JT \"Drug-induced hyperkalemia.\" Medicine (Baltimore) 64 (1985):  357-70[2] \"Product Information. Yasmin (drospirenone-ethinyl estradiol).\" Berlex Laboratories  (2001):", "alternatives_a": "Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248668, "ingredient1": "Drotrecogin alfa", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293929/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248669, "ingredient1": "Duloxetine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293930/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Ammonium chloride, Dimethyl sulfoxide, Solifenacin", "updated_at": 1767369485}, {"id": 248670, "ingredient1": "Edoxaban", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293931/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248671, "ingredient1": "Enalapril", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.", "source": "DDInter", "management_text": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293932/", "reference_text": "[1] Moore TJ, Crantz FR, Hollenberg NK \"Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.\" Hypertension 3 (1981):  168-73[2] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[3] Silberbauer K, Stanek B, Templ H \"Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.\" Br J Clin Pharmacol 14 (1982):  s87-93[4] Ahmad S \"Indomethacin-enalapril interaction: an alert.\" South Med J 84 (1991):  411-2[5] Allon M, Pasque CB, Rodriguez M \"Interaction of captopril and ibuprofen on glomerular and tubular function in humans.\" Am J Physiol 259 (1990):  f233-8[6] Seto S, Aoi W, Iwami K, et al. \"Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension.\" Clin Exp Hypertens 9 (1987):  623-7[7] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[8] Abdel-Haq B, Magagna A, Favilla S, Salvetti A \"Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects.\" J Cardiovasc Pharmacol 18 (1991):  s33-6[9] Morgan T, Anderson A \"Interaction of indomethacin with felodipine and enalapril.\" J Hypertens 11 (1993):  S338-9[10] \"Product Information. Daypro (oxaprozin).\" Searle  (2001):[11] Townend JN, Doran J, Lote CJ, Davies MK \"Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.\" Br Heart J 73 (1995):  434-41[12] Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueiragomes M \"Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients.\" J Hypertens 13 (1995):  925-31[13] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Indapamide, Bisoprolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Ammonium chloride, Dimethyl sulfoxide, Solifenacin", "updated_at": 1767369485}, {"id": 248672, "ingredient1": "Enoxacin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293933/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248673, "ingredient1": "Enoxaparin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293934/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248674, "ingredient1": "Eplerenone", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of eplerenone.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.", "source": "DDInter", "management_text": "Patients receiving eplerenone who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Patients receiving eplerenone who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293935/", "reference_text": "[1] Moore TJ, Crantz FR, Hollenberg NK \"Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.\" Hypertension 3 (1981):  168-73[2] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[3] Silberbauer K, Stanek B, Templ H \"Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.\" Br J Clin Pharmacol 14 (1982):  s87-93[4] Ahmad S \"Indomethacin-enalapril interaction: an alert.\" South Med J 84 (1991):  411-2[5] Allon M, Pasque CB, Rodriguez M \"Interaction of captopril and ibuprofen on glomerular and tubular function in humans.\" Am J Physiol 259 (1990):  f233-8[6] Seto S, Aoi W, Iwami K, et al. \"Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension.\" Clin Exp Hypertens 9 (1987):  623-7[7] Abdel-Haq B, Magagna A, Favilla S, Salvetti A \"Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects.\" J Cardiovasc Pharmacol 18 (1991):  s33-6[8] Morgan T, Anderson A \"Interaction of indomethacin with felodipine and enalapril.\" J Hypertens 11 (1993):  S338-9[9] Townend JN, Doran J, Lote CJ, Davies MK \"Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.\" Br Heart J 73 (1995):  434-41[10] Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueiragomes M \"Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients.\" J Hypertens 13 (1995):  925-31[11] \"Product Information. Inspra (eplerenone).\" Searle  (2002):", "alternatives_a": "Amiloride, Triamterene, Finerenone", "alternatives_b": "Fesoterodine, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248675, "ingredient1": "Epoprostenol", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Prostacyclin/prostacyclin analogs (e.g., epoprostenol, iloprost, treprostinil) inhibit platelet aggregation and may theoretically potentiate the risk of bleeding in patients treated with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hemorrhagic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293936/", "reference_text": "[1] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome  (2001):[2] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corporation  (2002):[3] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc  (2005):", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Fesoterodine, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Magnesium hydroxide, More", "updated_at": 1767369485}, {"id": 248676, "ingredient1": "Eprosartan", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293937/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Sacubitril, Nebivolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "updated_at": 1767369485}, {"id": 248677, "ingredient1": "Eptifibatide", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due to the additive inhibitory effects of salicylates on platelet function.  Arterial puncture sites may be most problematic.", "source": "DDInter", "management_text": "It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.  Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites.  Therapy should be discontinued immediately if serious or uncontrollable bleeding or thrombocytopenia occurs.", "mechanism_text": "Synergism", "recommendation": "It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293938/", "reference_text": "[1] \"Product Information. ReoPro (abciximab).\" Lilly, Eli and Company  (2001):[2] \"Product Information. Integrilin (eptifibatide).\" Schering Corporation  (2001):[3] Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S \"Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.\" Clin Pharmacol Ther 67 (2000):  305-13[4] Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians \"The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians.\" Chest 119(1 Suppl) (2001):  1S-2S", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248678, "ingredient1": "Erlotinib", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration of erlotinib with anti-angiogenic agents, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or taxane-based chemotherapy may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using erlotinib in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as anti-angiogenic agents, corticosteroids, NSAIDs, and taxane-based chemotherapy.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.  The manufacturer recommends that erlotinib should be permanently discontinued in patients who develop gastrointestinal perforation.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using erlotinib in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as anti-angiogenic agents, corticosteroids, NSAIDs, and taxane-based chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293939/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Tarceva (erlotinib).\" Genentech  (2018):[4] \"Product Information. Tarceva (erlotinib).\" Hoffmann-La Roche Limited  (2018):[5] \"Product Information. Tarceva (erlotinib).\" Roche Products Ltd  (2022):[6] \"Product Information. Tarceva (erlotinib).\" Roche Products Pty Ltd  (2022):[7] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248679, "ingredient1": "Escitalopram", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293940/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Tadalafil, More", "updated_at": 1767369485}, {"id": 248680, "ingredient1": "Esomeprazole", "ingredient2": "Phenyl salicylate", "severity": "Minor", "effect": "Coadministration with proton pump inhibitors may decrease the oral bioavailability of aspirin and other salicylates.", "source": "DDInter", "management_text": "In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates. It is only necessary to pay attention to the dosing interval.", "mechanism_text": "Absorption", "recommendation": "In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293941/", "reference_text": "[1] Nefesoglu FZ, Ayanoglu-Dulger G, Ulusoy NB, Imeryuz N \"Interaction of omeprazole with enteric-coated salicylate tablets.\" Int J Clin Pharmacol Ther 36 (1998):  549-53[2] Anand BS, Sanduja SK, Lichetenberger LM \"Effect of omeprazole on the bioavailability of aspirin: a randomized controlled study on healthy volunteers.\" Gastroenterology 116 (1999):  A371[3] Inarrea P, Esteva F, Cornudella R, Lanas A \"Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man.\" Scand J Gastroenterol 35 (2000):  242-6", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Nizatidine, Ranitidine, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248681, "ingredient1": "Etacrynic acid", "ingredient2": "Phenyl salicylate", "severity": "Minor", "effect": "Salicylates in anti-inflammatory dosages may blunt the diuretic and natriuretic response to loop diuretics.  The interaction has been demonstrated in patients with ascites secondary to liver cirrhosis and in normal volunteers.  Investigators theorize that salicylates may inhibit the renal effects of loop diuretics that are mediated by prostaglandins, including increases in sodium excretion, renal blood flow, and plasma renin activity.", "source": "DDInter", "management_text": "Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.  No clinical interventions are generally required, but the possibility of a potential interaction should be considered in patients with ascites treated with a loop diuretic and salicylate or salicylate-related product.", "mechanism_text": "Antagonism", "recommendation": "Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293942/", "reference_text": "[1] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981):  663-7[2] Salerno F, Lorenzano E, Maggi A, Badalamenti S, Minuz P, Degan M, Chinea B, Scotti A \"Effects of imidazole-salicylate on renal function and the diuretic action of furosemide in cirrhotic patients with ascites.\" J Hepatol 19 (1993):  279-84[3] Bartoli E, Arras S, Faedda R, Soggia G, Satta A, Olmeo NA \"Blunting of furosemide diuresis by aspirin in man.\" J Clin Pharmacol 20 (1980):  452-8[4] Tobert MB, Ostaszewski T, Reger B, Meisinger MA, Cook TJ \"Diflunisal-furosemide interaction.\" Clin Pharmacol Ther 27 (1980):  289-90[5] Planas R, Arroyo V, Rimola A, Perez-Ayuso RM, Rodes J \"Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites.\" Gastroenterology 84 (1983):  247-52[6] Wilson TW, McCauley FA, Wells HD \"Effects of low-dose aspirin on responsses to furosemide.\" J Clin Pharmacol 26 (1986):  100-5[7] Valette H, Apoil E \"Interaction between salicylate and two loop diuretics.\" Br J Clin Pharmacol 8 (1979):  592-4", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248682, "ingredient1": "Etidronic acid", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa.  Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.  Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools.  Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.  Serum creatinine should be assessed prior to each treatment, and treatment should be withheld in the presence of renal deterioration.  In patients treated for bone metastases, treatment should not be resumed until renal function returns to baseline.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293943/", "reference_text": "[1] \"Product Information. Didronel I.V. (etidronate).\" MGI Pharma Inc  (2022):[2] \"Product Information. Didronel (etidronate).\" Procter and Gamble Pharmaceuticals  (2022):[3] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Fosamax (alendronate).\" Merck & Co., Inc  (2001):[5] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals  (2001):[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals  (2001):[7] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001):  107-10[8] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001):  1862[9] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc  (2001):[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories  (2005):[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248683, "ingredient1": "Felodipine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.", "source": "DDInter", "management_text": "Monitoring for altered blood pressure control is recommended.", "mechanism_text": "Antagonism", "recommendation": "Monitoring for altered blood pressure control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293944/", "reference_text": "[1] Ring ME, Corrigan JJ, Fenster PE \"Effects of oral diltiazem on platelet function: alone and in combination with \"low dose\" aspirin.\" Thromb Res 44 (1986):  391-400[2] Altman R, Scazziota A, Dujovne C \"Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation.\" Clin Pharmacol Ther 44 (1988):  320-5[3] Cremer KF, Pieper JA, Joyal M, Mehta J \"Effects of diltiazem, dipyridamole, and their combination on hemostasis.\" Clin Pharmacol Ther 36 (1984):  641-4[4] Minuz P, Pancera P, Ribul M, et al. \"Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.\" Br J Clin Pharmacol 39 (1995):  45-50[5] Houston MC, Weir M, Gray J, et al. \"The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.\" Arch Intern Med 155 (1995):  1049-54[6] Deleeuw PW \"Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective.\" Drugs 51 (1996):  179-87[7] \"Product Information. DurAct (bromfenac).\" Wyeth-Ayerst Laboratories[8] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle  (2001):[9] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002):  1015-1022", "alternatives_a": "Propranolol, Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Ivabradine, Sotalol, Atenolol, Clevidipine, Mibefradil, Celecoxib, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, Magnesium hydroxide, More", "updated_at": 1767369485}, {"id": 248684, "ingredient1": "Fenfluramine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293945/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Brivaracetam, Topiramate, Ezogabine, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 248685, "ingredient1": "Fludrocortisone", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.", "source": "DDInter", "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293947/", "reference_text": "[1] Baer PA, Shore A, Ikeman RL \"Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis.\" Arthritis Rheum 30 (1987):  345-7[2] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L \"Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis.\" Ther Drug Monit 9 (1987):  177-9[3] Edelman J, Potter JM, Hackett LP \"The effect of intra-articular steroids on plasma salicylate concentrations.\" Br J Clin Pharmacol 21 (1986):  301-7[4] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991):  735-40[5] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD \"Risk of adverse gastrointestinal events from inhaled corticosteroids.\" Pharmacotherapy 28 (2008):  1325-34", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248686, "ingredient1": "Fluoxetine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293948/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Amitriptyline, Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248687, "ingredient1": "Fluvoxamine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293949/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Oxybutynin, More", "updated_at": 1767369485}, {"id": 248688, "ingredient1": "Fondaparinux", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293950/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248689, "ingredient1": "Fosinopril", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.", "source": "DDInter", "management_text": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293951/", "reference_text": "[1] Moore TJ, Crantz FR, Hollenberg NK \"Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.\" Hypertension 3 (1981):  168-73[2] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[3] Silberbauer K, Stanek B, Templ H \"Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.\" Br J Clin Pharmacol 14 (1982):  s87-93[4] Ahmad S \"Indomethacin-enalapril interaction: an alert.\" South Med J 84 (1991):  411-2[5] Allon M, Pasque CB, Rodriguez M \"Interaction of captopril and ibuprofen on glomerular and tubular function in humans.\" Am J Physiol 259 (1990):  f233-8[6] Seto S, Aoi W, Iwami K, et al. \"Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension.\" Clin Exp Hypertens 9 (1987):  623-7[7] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[8] Abdel-Haq B, Magagna A, Favilla S, Salvetti A \"Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects.\" J Cardiovasc Pharmacol 18 (1991):  s33-6[9] Morgan T, Anderson A \"Interaction of indomethacin with felodipine and enalapril.\" J Hypertens 11 (1993):  S338-9[10] \"Product Information. Daypro (oxaprozin).\" Searle  (2001):[11] Townend JN, Doran J, Lote CJ, Davies MK \"Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.\" Br Heart J 73 (1995):  434-41[12] Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueiragomes M \"Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients.\" J Hypertens 13 (1995):  925-31[13] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Indapamide, Bisoprolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248690, "ingredient1": "Furosemide", "ingredient2": "Phenyl salicylate", "severity": "Minor", "effect": "Salicylates in anti-inflammatory dosages may blunt the diuretic and natriuretic response to loop diuretics.  The interaction has been demonstrated in patients with ascites secondary to liver cirrhosis and in normal volunteers.  Investigators theorize that salicylates may inhibit the renal effects of loop diuretics that are mediated by prostaglandins, including increases in sodium excretion, renal blood flow, and plasma renin activity.", "source": "DDInter", "management_text": "Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.  No clinical interventions are generally required, but the possibility of a potential interaction should be considered in patients with ascites treated with a loop diuretic and salicylate or salicylate-related product.", "mechanism_text": "Antagonism", "recommendation": "Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293952/", "reference_text": "[1] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981):  663-7[2] Salerno F, Lorenzano E, Maggi A, Badalamenti S, Minuz P, Degan M, Chinea B, Scotti A \"Effects of imidazole-salicylate on renal function and the diuretic action of furosemide in cirrhotic patients with ascites.\" J Hepatol 19 (1993):  279-84[3] Bartoli E, Arras S, Faedda R, Soggia G, Satta A, Olmeo NA \"Blunting of furosemide diuresis by aspirin in man.\" J Clin Pharmacol 20 (1980):  452-8[4] Tobert MB, Ostaszewski T, Reger B, Meisinger MA, Cook TJ \"Diflunisal-furosemide interaction.\" Clin Pharmacol Ther 27 (1980):  289-90[5] Planas R, Arroyo V, Rimola A, Perez-Ayuso RM, Rodes J \"Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites.\" Gastroenterology 84 (1983):  247-52[6] Wilson TW, McCauley FA, Wells HD \"Effects of low-dose aspirin on responsses to furosemide.\" J Clin Pharmacol 26 (1986):  100-5[7] Valette H, Apoil E \"Interaction between salicylate and two loop diuretics.\" Br J Clin Pharmacol 8 (1979):  592-4", "alternatives_a": "Bendroflumethiazide, Trichlormethiazide, Chlorthalidone, Metolazone, Hydrochlorothiazide, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Ammonium chloride, Dimethyl sulfoxide, Solifenacin", "updated_at": 1767369485}, {"id": 248691, "ingredient1": "Gatifloxacin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293953/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248692, "ingredient1": "Gemifloxacin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293954/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248693, "ingredient1": "Gentamicin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods.", "source": "DDInter", "management_text": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.  During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293955/", "reference_text": "[1] Zarfin Y, Koren G, Maresky D, et al. \"Clinical and laboratory observations: possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 106 (1985):  511-3[2] Scott CS, RetschBogart GZ, Henry MM \"Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen.\" Pediat Pulm 31 (2001):  314-6[3] Kovesi TA, Swartz R, MacDonald N \"Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.\" N Engl J Med 338 (1998):  65-6[4] Gagliardi L \"Possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 107 (1985):  991-2[5] Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S \"Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium.\" Clin Sci 91 (1996):  187-91[6] Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M \"Prostaglandins and aminoglycoside nephrotoxicity.\" Toxicol Appl Pharmacol 78 (1985):  386-94", "alternatives_a": "Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248694, "ingredient1": "Glimepiride", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293956/", "reference_text": "[1] Petitpierre B, Perrin L, Rudhardt M, et al. \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972):  120-4[2] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[3] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[4] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[5] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984):  470-2[6] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[7] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[8] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[9] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967):  889-94[10] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[11] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[12] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[13] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[14] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[15] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[16] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[17] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[18] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[19] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[20] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[21] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[22] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[23] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990):  s30-4[24] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[25] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[26] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[27] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976):  58-63[28] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[29] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[30] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[31] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[32] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[33] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[34] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985):  482-5[35] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[36] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[37] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987):  245-7[38] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992):  317-9[39] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974):  344[40] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[41] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971):  1092-3[42] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[43] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977):  573-9[44] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[45] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971):  29-30[46] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[47] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[48] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[49] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn  (2002):[50] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[51] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[52] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[53] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[54] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[55] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[56] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[57] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[58] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[59] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[60] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[61] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[62] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[63] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[64] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[65] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[66] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[67] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994):  163-76[68] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994):  997-1002[69] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[70] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[71] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[72] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[73] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[74] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[75] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[76] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[77] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990):  245-52[78] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[79] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982):  123-6[80] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[81] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[82] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[83] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[84] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[85] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[86] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[87] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[88] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001):  194-200[89] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[90] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[91] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002):  1772-8[92] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[93] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997):  31-36[94] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[95] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[96] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001):  344[97] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001):  1845-6[98] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[99] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[100] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[101] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[102] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "updated_at": 1767369485}, {"id": 248695, "ingredient1": "Glipizide", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293957/", "reference_text": "[1] Petitpierre B, Perrin L, Rudhardt M, et al. \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972):  120-4[2] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[3] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[4] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[5] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984):  470-2[6] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[7] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[8] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[9] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967):  889-94[10] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[11] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[12] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[13] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[14] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[15] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[16] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[17] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[18] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[19] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[20] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[21] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[22] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[23] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990):  s30-4[24] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[25] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[26] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[27] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976):  58-63[28] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[29] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[30] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[31] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[32] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[33] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[34] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985):  482-5[35] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[36] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[37] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987):  245-7[38] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992):  317-9[39] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974):  344[40] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[41] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971):  1092-3[42] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[43] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977):  573-9[44] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[45] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971):  29-30[46] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[47] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[48] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[49] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn  (2002):[50] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[51] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[52] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[53] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[54] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[55] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[56] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[57] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[58] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[59] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[60] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[61] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[62] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[63] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[64] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[65] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[66] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[67] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994):  163-76[68] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994):  997-1002[69] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[70] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[71] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[72] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[73] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[74] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[75] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[76] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[77] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990):  245-52[78] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[79] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982):  123-6[80] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[81] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[82] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[83] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[84] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[85] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[86] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[87] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[88] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001):  194-200[89] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[90] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[91] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002):  1772-8[92] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[93] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997):  31-36[94] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[95] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[96] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001):  344[97] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001):  1845-6[98] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[99] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[100] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[101] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[102] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248696, "ingredient1": "Glyburide", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293958/", "reference_text": "[1] Petitpierre B, Perrin L, Rudhardt M, et al. \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972):  120-4[2] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[3] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[4] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[5] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984):  470-2[6] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[7] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[8] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[9] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967):  889-94[10] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[11] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[12] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[13] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[14] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[15] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[16] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[17] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[18] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[19] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[20] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[21] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[22] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[23] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990):  s30-4[24] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[25] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[26] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[27] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976):  58-63[28] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[29] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[30] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[31] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[32] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[33] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[34] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985):  482-5[35] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[36] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[37] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987):  245-7[38] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992):  317-9[39] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974):  344[40] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[41] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971):  1092-3[42] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[43] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977):  573-9[44] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[45] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971):  29-30[46] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[47] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[48] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[49] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn  (2002):[50] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[51] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[52] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[53] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[54] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[55] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[56] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[57] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[58] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[59] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[60] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[61] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[62] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[63] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[64] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[65] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[66] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[67] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994):  163-76[68] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994):  997-1002[69] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[70] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[71] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[72] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[73] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[74] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[75] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[76] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[77] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990):  245-52[78] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[79] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982):  123-6[80] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[81] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[82] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[83] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[84] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[85] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[86] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[87] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[88] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001):  194-200[89] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[90] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[91] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002):  1772-8[92] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[93] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997):  31-36[94] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[95] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[96] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001):  344[97] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001):  1845-6[98] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[99] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[100] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[101] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[102] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248697, "ingredient1": "Grepafloxacin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293959/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Oxybutynin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248698, "ingredient1": "Heparin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293960/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine, More", "alternatives_b": "Apomorphine, Fesoterodine, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 248699, "ingredient1": "Diamorphine", "ingredient2": "Methylene blue", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Synergism", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293961/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[3] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[4] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[5] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[6] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987):  251-2[7] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993):  1270-1[8] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[9] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[10] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[11] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[12] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[13] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[14] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[15] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[16] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Acamprosate, Lofexidine, Naltrexone, Varenicline, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 248700, "ingredient1": "Hyaluronidase", "ingredient2": "Phenyl salicylate", "severity": "Minor", "effect": "Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines.  These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.", "source": "DDInter", "management_text": "Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines.  These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.", "mechanism_text": "Antagonism", "recommendation": "Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293962/", "reference_text": "[1] \"Product Information. Vitrase (hyaluronidase).\" Bausch and Lomb Americas, Inc.  (2004):", "alternatives_a": "Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248701, "ingredient1": "Hydralazine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine.", "source": "DDInter", "management_text": "Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.", "mechanism_text": "Antagonism", "recommendation": "Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293963/", "reference_text": "[1] Cinquegrani MP, Liang CS \"Indomethacin attenuates the hypotensive action of hydralazine.\" Clin Pharmacol Ther 39 (1986):  564-70", "alternatives_a": "Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248702, "ingredient1": "Hydrocortisone", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.", "source": "DDInter", "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293964/", "reference_text": "[1] Baer PA, Shore A, Ikeman RL \"Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis.\" Arthritis Rheum 30 (1987):  345-7[2] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L \"Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis.\" Ther Drug Monit 9 (1987):  177-9[3] Edelman J, Potter JM, Hackett LP \"The effect of intra-articular steroids on plasma salicylate concentrations.\" Br J Clin Pharmacol 21 (1986):  301-7[4] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991):  735-40[5] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD \"Risk of adverse gastrointestinal events from inhaled corticosteroids.\" Pharmacotherapy 28 (2008):  1325-34", "alternatives_a": "Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac, Tetracycline, Minocycline, Amphotericin B, Miconazole, Doxycycline, Metronidazole, Clotrimazole, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248703, "ingredient1": "Ibandronate", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa.  Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.  Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools.  Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.  Serum creatinine should be assessed prior to each treatment, and treatment should be withheld in the presence of renal deterioration.  In patients treated for bone metastases, treatment should not be resumed until renal function returns to baseline.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293965/", "reference_text": "[1] \"Product Information. Didronel I.V. (etidronate).\" MGI Pharma Inc  (2022):[2] \"Product Information. Didronel (etidronate).\" Procter and Gamble Pharmaceuticals  (2022):[3] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Fosamax (alendronate).\" Merck & Co., Inc  (2001):[5] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals  (2001):[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals  (2001):[7] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001):  107-10[8] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001):  1862[9] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc  (2001):[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories  (2005):[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248704, "ingredient1": "Iloprost", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Prostacyclin/prostacyclin analogs (e.g., epoprostenol, iloprost, treprostinil) inhibit platelet aggregation and may theoretically potentiate the risk of bleeding in patients treated with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hemorrhagic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293966/", "reference_text": "[1] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome  (2001):[2] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corporation  (2002):[3] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc  (2005):", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Fesoterodine, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Oxybutynin, Magnesium hydroxide, More", "updated_at": 1767369485}, {"id": 248705, "ingredient1": "Imipramine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Preliminary evidence suggests that aspirin may increase the plasma free concentration and pharmacologic effects of imipramine by displacing it from plasma protein binding sites.", "source": "DDInter", "management_text": "Pharmacologic response to imipramine should be monitored more closely whenever a salicylate is added to or withdrawn from therapy, and the imipramine dosage adjusted as necessary.  Patients should be advised to notify their physician if they experience increased adverse effects of imipramine such as dry mouth, constipation, urinary retention, blurred vision, palpitations, and tachycardia.", "mechanism_text": "Distribution", "recommendation": "Pharmacologic response to imipramine should be monitored more closely whenever a salicylate is added to or withdrawn from therapy, and the imipramine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293967/", "reference_text": "[1] Juarez-Olguin H, Jung-Cook H, Flores-Perez J, Asseff IL \"Clinical Evidence of an Interaction Between Imipramine and Acetylsalicylic Acid on Protein Binding in Depressed Patients.\" Clin Neuropharmacol 25 (2002):  32-36", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Avanafil, Tadalafil, Magnesium hydroxide, Acetohydroxamic acid, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248706, "ingredient1": "Insulin human", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293970/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248707, "ingredient1": "Insulin aspart (aspart)", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293971/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248708, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293972/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248709, "ingredient1": "Insulin degludec", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293973/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248710, "ingredient1": "Insulin detemir", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293974/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248711, "ingredient1": "Insulin glargine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293975/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248712, "ingredient1": "Insulin glulisine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293976/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248713, "ingredient1": "Insulin human (inhalation, rapid acting)", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293977/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248714, "ingredient1": "Insulin lispro", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293978/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248715, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293979/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248716, "ingredient1": "Insulin human (zinc)", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293980/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248717, "ingredient1": "Insulin human (zinc extended)", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293981/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248718, "ingredient1": "Irbesartan", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293982/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Sacubitril, Nebivolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Magnesium hydroxide, More", "updated_at": 1767369485}, {"id": 248719, "ingredient1": "Isradipine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.", "source": "DDInter", "management_text": "Monitoring for altered blood pressure control is recommended.", "mechanism_text": "Antagonism", "recommendation": "Monitoring for altered blood pressure control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293983/", "reference_text": "[1] Ring ME, Corrigan JJ, Fenster PE \"Effects of oral diltiazem on platelet function: alone and in combination with \"low dose\" aspirin.\" Thromb Res 44 (1986):  391-400[2] Altman R, Scazziota A, Dujovne C \"Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation.\" Clin Pharmacol Ther 44 (1988):  320-5[3] Cremer KF, Pieper JA, Joyal M, Mehta J \"Effects of diltiazem, dipyridamole, and their combination on hemostasis.\" Clin Pharmacol Ther 36 (1984):  641-4[4] Minuz P, Pancera P, Ribul M, et al. \"Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.\" Br J Clin Pharmacol 39 (1995):  45-50[5] Houston MC, Weir M, Gray J, et al. \"The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.\" Arch Intern Med 155 (1995):  1049-54[6] Deleeuw PW \"Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective.\" Drugs 51 (1996):  179-87[7] \"Product Information. DurAct (bromfenac).\" Wyeth-Ayerst Laboratories[8] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle  (2001):[9] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002):  1015-1022", "alternatives_a": "Clevidipine, Mibefradil, Celecoxib", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, More", "updated_at": 1767369485}, {"id": 248720, "ingredient1": "Phenyl salicylate", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods.", "source": "DDInter", "management_text": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.  During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293984/", "reference_text": "[1] Zarfin Y, Koren G, Maresky D, et al. \"Clinical and laboratory observations: possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 106 (1985):  511-3[2] Scott CS, RetschBogart GZ, Henry MM \"Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen.\" Pediat Pulm 31 (2001):  314-6[3] Kovesi TA, Swartz R, MacDonald N \"Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.\" N Engl J Med 338 (1998):  65-6[4] Gagliardi L \"Possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 107 (1985):  991-2[5] Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S \"Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium.\" Clin Sci 91 (1996):  187-91[6] Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M \"Prostaglandins and aminoglycoside nephrotoxicity.\" Toxicol Appl Pharmacol 78 (1985):  386-94", "alternatives_a": "Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248721, "ingredient1": "Phenyl salicylate", "ingredient2": "Lansoprazole", "severity": "Minor", "effect": "Coadministration with proton pump inhibitors may decrease the oral bioavailability of aspirin and other salicylates.", "source": "DDInter", "management_text": "In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates. It is only necessary to pay attention to the dosing interval.", "mechanism_text": "Absorption", "recommendation": "In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293986/", "reference_text": "[1] Nefesoglu FZ, Ayanoglu-Dulger G, Ulusoy NB, Imeryuz N \"Interaction of omeprazole with enteric-coated salicylate tablets.\" Int J Clin Pharmacol Ther 36 (1998):  549-53[2] Anand BS, Sanduja SK, Lichetenberger LM \"Effect of omeprazole on the bioavailability of aspirin: a randomized controlled study on healthy volunteers.\" Gastroenterology 116 (1999):  A371[3] Inarrea P, Esteva F, Cornudella R, Lanas A \"Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man.\" Scand J Gastroenterol 35 (2000):  242-6", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Nizatidine, Ranitidine, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 248722, "ingredient1": "Phenyl salicylate", "ingredient2": "Leflunomide", "severity": "Major", "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide.  The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.", "source": "DDInter", "management_text": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity.  Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter.  Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide.  Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.  Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary.  All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, light colored stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293987/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion Roussel  (2001):[2] EMEA \"EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.  Available from URL: http://www.eudra.org/emea.html\"   (2001):[3] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation  (2012):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Acetohydroxamic acid, Alprostadil, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Avanafil, More", "updated_at": 1767369485}, {"id": 248723, "ingredient1": "Phenyl salicylate", "ingredient2": "Lepirudin", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293988/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248724, "ingredient1": "Phenyl salicylate", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.", "source": "DDInter", "management_text": "Monitoring for altered blood pressure control is recommended.", "mechanism_text": "Antagonism", "recommendation": "Monitoring for altered blood pressure control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293989/", "reference_text": "[1] Ring ME, Corrigan JJ, Fenster PE \"Effects of oral diltiazem on platelet function: alone and in combination with \"low dose\" aspirin.\" Thromb Res 44 (1986):  391-400[2] Altman R, Scazziota A, Dujovne C \"Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation.\" Clin Pharmacol Ther 44 (1988):  320-5[3] Cremer KF, Pieper JA, Joyal M, Mehta J \"Effects of diltiazem, dipyridamole, and their combination on hemostasis.\" Clin Pharmacol Ther 36 (1984):  641-4[4] Minuz P, Pancera P, Ribul M, et al. \"Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.\" Br J Clin Pharmacol 39 (1995):  45-50[5] Houston MC, Weir M, Gray J, et al. \"The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.\" Arch Intern Med 155 (1995):  1049-54[6] Deleeuw PW \"Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective.\" Drugs 51 (1996):  179-87[7] \"Product Information. DurAct (bromfenac).\" Wyeth-Ayerst Laboratories[8] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle  (2001):[9] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002):  1015-1022", "alternatives_a": "Clevidipine, Mibefradil, Celecoxib", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Tolterodine, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, More", "updated_at": 1767369485}, {"id": 248725, "ingredient1": "Phenyl salicylate", "ingredient2": "Levofloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293990/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Nizatidine, Ranitidine, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More", "updated_at": 1767369485}, {"id": 248726, "ingredient1": "Phenyl salicylate", "ingredient2": "Levomilnacipran", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293991/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248727, "ingredient1": "Phenyl salicylate", "ingredient2": "Lisinopril", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.", "source": "DDInter", "management_text": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293992/", "reference_text": "[1] Moore TJ, Crantz FR, Hollenberg NK \"Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.\" Hypertension 3 (1981):  168-73[2] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[3] Silberbauer K, Stanek B, Templ H \"Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.\" Br J Clin Pharmacol 14 (1982):  s87-93[4] Ahmad S \"Indomethacin-enalapril interaction: an alert.\" South Med J 84 (1991):  411-2[5] Allon M, Pasque CB, Rodriguez M \"Interaction of captopril and ibuprofen on glomerular and tubular function in humans.\" Am J Physiol 259 (1990):  f233-8[6] Seto S, Aoi W, Iwami K, et al. \"Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension.\" Clin Exp Hypertens 9 (1987):  623-7[7] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[8] Abdel-Haq B, Magagna A, Favilla S, Salvetti A \"Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects.\" J Cardiovasc Pharmacol 18 (1991):  s33-6[9] Morgan T, Anderson A \"Interaction of indomethacin with felodipine and enalapril.\" J Hypertens 11 (1993):  S338-9[10] \"Product Information. Daypro (oxaprozin).\" Searle  (2001):[11] Townend JN, Doran J, Lote CJ, Davies MK \"Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.\" Br Heart J 73 (1995):  434-41[12] Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueiragomes M \"Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients.\" J Hypertens 13 (1995):  925-31[13] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Indapamide, Bisoprolol, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Pravastatin, Ezetimibe, Bempedoic acid, Indapamide, Fenofibrate", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Ammonium chloride, Dimethyl sulfoxide, Solifenacin", "updated_at": 1767369485}, {"id": 248728, "ingredient1": "Phenyl salicylate", "ingredient2": "Lithium carbonate", "severity": "Minor", "effect": "Most studies have shown that aspirin and other salicylates do not significantly affect the serum concentrations of lithium.", "source": "DDInter", "management_text": "In general, no particular precaution should be necessary when lithium is coadministered with salicylates.", "mechanism_text": "Others", "recommendation": "In general, no particular precaution should be necessary when lithium is coadministered with salicylates.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293993/", "reference_text": "[1] Reimann IW, Diener U, Frolich JC \"Indomethacin but not aspirin increases plasma lithium ion levels.\" Arch Gen Psychiatry 40 (1983):  283-6[2] Ragheb M \"The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions.\" J Clin Psychopharmacol 10 (1990):  350-4[3] Johnson AG, Nguyen TV, Day RO \"Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.\" Ann Intern Med 121 (1994):  289-300[4] Phelan KM, Mosholder AD, Lu S \"Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.\" J Clin Psychiatry 64 (2003):  1328-34", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Acetohydroxamic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248729, "ingredient1": "Phenyl salicylate", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293994/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More", "updated_at": 1767369485}, {"id": 248730, "ingredient1": "Phenyl salicylate", "ingredient2": "Losartan", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293995/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Sacubitril, Nebivolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Magnesium hydroxide, Ammonium chloride, More", "updated_at": 1767369485}, {"id": 248731, "ingredient1": "Phenyl salicylate", "ingredient2": "Macimorelin", "severity": "Moderate", "effect": "Drugs that directly affect the pituitary secretion of growth hormone (e.g., somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors such as aspirin and nonsteroidal anti-inflammatory drugs) and drugs that may transiently elevate growth hormone levels (e.g., clonidine, levodopa, insulin) may impact the accuracy of the macimorelin diagnostic test.", "source": "DDInter", "management_text": "Concomitant use of macimorelin with drugs affecting growth hormone levels should generally be avoided.  A sufficient washout period following discontinuation of these drugs is recommended prior to macimorelin administration.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of macimorelin with drugs affecting growth hormone levels should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293996/", "reference_text": "[1] \"Product Information. Macrilen (macimorelin).\" Aeterna Zentaris  (2018):", "alternatives_a": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Methacholine, Folic acid, More", "alternatives_b": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 248732, "ingredient1": "Phenyl salicylate", "ingredient2": "Magaldrate", "severity": "Moderate", "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance", "source": "DDInter", "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293997/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987):  607-17[2] Gaspari F, Vigano G, Locatelli M, Remuzzi G \"Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis.\" Am J Kidney Dis 11 (1988):  338-42[3] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988):  58-62[4] Miners JO \"Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.\" Clin Pharmacokinet 17 (1989):  327-44[5] Levy G, Lampman T, Kamath BL, Garrettson LK \"Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid.\" N Engl J Med 293 (1975):  323-5[6] Shastri RA \"Effect of antacids on salicylate kinetics.\" Int J Clin Pharmacol Ther Toxicol 23 (1985):  480-4[7] Covington TR, eds., Lawson LC, Young LL \"Handbook of Nonprescription Drugs.\" Washington, DC: American Pharmaceutical Association  (1993):[8] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248733, "ingredient1": "Phenyl salicylate", "ingredient2": "Magnesium carbonate", "severity": "Moderate", "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance", "source": "DDInter", "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293998/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987):  607-17[2] Gaspari F, Vigano G, Locatelli M, Remuzzi G \"Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis.\" Am J Kidney Dis 11 (1988):  338-42[3] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988):  58-62[4] Miners JO \"Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.\" Clin Pharmacokinet 17 (1989):  327-44[5] Levy G, Lampman T, Kamath BL, Garrettson LK \"Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid.\" N Engl J Med 293 (1975):  323-5[6] Shastri RA \"Effect of antacids on salicylate kinetics.\" Int J Clin Pharmacol Ther Toxicol 23 (1985):  480-4[7] Covington TR, eds., Lawson LC, Young LL \"Handbook of Nonprescription Drugs.\" Washington, DC: American Pharmaceutical Association  (1993):[8] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248734, "ingredient1": "Phenyl salicylate", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance", "source": "DDInter", "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/293999/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987):  607-17[2] Gaspari F, Vigano G, Locatelli M, Remuzzi G \"Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis.\" Am J Kidney Dis 11 (1988):  338-42[3] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988):  58-62[4] Miners JO \"Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.\" Clin Pharmacokinet 17 (1989):  327-44[5] Levy G, Lampman T, Kamath BL, Garrettson LK \"Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid.\" N Engl J Med 293 (1975):  323-5[6] Shastri RA \"Effect of antacids on salicylate kinetics.\" Int J Clin Pharmacol Ther Toxicol 23 (1985):  480-4[7] Covington TR, eds., Lawson LC, Young LL \"Handbook of Nonprescription Drugs.\" Washington, DC: American Pharmaceutical Association  (1993):[8] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "updated_at": 1767369485}, {"id": 248735, "ingredient1": "Phenyl salicylate", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance", "source": "DDInter", "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294000/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987):  607-17[2] Gaspari F, Vigano G, Locatelli M, Remuzzi G \"Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis.\" Am J Kidney Dis 11 (1988):  338-42[3] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988):  58-62[4] Miners JO \"Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.\" Clin Pharmacokinet 17 (1989):  327-44[5] Levy G, Lampman T, Kamath BL, Garrettson LK \"Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid.\" N Engl J Med 293 (1975):  323-5[6] Shastri RA \"Effect of antacids on salicylate kinetics.\" Int J Clin Pharmacol Ther Toxicol 23 (1985):  480-4[7] Covington TR, eds., Lawson LC, Young LL \"Handbook of Nonprescription Drugs.\" Washington, DC: American Pharmaceutical Association  (1993):[8] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248736, "ingredient1": "Phenyl salicylate", "ingredient2": "Methylprednisolone", "severity": "Moderate", "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.", "source": "DDInter", "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294002/", "reference_text": "[1] Baer PA, Shore A, Ikeman RL \"Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis.\" Arthritis Rheum 30 (1987):  345-7[2] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L \"Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis.\" Ther Drug Monit 9 (1987):  177-9[3] Edelman J, Potter JM, Hackett LP \"The effect of intra-articular steroids on plasma salicylate concentrations.\" Br J Clin Pharmacol 21 (1986):  301-7[4] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991):  735-40[5] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD \"Risk of adverse gastrointestinal events from inhaled corticosteroids.\" Pharmacotherapy 28 (2008):  1325-34", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Avanafil, More", "updated_at": 1767369485}, {"id": 248737, "ingredient1": "Phenyl salicylate", "ingredient2": "Milnacipran", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294003/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248738, "ingredient1": "Phenyl salicylate", "ingredient2": "Moexipril", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.", "source": "DDInter", "management_text": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294004/", "reference_text": "[1] Moore TJ, Crantz FR, Hollenberg NK \"Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.\" Hypertension 3 (1981):  168-73[2] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[3] Silberbauer K, Stanek B, Templ H \"Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.\" Br J Clin Pharmacol 14 (1982):  s87-93[4] Ahmad S \"Indomethacin-enalapril interaction: an alert.\" South Med J 84 (1991):  411-2[5] Allon M, Pasque CB, Rodriguez M \"Interaction of captopril and ibuprofen on glomerular and tubular function in humans.\" Am J Physiol 259 (1990):  f233-8[6] Seto S, Aoi W, Iwami K, et al. \"Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension.\" Clin Exp Hypertens 9 (1987):  623-7[7] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[8] Abdel-Haq B, Magagna A, Favilla S, Salvetti A \"Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects.\" J Cardiovasc Pharmacol 18 (1991):  s33-6[9] Morgan T, Anderson A \"Interaction of indomethacin with felodipine and enalapril.\" J Hypertens 11 (1993):  S338-9[10] \"Product Information. Daypro (oxaprozin).\" Searle  (2001):[11] Townend JN, Doran J, Lote CJ, Davies MK \"Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.\" Br Heart J 73 (1995):  434-41[12] Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueiragomes M \"Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients.\" J Hypertens 13 (1995):  925-31[13] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Indapamide, Bisoprolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248739, "ingredient1": "Phenyl salicylate", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294005/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248740, "ingredient1": "Phenyl salicylate", "ingredient2": "Moxifloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294006/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248741, "ingredient1": "Phenyl salicylate", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294007/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248742, "ingredient1": "Phenyl salicylate", "ingredient2": "Nateglinide", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294008/", "reference_text": "[1] Petitpierre B, Perrin L, Rudhardt M, et al. \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972):  120-4[2] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[3] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[4] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[5] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984):  470-2[6] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[7] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[8] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[9] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967):  889-94[10] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[11] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[12] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[13] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[14] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[15] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[16] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[17] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[18] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[19] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[20] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[21] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[22] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[23] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990):  s30-4[24] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[25] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[26] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[27] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976):  58-63[28] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[29] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[30] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[31] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[32] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[33] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[34] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985):  482-5[35] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[36] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[37] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987):  245-7[38] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992):  317-9[39] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974):  344[40] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[41] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971):  1092-3[42] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[43] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977):  573-9[44] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[45] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971):  29-30[46] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[47] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[48] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[49] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn  (2002):[50] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[51] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[52] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[53] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[54] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[55] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[56] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[57] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[58] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[59] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[60] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[61] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[62] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[63] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[64] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[65] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[66] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[67] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994):  163-76[68] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994):  997-1002[69] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[70] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[71] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[72] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[73] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[74] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[75] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[76] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[77] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990):  245-52[78] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[79] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982):  123-6[80] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[81] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[82] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[83] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[84] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[85] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[86] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[87] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[88] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001):  194-200[89] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[90] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[91] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002):  1772-8[92] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[93] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997):  31-36[94] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[95] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[96] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001):  344[97] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001):  1845-6[98] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[99] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[100] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[101] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[102] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Darifenacin, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "updated_at": 1767369485}, {"id": 248743, "ingredient1": "Phenyl salicylate", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods.", "source": "DDInter", "management_text": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.  During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294009/", "reference_text": "[1] Zarfin Y, Koren G, Maresky D, et al. \"Clinical and laboratory observations: possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 106 (1985):  511-3[2] Scott CS, RetschBogart GZ, Henry MM \"Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen.\" Pediat Pulm 31 (2001):  314-6[3] Kovesi TA, Swartz R, MacDonald N \"Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.\" N Engl J Med 338 (1998):  65-6[4] Gagliardi L \"Possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 107 (1985):  991-2[5] Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S \"Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium.\" Clin Sci 91 (1996):  187-91[6] Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M \"Prostaglandins and aminoglycoside nephrotoxicity.\" Toxicol Appl Pharmacol 78 (1985):  386-94", "alternatives_a": "Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248744, "ingredient1": "Phenyl salicylate", "ingredient2": "Niacin", "severity": "Minor", "effect": "Salicylates may cause an elevation in serum levels of nicotinic acid.  The mechanism is not completely understood.", "source": "DDInter", "management_text": "Data are available for aspirin only.  No special precautions appear to be necessary.", "mechanism_text": "Others", "recommendation": "Data are available for aspirin only.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294010/", "reference_text": "[1] Ding RW, Kolbe K, Merz B, de Vries J, Weber E, Benet LZ \"Pharmacokinetics of nicotinic acid-salicylic acid interaction.\" Clin Pharmacol Ther 46 (1989):  642-7", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Lomitapide, Ezetimibe, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 248745, "ingredient1": "Phenyl salicylate", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.", "source": "DDInter", "management_text": "Monitoring for altered blood pressure control is recommended.", "mechanism_text": "Antagonism", "recommendation": "Monitoring for altered blood pressure control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294011/", "reference_text": "[1] Ring ME, Corrigan JJ, Fenster PE \"Effects of oral diltiazem on platelet function: alone and in combination with \"low dose\" aspirin.\" Thromb Res 44 (1986):  391-400[2] Altman R, Scazziota A, Dujovne C \"Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation.\" Clin Pharmacol Ther 44 (1988):  320-5[3] Cremer KF, Pieper JA, Joyal M, Mehta J \"Effects of diltiazem, dipyridamole, and their combination on hemostasis.\" Clin Pharmacol Ther 36 (1984):  641-4[4] Minuz P, Pancera P, Ribul M, et al. \"Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.\" Br J Clin Pharmacol 39 (1995):  45-50[5] Houston MC, Weir M, Gray J, et al. \"The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.\" Arch Intern Med 155 (1995):  1049-54[6] Deleeuw PW \"Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective.\" Drugs 51 (1996):  179-87[7] \"Product Information. DurAct (bromfenac).\" Wyeth-Ayerst Laboratories[8] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle  (2001):[9] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002):  1015-1022", "alternatives_a": "Clevidipine, Mibefradil, Celecoxib", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Tolterodine, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248746, "ingredient1": "Phenyl salicylate", "ingredient2": "Nifedipine", "severity": "Moderate", "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.", "source": "DDInter", "management_text": "Monitoring for altered blood pressure control is recommended.", "mechanism_text": "Antagonism", "recommendation": "Monitoring for altered blood pressure control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294012/", "reference_text": "[1] Ring ME, Corrigan JJ, Fenster PE \"Effects of oral diltiazem on platelet function: alone and in combination with \"low dose\" aspirin.\" Thromb Res 44 (1986):  391-400[2] Altman R, Scazziota A, Dujovne C \"Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation.\" Clin Pharmacol Ther 44 (1988):  320-5[3] Cremer KF, Pieper JA, Joyal M, Mehta J \"Effects of diltiazem, dipyridamole, and their combination on hemostasis.\" Clin Pharmacol Ther 36 (1984):  641-4[4] Minuz P, Pancera P, Ribul M, et al. \"Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.\" Br J Clin Pharmacol 39 (1995):  45-50[5] Houston MC, Weir M, Gray J, et al. \"The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.\" Arch Intern Med 155 (1995):  1049-54[6] Deleeuw PW \"Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective.\" Drugs 51 (1996):  179-87[7] \"Product Information. DurAct (bromfenac).\" Wyeth-Ayerst Laboratories[8] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle  (2001):[9] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002):  1015-1022", "alternatives_a": "Clevidipine, Mibefradil, Celecoxib, Propranolol, Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Ivabradine, Sotalol, Atenolol", "alternatives_b": "Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Darifenacin, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248747, "ingredient1": "Phenyl salicylate", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.", "source": "DDInter", "management_text": "Monitoring for altered blood pressure control is recommended.", "mechanism_text": "Antagonism", "recommendation": "Monitoring for altered blood pressure control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294013/", "reference_text": "[1] Ring ME, Corrigan JJ, Fenster PE \"Effects of oral diltiazem on platelet function: alone and in combination with \"low dose\" aspirin.\" Thromb Res 44 (1986):  391-400[2] Altman R, Scazziota A, Dujovne C \"Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation.\" Clin Pharmacol Ther 44 (1988):  320-5[3] Cremer KF, Pieper JA, Joyal M, Mehta J \"Effects of diltiazem, dipyridamole, and their combination on hemostasis.\" Clin Pharmacol Ther 36 (1984):  641-4[4] Minuz P, Pancera P, Ribul M, et al. \"Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.\" Br J Clin Pharmacol 39 (1995):  45-50[5] Houston MC, Weir M, Gray J, et al. \"The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.\" Arch Intern Med 155 (1995):  1049-54[6] Deleeuw PW \"Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective.\" Drugs 51 (1996):  179-87[7] \"Product Information. DurAct (bromfenac).\" Wyeth-Ayerst Laboratories[8] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle  (2001):[9] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002):  1015-1022", "alternatives_a": "Clevidipine, Mibefradil, Celecoxib", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Tolterodine, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248748, "ingredient1": "Phenyl salicylate", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.", "source": "DDInter", "management_text": "Monitoring for altered blood pressure control is recommended.", "mechanism_text": "Antagonism", "recommendation": "Monitoring for altered blood pressure control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294014/", "reference_text": "[1] Ring ME, Corrigan JJ, Fenster PE \"Effects of oral diltiazem on platelet function: alone and in combination with \"low dose\" aspirin.\" Thromb Res 44 (1986):  391-400[2] Altman R, Scazziota A, Dujovne C \"Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation.\" Clin Pharmacol Ther 44 (1988):  320-5[3] Cremer KF, Pieper JA, Joyal M, Mehta J \"Effects of diltiazem, dipyridamole, and their combination on hemostasis.\" Clin Pharmacol Ther 36 (1984):  641-4[4] Minuz P, Pancera P, Ribul M, et al. \"Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.\" Br J Clin Pharmacol 39 (1995):  45-50[5] Houston MC, Weir M, Gray J, et al. \"The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.\" Arch Intern Med 155 (1995):  1049-54[6] Deleeuw PW \"Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective.\" Drugs 51 (1996):  179-87[7] \"Product Information. DurAct (bromfenac).\" Wyeth-Ayerst Laboratories[8] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle  (2001):[9] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002):  1015-1022", "alternatives_a": "Clevidipine, Mibefradil, Celecoxib", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Papaverine, Oxybutynin, More", "updated_at": 1767369485}, {"id": 248749, "ingredient1": "Phenyl salicylate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294015/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Ampicillin, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More", "updated_at": 1767369485}, {"id": 248750, "ingredient1": "Phenyl salicylate", "ingredient2": "Ofloxacin", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294016/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Rifamycin, Ampicillin, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248751, "ingredient1": "Phenyl salicylate", "ingredient2": "Olmesartan", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294017/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Sacubitril, Nebivolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "updated_at": 1767369485}, {"id": 248752, "ingredient1": "Phenyl salicylate", "ingredient2": "Omeprazole", "severity": "Minor", "effect": "Coadministration with proton pump inhibitors may decrease the oral bioavailability of aspirin and other salicylates.", "source": "DDInter", "management_text": "In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates. It is only necessary to pay attention to the dosing interval.", "mechanism_text": "Absorption", "recommendation": "In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294018/", "reference_text": "[1] Nefesoglu FZ, Ayanoglu-Dulger G, Ulusoy NB, Imeryuz N \"Interaction of omeprazole with enteric-coated salicylate tablets.\" Int J Clin Pharmacol Ther 36 (1998):  549-53[2] Anand BS, Sanduja SK, Lichetenberger LM \"Effect of omeprazole on the bioavailability of aspirin: a randomized controlled study on healthy volunteers.\" Gastroenterology 116 (1999):  A371[3] Inarrea P, Esteva F, Cornudella R, Lanas A \"Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man.\" Scand J Gastroenterol 35 (2000):  242-6", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Nizatidine, Ranitidine, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 248753, "ingredient1": "Phenyl salicylate", "ingredient2": "Pamidronic acid", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa.  Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.  Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools.  Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.  Serum creatinine should be assessed prior to each treatment, and treatment should be withheld in the presence of renal deterioration.  In patients treated for bone metastases, treatment should not be resumed until renal function returns to baseline.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294019/", "reference_text": "[1] \"Product Information. Didronel I.V. (etidronate).\" MGI Pharma Inc  (2022):[2] \"Product Information. Didronel (etidronate).\" Procter and Gamble Pharmaceuticals  (2022):[3] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Fosamax (alendronate).\" Merck & Co., Inc  (2001):[5] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals  (2001):[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals  (2001):[7] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001):  107-10[8] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001):  1862[9] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc  (2001):[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories  (2005):[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Trospium, Flavoxate, More", "updated_at": 1767369485}, {"id": 248754, "ingredient1": "Phenyl salicylate", "ingredient2": "Pantoprazole", "severity": "Minor", "effect": "Coadministration with proton pump inhibitors may decrease the oral bioavailability of aspirin and other salicylates.", "source": "DDInter", "management_text": "In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates. It is only necessary to pay attention to the dosing interval.", "mechanism_text": "Absorption", "recommendation": "In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294020/", "reference_text": "[1] Nefesoglu FZ, Ayanoglu-Dulger G, Ulusoy NB, Imeryuz N \"Interaction of omeprazole with enteric-coated salicylate tablets.\" Int J Clin Pharmacol Ther 36 (1998):  549-53[2] Anand BS, Sanduja SK, Lichetenberger LM \"Effect of omeprazole on the bioavailability of aspirin: a randomized controlled study on healthy volunteers.\" Gastroenterology 116 (1999):  A371[3] Inarrea P, Esteva F, Cornudella R, Lanas A \"Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man.\" Scand J Gastroenterol 35 (2000):  242-6", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Nizatidine, Ranitidine, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 248755, "ingredient1": "Phenyl salicylate", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294021/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Magnesium hydroxide, Ammonium chloride, More", "updated_at": 1767369485}, {"id": 248756, "ingredient1": "Phenyl salicylate", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations of pemetrexed.  The mechanism has not been described but may be related to NSAID inhibition of renal prostaglandins.", "source": "DDInter", "management_text": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function.  However, caution is advised in patients with mild to moderate renal insufficiency (creatinine clearance 45 to 79 mL/min).  These patients should avoid taking NSAIDs with short elimination half-lives (e.g., diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, sulindac, tolmetin, low dosages of salicylates) 2 days before to 2 days after pemetrexed administration.  If concomitant administration is necessary, patients should be monitored closely for toxicity, especially myelosuppression, nephrotoxicity, and gastrointestinal toxicity.  In the absence of data regarding use with NSAIDs with longer half-lives, withholding NSAID dosing for at least 5 days before to 2 days after pemetrexed administration is recommended.", "mechanism_text": "Synergism", "recommendation": "Ibuprofen at 400 mg and aspirin at 325 mg four times a day, or less, may be used with pemetrexed in patients with normal renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294023/", "reference_text": "[1] Wendland ML, Wagoner RD, Holley KE \"Renal failure associated with fenoprofen.\" Mayo Clin Proc 55 (1980):  103-7[2] Curt GA, Kaldany A, Whitley LG, et al. \"Reversible rapidly progressive renal failure with nephrotic syndrome due to fenoprofen calcium.\" Ann Intern Med 92 (1980):  72-3[3] Artinano M, Etheridge WB, Stroehlein KB, Barcenas CG \"Progression of minimal-change glomerulopathy to focal glomerulosclerosis in a patient with fenoprofen nephropathy.\" Am J Nephrol 6 (1986):  353-7[4] Shah GM, Muhalwas KK, Winer RL \"Renal papillary necrosis due to ibuprofen.\" Arthritis Rheum 24 (1981):  1208-10[5] Fong HJ, Cohen AH \"Ibuprofen-induced acute renal failure with acute tubular necrosis.\" Am J Nephrol 2 (1982):  28-31[6] Gary NE, Dodelson R, Eisinger RP \"Indomethacin-associated acute renal failure.\" Am J Med 69 (1980):  135-6[7] Blackshear JL, Davidman M, Stillman MT \"Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs.\" Arch Intern Med 143 (1983):  1130-4[8] Poitirt TI \"Reversible renal failure associated with ibuprofen: case report and review of the literature.\" Drug Intell Clin Pharm 18 (1984):  27-32[9] Moss AH, Riley R, Murgo A, Skaff LA \"Over-the-counter ibuprofen and nephrotic syndrome.\" Ann Intern Med 105 (1986):  303[10] Bonney SL, Northington RS, Hedrich DA, Walker BR \"Renal safety of two analgesics used over the counter: ibuprofen and aspirin.\" Clin Pharmacol Ther 40 (1986):  373-7[11] Zawada ET \"Renal consequences of nonsteroidal antiinflammatory drugs.\" Postgrad Med J 71 (1982):  223-30[12] Munn E, Lynn KL, Bailey RR \"Renal papillary necrosis following regular consumption of non-steroidal anti-inflammatory drugs.\" N Z Med J 95 (1982):  213-4[13] McCarthy JT, Torres VE, Romero JC, et al. \"Acute intrinsic renal failure induced by indomethacin.\" Mayo Clin Proc 57 (1982):  289-96[14] Marasco WA, Gikas PW, Azziz-Baumgartner R, et al. \"Ibuprofen-associated renal dysfunction: pathophysiologic mechanisms of acute renal failure, hyperkalemia, tubular necrosis, and proteinuria.\" Arch Intern Med 147 (1987):  2107-16[15] Blackshear JL, Davidman M, Stillman MT \"Identification of risk for renal insufficiency from nonsteroidal anti-inflammatory drugs.\" Arch Intern Med 143 (1983):  1130-4[16] Morgenstern SJ, Bruns FJ, Fraley DS, et al. \"Ibuprofen-associated lipoid nephrosis without interstitial nephritis.\" Am J Kidney Dis 14 (1989):  50-2[17] Handa SP \"Drug-induced acute interstitial nephritis: report of 10 cases.\" Can Med Assoc J 135 (1986):  1278-81[18] Boiskin I, Saven A, Mendez M, Raja RM \"Indomethacin and the nephrotic syndrome.\" Ann Intern Med 106 (1987):  776-7[19] Sennesael J, Van den Houte K, Verbeelen D \"Reversible membranous glomerulonephritis associated with ketoprofen.\" Clin Nephrol 26 (1986):  213-5[20] Pazmino PA, Pazmino PB \"Ketoprofen-induced irreversible renal failure.\" Nephron 50 (1988):  70-1[21] Schwarz A, Krause PH, Keller F, et al. \"Granulomatous interstitial nephritis after nonsteroidal anti-inflammatory drugs.\" Am J Nephrol 8 (1988):  410-6[22] Kharasch MS, Johnson KM, Strange GR \"Cardiac arrest secondary to indomethacin-induced renal failure: a case report.\" J Emerg Med 8 (1990):  51-4[23] Brezin JH, Katz SM, Schwartz AB, Chinitz JL \"Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs.\" N Engl J Med 301 (1979):  1271-4[24] Ling BN, Bourke E, Campbell WG, Delaney VB \"Naproxen-induced nephropathy in systemic lupus erythematosus.\" Nephron 54 (1990):  249-55[25] Shpilberg O, Douer D, Ehrenfeld M, et al. \"Naproxen-associated fatal acute renal failure in multiple myeloma.\" Nephron 55 (1990):  448-9[26] Turner R \"Hepatic and renal tolerability of long-term naproxen treatment in patients with rheumatoid arthritis.\" Semin Arthritis Rheum 17 (1988):  29-35[27] Watson WA, Freer JP, Katz RS, Basch C \"Kidney function during naproxen therapy in patients at risk for renal insufficiency.\" Semin Arthritis Rheum 17 (1988):  12-6[28] Caruana RJ, Semble EL \"Renal papillary necrosis due to naproxen.\" J Rheumatol 11 (1984):  90-1[29] Reeve PA, Moshiri M, Bell GD \"Pulmonary oedema, jaundice and renal impairment with naproxen.\" Br J Rheumatol 26 (1987):  70-1[30] Vitting KE, Nichols NJ, Seligson GR \"Naproxen and acute renal failure in a runner.\" Ann Intern Med 105 (1986):  144[31] Schwartzman M, D'Agati V \"Spontaneous relapse of naproxen-related nephrotic syndrome.\" Am J Med 82 (1987):  329-32[32] Brater DC, Anderson SA, Brown D \"Reversible acute decrease in renal function by NSAIDs in cirrhosis.\" Am J Med Sci 294 (1987):  168-74[33] Lomvardias S, Pinn VW, Wadhwa ML, et al. \"Nephrotic syndrome associated with sulindac.\" N Engl J Med 304 (1981):  424[34] Whelton A, Bender W, Vaghaiwalla F, et al. \"Sulindac and renal impairment.\" JAMA 249 (1983):  2892-3[35] Turner GA, Walker RJ, Bailey RR, et al. \"Sulindac-induced acute interstitial nephritis.\" N Z Med J 97 (1984):  239-40[36] de Crespigny PJ, Becker GJ, Ihle BU, et al. \"Renal failure and nephrotic syndrome associated with sulindac.\" Clin Nephrol 30 (1988):  52-5[37] Chatterjee GP \"Nephrotic syndrome induced by tolmetin.\" JAMA 246 (1981):  1589[38] Katz SM, Capaldo R, Everts EA, DiGregorio JG \"Tolmetin: association with reversible renal failure and acute interstitial nephritis.\" JAMA 246 (1981):  243-5[39] Wellborne FR, Claypool RG, Copley JB \"Nephrotic range pseudoproteinuria in a tolmetin-treated patient.\" Clin Nephrol 19 (1983):  211-2[40] Pascoe MD, Gordon GD, Temple-Camp CR \"Tolmetin-induced acute renal failure.\" S Afr Med J 70 (1986):  232-3[41] Tietjen DP \"Recurrence and specificity of nephrotic syndrome due to tolmetin.\" Am J Med 87 (1989):  354-5[42] Kimberly RP, Plotz PH \"Aspirin-induced depression of renal function.\" N Engl J Med 296 (1977):  418-24[43] Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K \"Effects of acetylsalicylic acid on renal function in patients with chronic heart failure.\" Am J Med 90 (1991):  571-5[44] Murray MD, Greene PK, Brater DC, et al. \"Effects of flurbiprofen on renal function in patients with moderate renal insufficiency.\" Br J Clin Pharmacol 33 (1992):  385-93[45] Aitken HA, Burns JW, McArdle CS, Kenny GNC \"Effects of ketorolac trometamol on renal function.\" Br J Anaesth 68 (1992):  481-5[46] Boras-Uber LA, Brackett NC Jr \"Ketorolac-induced acute renal failure.\" Am J Med 92 (1992):  450-2[47] Carmichael J, Shankel SW \"Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function.\" Am J Med 78 (1985):  992-1000[48] Perazella MA, Buller GK \"Can ibuprofen cause acute renal failure in a normal individual? A case of acute overdose.\" Am J Kidney Dis 18 (1991):  600-2[49] Bergamo RR, Cominelli F, Kopple JD, Zipser RD \"Comparative acute effects of aspirin, diflunisal, ibuprofen and indomethacin on renal function in healthy men.\" Am J Nephrol 9 (1989):  460-3[50] Berg KJ, Talseth T \"Acute renal effects of sulindac and indomethacin in chronic renal failure.\" Clin Pharmacol Ther 37 (1985):  447-52[51] Shand DG, Epstein C, Kinberg-Calhoun J, et al. \"The effect of etodolac administration on renal function in patients with arthritis.\" J Clin Pharmacol 26 (1986):  269-74[52] Feinfeld DA, Olesnicky L, Pirani CL, Appel GB \"Nephrotic syndrome associated with use of the nonsteroidal anti-inflammatory drugs: case report and review of the literature.\" Nephron 37 (1984):  174-9[53] Chan XM \"Fatal renal failure due to indomethacin.\" Lancet 2 (1987):  340[54] Maher JF \"Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America.\" Am J Med 76 (1984):  345-8[55] Kaufhold J, Wilkowski M, McCabe K \"Flurbiprofen-associated acute tubulointerstitial nephritis.\" Am J Nephrol 11 (1991):  144-6[56] Colome Nafria E, Solans R, Espinach J, Delgadillo J, Fonollosa V \"Renal papillary necrosis induced by flurbiprofen .\" DICP 25 (1991):  870-1[57] Beun GD, Leunissen KM, Van Breda Vriesman PJ, Van Hooff JP, Grave W \"Isolated minimal change nephropathy associated with diclofenac.\" Br Med J (Clin Res Ed) 295 (1987):  182-3[58] Schwartz J, Altshuler E, Madjar J, Habot B \"Acute renal failure associated with diclofenac treatment in an elderly woman .\" J Am Geriatr Soc 36 (1988):  482[59] Tattersall J, Greenwood R, Farrington K \"Membranous nephropathy associated with diclofenac .\" Postgrad Med J 68 (1992):  392-3[60] Hannedouche T, Dehaine V, Noel LH, Jungers P \"Acute tubular necrosis associated with acute pyelonephritis and concomitant diclofenac therapy .\" Clin Nephrol 28 (1987):  103-4[61] Rossi E, Ferraccioli GF, Cavalieri F, Menta R, Dall'Aglio PP, Migone L \"Diclofenac-associated acute renal failure. Report of 2 cases.\" Nephron 40 (1985):  491-3[62] Wong F, Massie D, Hsu P, Dudley F \"Indomethacin-induced renal dysfunction in patients with well- compensated cirrhosis.\" Gastroenterology 104 (1993):  869-76[63] Pearce CJ, Gonzalez FM, Wallin JD \"Renal failure and hyperkalemia associated with ketorolac tromethamine.\" Arch Intern Med 153 (1993):  1000-2[64] Fong J, Gora ML \"Reversible renal insufficiency following ketorolac therapy.\" Ann Pharmacother 27 (1993):  510-2[65] Jick H, Derby LE, Garcia Rodriguez LA, Jick SS, Dean AD \"Nonsteroidal antiinflammatory drugs and certain rare, serious adverse events: a cohort study.\" Pharmacotherapy 13 (1993):  212-7[66] Frais MA, Burgess ED, Mitchell LB \"Piroxicam-induced renal failure and hyperkalemia.\" Ann Intern Med 99 (1983):  129-30[67] Mitnick PD, Klein WJ, Jr \"Piroxicam-induced renal disease.\" Arch Intern Med 144 (1984):  63-4[68] Loeffler M, Hanson G, Philp T \"Piroxicam-induced renal failure following relief of chronic retention.\" Br J Urol 63 (1989):  438-9[69] Goebel KM, Mueller-Brodmann W \"Reversible overt nephropathy with Henoch-Schonlein purpura due to piroxicam.\" Br Med J (Clin Res Ed) 284 (1982):  311-2[70] Fellner SK \"Piroxicam-induced acute interstitial nephritis and minimal-change nephrotic syndrome.\" Am J Nephrol 5 (1985):  142-3[71] Sarma PS \"Fatal acute renal failure after piroxicam.\" Clin Nephrol 31 (1989):  54[72] Gerber D \"Adverse reactions of piroxicam.\" Drug Intell Clin Pharm 21 (1987):  707-10[73] Brater DC, Brown-Cartwright D, Anderson SA, Uaamnuichai M \"Effect of high-dose etodolac on renal function.\" Clin Pharmacol Ther 42 (1987):  283-9[74] Mitnick PD, Greenberg A, DeOreo PB, Weiner BM, Coffman TM, Walker BR, Agus ZS, Goldfarb S \"Effects of two nonsteroidal anti-inflammatory drugs, indomethacin and oxaprozin, on the kidney.\" Clin Pharmacol Ther 28 (1980):  680-9[75] Quan DJ, Kayser SR \"Ketorolac induced acute renal failure following a single dose.\" J Toxicol Clin Toxicol 32 (1994):  305-9[76] Haragsim L, Dalal R, Bagga H, Bastani B \"Ketorolac-induced acute renal failure and hyperkalemia: report of three cases.\" Am J Kidney Dis 24 (1994):  578-80[77] Perneger TV, Whelton PK, Klag MJ \"Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs.\" N Engl J Med 331 (1994):  1675-9[78] van Biljon G \"Reversible renal failure associated with ibuprofen in a child. A case report.\" S Afr Med J 76 (1989):  34-5[79] Delmas PD \"Non-steroidal anti-inflammatory drugs and renal function.\" Br J Rheumatol 34 Suppl (1995):  25-8[80] Segasothy M, Chin GL, Sia KK, Zulfiqar A, Samad SA \"Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis.\" Br J Rheumatol 34 (1995):  162-5[81] Whelton A \"Renal effects of over-the-counter analgesics.\" J Clin Pharmacol 35 (1995):  454-63[82] Blackwell E, Loughlin K, Dumler F, Smythe M \"Nabumetone-associated interstitial nephritis.\" Pharmacotherapy 15 (1995):  669-72[83] Jonsson CE, Ericsson F \"Impairment of renal function after treatment of a burn patient with diclofenac, a non-steroidal anti-inflammatory drug.\" Burns 21 (1995):  471-3[84] Kelley M, Bastani B \"Ketorolac-induced acute renal failure and hyperkalemia.\" Clin Nephrol 44 (1995):  276-7[85] Radford RG, Holley KE, Grande JP, Larson TS, Wagoner RD, Donadio JV, Mccarthy JT \"Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs.\" JAMA 276 (1996):  466-9[86] Buck ML, Norwood VF \"Ketorolac-induced acute renal failure in a previously healthy adolescent.\" Pediatrics 98 (1996):  294-6[87] Ogawa M, Ueda S, Hamano Y, Ito K, Saisho H, Akikusa B \"Membranous nephropathy associated with oxaprozin treatment.\" Nephron 74 (1996):  439-40[88] Feldman HI, Kinman JL, Berlin JA, et al. \"Parenteral ketorolac: the risk for acute renal failure.\" Ann Intern Med 126 (1997):  193-9[89] Buller GK, Perazella MA \"Acute renal failure and ketorolac.\" Ann Intern Med 127 (1997):  493[90] Feldman HI, Kinman JL, Strom BL \"Acute renal failure and ketorolac.\" Ann Intern Med 127 (1997):  493-4[91] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):[92] Cangiano JL, Figueroa J, Palmer R \"Renal hemodynamic effects of nabumetone, sulindac, and placebo in patients with osteoarthritis.\" Clin Ther 21 (1999):  503-12[93] Wolf G, Porth J, Stahl RA \"Acute renal failure associated with rofecoxib.\" Ann Intern Med 133 (2000):  394[94] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company  (2004):", "alternatives_a": "Methotrexate, Fluorouracil, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248757, "ingredient1": "Phenyl salicylate", "ingredient2": "Perindopril", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.", "source": "DDInter", "management_text": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294024/", "reference_text": "[1] Moore TJ, Crantz FR, Hollenberg NK \"Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.\" Hypertension 3 (1981):  168-73[2] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[3] Silberbauer K, Stanek B, Templ H \"Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.\" Br J Clin Pharmacol 14 (1982):  s87-93[4] Ahmad S \"Indomethacin-enalapril interaction: an alert.\" South Med J 84 (1991):  411-2[5] Allon M, Pasque CB, Rodriguez M \"Interaction of captopril and ibuprofen on glomerular and tubular function in humans.\" Am J Physiol 259 (1990):  f233-8[6] Seto S, Aoi W, Iwami K, et al. \"Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension.\" Clin Exp Hypertens 9 (1987):  623-7[7] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[8] Abdel-Haq B, Magagna A, Favilla S, Salvetti A \"Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects.\" J Cardiovasc Pharmacol 18 (1991):  s33-6[9] Morgan T, Anderson A \"Interaction of indomethacin with felodipine and enalapril.\" J Hypertens 11 (1993):  S338-9[10] \"Product Information. Daypro (oxaprozin).\" Searle  (2001):[11] Townend JN, Doran J, Lote CJ, Davies MK \"Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.\" Br Heart J 73 (1995):  434-41[12] Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueiragomes M \"Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients.\" J Hypertens 13 (1995):  925-31[13] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Indapamide, Bisoprolol, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Pravastatin, Ezetimibe, Bempedoic acid, Indapamide, Fenofibrate", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248758, "ingredient1": "Plazomicin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods.", "source": "DDInter", "management_text": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.  During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294025/", "reference_text": "[1] Zarfin Y, Koren G, Maresky D, et al. \"Clinical and laboratory observations: possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 106 (1985):  511-3[2] Scott CS, RetschBogart GZ, Henry MM \"Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen.\" Pediat Pulm 31 (2001):  314-6[3] Kovesi TA, Swartz R, MacDonald N \"Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.\" N Engl J Med 338 (1998):  65-6[4] Gagliardi L \"Possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 107 (1985):  991-2[5] Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S \"Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium.\" Clin Sci 91 (1996):  187-91[6] Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M \"Prostaglandins and aminoglycoside nephrotoxicity.\" Toxicol Appl Pharmacol 78 (1985):  386-94", "alternatives_a": "Neomycin", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248759, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294026/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248760, "ingredient1": "Potassium citrate", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to increased urinary pH, resulting in increased renal salicylate clearance especially above urine pH of 7.  This interaction is sometimes exploited in the treatment of salicylate toxicity.", "source": "DDInter", "management_text": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294027/", "reference_text": "[1] Berg KJ \"Acute acetylsalicylic acid poisoning: treatment with forced alkaline diuresis and diuretics.\" Eur J Clin Pharmacol 12 (1977):  111-6[2] Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT \"Diuresis or urinary alkalinisation for salicylate poisoning?\" Br Med J (Clin Res Ed) 285 (1982):  1383-6[3] Balali-Mood M, Prescott LF \"Failure of alkaline diuresis to enhance diflunisal elimination.\" Br J Clin Pharmacol 10 (1980):  163-5[4] Berg KJ \"Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency.\" Eur J Clin Pharmacol 11 (1977):  111-6[5] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More", "updated_at": 1767369485}, {"id": 248761, "ingredient1": "Prasugrel", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Concomitant use of prasugrel with other agents that affect hemostasis including aspirin may increase the risk of bleeding.", "source": "DDInter", "management_text": "Although prasugrel may be used with aspirin, caution is advised during coadministration with any salicylate, especially in patients at risk for gastrointestinal ulceration or bleeding.  Close clinical and laboratory observation for hemorrhagic complications is recommended.  Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, hematemesis, anorexia, and/or black, tarry stools.", "mechanism_text": "Synergism", "recommendation": "Although prasugrel may be used with aspirin, caution is advised during coadministration with any salicylate, especially in patients at risk for gastrointestinal ulceration or bleeding.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294028/", "reference_text": "[1] \"Product Information. Effient (prasugrel).\" Lilly, Eli and Company  (2009):", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248762, "ingredient1": "Prednisolone", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.", "source": "DDInter", "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294029/", "reference_text": "[1] Baer PA, Shore A, Ikeman RL \"Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis.\" Arthritis Rheum 30 (1987):  345-7[2] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L \"Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis.\" Ther Drug Monit 9 (1987):  177-9[3] Edelman J, Potter JM, Hackett LP \"The effect of intra-articular steroids on plasma salicylate concentrations.\" Br J Clin Pharmacol 21 (1986):  301-7[4] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991):  735-40[5] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD \"Risk of adverse gastrointestinal events from inhaled corticosteroids.\" Pharmacotherapy 28 (2008):  1325-34", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluorometholone, Indomethacin, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Avanafil, More", "updated_at": 1767369485}, {"id": 248763, "ingredient1": "Prednisone", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.", "source": "DDInter", "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294030/", "reference_text": "[1] Baer PA, Shore A, Ikeman RL \"Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis.\" Arthritis Rheum 30 (1987):  345-7[2] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L \"Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis.\" Ther Drug Monit 9 (1987):  177-9[3] Edelman J, Potter JM, Hackett LP \"The effect of intra-articular steroids on plasma salicylate concentrations.\" Br J Clin Pharmacol 21 (1986):  301-7[4] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991):  735-40[5] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD \"Risk of adverse gastrointestinal events from inhaled corticosteroids.\" Pharmacotherapy 28 (2008):  1325-34", "alternatives_a": "Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 248764, "ingredient1": "Probenecid", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Large, anti-inflammatory doses of salicylates may inhibit the uricosuric effect of probenecid.", "source": "DDInter", "management_text": "Large doses of salicylates should be avoided in patients who require probenecid for the treatment of hyperuricemia or gout.  However, occasional use of low dosages for analgesia or daily use of cardioprotective dosages should generally not be a concern.", "mechanism_text": "Antagonism", "recommendation": "Large doses of salicylates should be avoided in patients who require probenecid for the treatment of hyperuricemia or gout.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294031/", "reference_text": "[1] Diamond JS, Paolino JS \"Evidence for a postsecretory reabsorptive site for uric acid in man.\" J Clin Invest 52 (1973):  1491-9[2] Regal RE \"Aspirin and uricosurics: interaction revisited.\" Drug Intell Clin Pharm 21 (1987):  219-20[3] Harris M, Bryant LR, Danaher P, Alloway J \"Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis.\" J Rheumatol 27 (2000):  2873-6[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Allopurinol, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248765, "ingredient1": "Quinapril", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.", "source": "DDInter", "management_text": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294032/", "reference_text": "[1] Moore TJ, Crantz FR, Hollenberg NK \"Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.\" Hypertension 3 (1981):  168-73[2] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[3] Silberbauer K, Stanek B, Templ H \"Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.\" Br J Clin Pharmacol 14 (1982):  s87-93[4] Ahmad S \"Indomethacin-enalapril interaction: an alert.\" South Med J 84 (1991):  411-2[5] Allon M, Pasque CB, Rodriguez M \"Interaction of captopril and ibuprofen on glomerular and tubular function in humans.\" Am J Physiol 259 (1990):  f233-8[6] Seto S, Aoi W, Iwami K, et al. \"Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension.\" Clin Exp Hypertens 9 (1987):  623-7[7] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[8] Abdel-Haq B, Magagna A, Favilla S, Salvetti A \"Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects.\" J Cardiovasc Pharmacol 18 (1991):  s33-6[9] Morgan T, Anderson A \"Interaction of indomethacin with felodipine and enalapril.\" J Hypertens 11 (1993):  S338-9[10] \"Product Information. Daypro (oxaprozin).\" Searle  (2001):[11] Townend JN, Doran J, Lote CJ, Davies MK \"Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.\" Br Heart J 73 (1995):  434-41[12] Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueiragomes M \"Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients.\" J Hypertens 13 (1995):  925-31[13] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Indapamide, Bisoprolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, More", "updated_at": 1767369485}, {"id": 248766, "ingredient1": "Rabeprazole", "ingredient2": "Phenyl salicylate", "severity": "Minor", "effect": "Coadministration with proton pump inhibitors may decrease the oral bioavailability of aspirin and other salicylates.", "source": "DDInter", "management_text": "In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates. It is only necessary to pay attention to the dosing interval.", "mechanism_text": "Absorption", "recommendation": "In clinical practice, proton pump inhibitors are frequently used to attenuate gastric mucosal damage caused by salicylates.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294033/", "reference_text": "[1] Nefesoglu FZ, Ayanoglu-Dulger G, Ulusoy NB, Imeryuz N \"Interaction of omeprazole with enteric-coated salicylate tablets.\" Int J Clin Pharmacol Ther 36 (1998):  549-53[2] Anand BS, Sanduja SK, Lichetenberger LM \"Effect of omeprazole on the bioavailability of aspirin: a randomized controlled study on healthy volunteers.\" Gastroenterology 116 (1999):  A371[3] Inarrea P, Esteva F, Cornudella R, Lanas A \"Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man.\" Scand J Gastroenterol 35 (2000):  242-6", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Nizatidine, Ranitidine, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 248767, "ingredient1": "Ramipril", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.", "source": "DDInter", "management_text": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294034/", "reference_text": "[1] Moore TJ, Crantz FR, Hollenberg NK \"Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.\" Hypertension 3 (1981):  168-73[2] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[3] Silberbauer K, Stanek B, Templ H \"Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.\" Br J Clin Pharmacol 14 (1982):  s87-93[4] Ahmad S \"Indomethacin-enalapril interaction: an alert.\" South Med J 84 (1991):  411-2[5] Allon M, Pasque CB, Rodriguez M \"Interaction of captopril and ibuprofen on glomerular and tubular function in humans.\" Am J Physiol 259 (1990):  f233-8[6] Seto S, Aoi W, Iwami K, et al. \"Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension.\" Clin Exp Hypertens 9 (1987):  623-7[7] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[8] Abdel-Haq B, Magagna A, Favilla S, Salvetti A \"Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects.\" J Cardiovasc Pharmacol 18 (1991):  s33-6[9] Morgan T, Anderson A \"Interaction of indomethacin with felodipine and enalapril.\" J Hypertens 11 (1993):  S338-9[10] \"Product Information. Daypro (oxaprozin).\" Searle  (2001):[11] Townend JN, Doran J, Lote CJ, Davies MK \"Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.\" Br Heart J 73 (1995):  434-41[12] Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueiragomes M \"Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients.\" J Hypertens 13 (1995):  925-31[13] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Indapamide, Bisoprolol, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Pravastatin, Ezetimibe, Bempedoic acid, Indapamide, Fenofibrate", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Ammonium chloride, Dimethyl sulfoxide, Solifenacin", "updated_at": 1767369485}, {"id": 248768, "ingredient1": "Ramucirumab", "ingredient2": "Phenyl salicylate", "severity": "Major", "effect": "Theoretical concerns exist that nonsteroid anti-inflammatory drugs (NSAIDs) and salicylates may potentiate the risk of bleeding and gastrointestinal perforation associated with ramucirumab therapy.", "source": "DDInter", "management_text": "Caution is advised if ramucirumab must be used with chronic NSAID or salicylate therapy.  Close clinical and laboratory observation for bleeding complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Ramucirumab should be permanently discontinued in patients who experience severe bleeding or gastrointestinal perforation.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ramucirumab must be used with chronic NSAID or salicylate therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294035/", "reference_text": "[1] \"Product Information. Cyramza (ramucirumab).\" Eli Lilly and Company  (2014):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248769, "ingredient1": "Repaglinide", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294036/", "reference_text": "[1] Petitpierre B, Perrin L, Rudhardt M, et al. \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972):  120-4[2] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[3] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[4] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[5] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984):  470-2[6] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[7] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[8] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[9] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967):  889-94[10] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[11] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[12] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[13] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[14] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[15] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[16] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[17] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[18] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[19] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[20] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[21] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[22] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[23] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990):  s30-4[24] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[25] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[26] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[27] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976):  58-63[28] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[29] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[30] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[31] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[32] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[33] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[34] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985):  482-5[35] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[36] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[37] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987):  245-7[38] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992):  317-9[39] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974):  344[40] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[41] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971):  1092-3[42] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[43] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977):  573-9[44] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[45] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971):  29-30[46] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[47] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[48] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[49] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn  (2002):[50] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[51] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[52] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[53] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[54] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[55] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[56] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[57] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[58] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[59] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[60] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[61] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[62] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[63] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[64] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[65] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[66] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[67] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994):  163-76[68] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994):  997-1002[69] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[70] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[71] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[72] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[73] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[74] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[75] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[76] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[77] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990):  245-52[78] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[79] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982):  123-6[80] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[81] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[82] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[83] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[84] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[85] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[86] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[87] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[88] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001):  194-200[89] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[90] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[91] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002):  1772-8[92] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[93] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997):  31-36[94] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[95] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[96] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001):  344[97] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001):  1845-6[98] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[99] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[100] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[101] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[102] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248770, "ingredient1": "Reteplase", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.", "source": "DDInter", "management_text": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.  Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment.", "mechanism_text": "Synergism", "recommendation": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294037/", "reference_text": "[1] \"Product Information. Ticlid (ticlopidine).\" Syntex Laboratories Inc  (2001):[2] \"Product Information. Abbokinase (urokinase).\" Abbott Pharmaceutical  (2001):[3] \"Product Information. Activase (alteplase).\" Genentech  (2001):[4] \"Product Information. Streptase (streptokinase).\" Astra-Zeneca Pharmaceuticals  (2001):[5] \"Product Information. Retavase (reteplase).\" Boehringer Mannheim  (2001):[6] \"Product Information. TNKase (tenecteplase).\" Genentech  (2001):[7] Harder S, Klinkhardt U \"Thrombolytics: drug interactions of clinical significance.\" Drug Saf 23 (2000):  391-9[8] Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians \"The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians.\" Chest 119(1 Suppl) (2001):  1S-2S", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248771, "ingredient1": "Risedronic acid", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa.  Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.  Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools.  Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.  Serum creatinine should be assessed prior to each treatment, and treatment should be withheld in the presence of renal deterioration.  In patients treated for bone metastases, treatment should not be resumed until renal function returns to baseline.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294038/", "reference_text": "[1] \"Product Information. Didronel I.V. (etidronate).\" MGI Pharma Inc  (2022):[2] \"Product Information. Didronel (etidronate).\" Procter and Gamble Pharmaceuticals  (2022):[3] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Fosamax (alendronate).\" Merck & Co., Inc  (2001):[5] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals  (2001):[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals  (2001):[7] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001):  107-10[8] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001):  1862[9] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc  (2001):[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories  (2005):[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 248772, "ingredient1": "Rivaroxaban", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294039/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248773, "ingredient1": "Salsalate", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding, ulceration) and bruising or bleeding.", "source": "DDInter", "management_text": "Concomitant use of more than one salicylate at a time should generally be avoided.  Patients treated with a salicylate should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of more than one salicylate at a time should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294040/", "reference_text": "[1] \"Product Information. Pepto-Bismol (bismuth subsalicylate).\" Procter and Gamble Pharmaceuticals  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Diflunisal, Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248774, "ingredient1": "Sertraline", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294041/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248775, "ingredient1": "Sibutramine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294042/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248776, "ingredient1": "Sodium acetate", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to increased urinary pH, resulting in increased renal salicylate clearance especially above urine pH of 7.  This interaction is sometimes exploited in the treatment of salicylate toxicity.", "source": "DDInter", "management_text": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294043/", "reference_text": "[1] Berg KJ \"Acute acetylsalicylic acid poisoning: treatment with forced alkaline diuresis and diuretics.\" Eur J Clin Pharmacol 12 (1977):  111-6[2] Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT \"Diuresis or urinary alkalinisation for salicylate poisoning?\" Br Med J (Clin Res Ed) 285 (1982):  1383-6[3] Balali-Mood M, Prescott LF \"Failure of alkaline diuresis to enhance diflunisal elimination.\" Br J Clin Pharmacol 10 (1980):  163-5[4] Berg KJ \"Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency.\" Eur J Clin Pharmacol 11 (1977):  111-6[5] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Calcium chloride, Potassium chloride, Magnesium sulfate, Zinc sulfate, Arginine, Sodium glycerophosphate, Zinc chloride, Sodium chloride, Potassium acetate, Ammonium chloride, Magnesium chloride", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248777, "ingredient1": "Sodium bicarbonate", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to increased urinary pH, resulting in increased renal salicylate clearance especially above urine pH of 7.  This interaction is sometimes exploited in the treatment of salicylate toxicity.", "source": "DDInter", "management_text": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294044/", "reference_text": "[1] Berg KJ \"Acute acetylsalicylic acid poisoning: treatment with forced alkaline diuresis and diuretics.\" Eur J Clin Pharmacol 12 (1977):  111-6[2] Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT \"Diuresis or urinary alkalinisation for salicylate poisoning?\" Br Med J (Clin Res Ed) 285 (1982):  1383-6[3] Balali-Mood M, Prescott LF \"Failure of alkaline diuresis to enhance diflunisal elimination.\" Br J Clin Pharmacol 10 (1980):  163-5[4] Berg KJ \"Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency.\" Eur J Clin Pharmacol 11 (1977):  111-6[5] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Sorbitol, Sulfamethizole, Magnesium citrate, Sodium chloride, Mannitol, Chlorhexidine, Neomycin, Calcium chloride, Potassium chloride, Magnesium sulfate, Zinc sulfate, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Trospium, Flavoxate, More", "updated_at": 1767369485}, {"id": 248778, "ingredient1": "Sodium citrate", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to increased urinary pH, resulting in increased renal salicylate clearance especially above urine pH of 7.  This interaction is sometimes exploited in the treatment of salicylate toxicity.", "source": "DDInter", "management_text": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294045/", "reference_text": "[1] Berg KJ \"Acute acetylsalicylic acid poisoning: treatment with forced alkaline diuresis and diuretics.\" Eur J Clin Pharmacol 12 (1977):  111-6[2] Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT \"Diuresis or urinary alkalinisation for salicylate poisoning?\" Br Med J (Clin Res Ed) 285 (1982):  1383-6[3] Balali-Mood M, Prescott LF \"Failure of alkaline diuresis to enhance diflunisal elimination.\" Br J Clin Pharmacol 10 (1980):  163-5[4] Berg KJ \"Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency.\" Eur J Clin Pharmacol 11 (1977):  111-6[5] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Sorbitol, Sulfamethizole, Magnesium citrate, Sodium chloride, Mannitol, Chlorhexidine, Neomycin", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248779, "ingredient1": "Iodide I-123", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.", "source": "DDInter", "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.  Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week.  Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.", "mechanism_text": "Others", "recommendation": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294046/", "reference_text": "[1] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare  (2022):", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248780, "ingredient1": "Iodide I-131", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.", "source": "DDInter", "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.  Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week.  Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.", "mechanism_text": "Others", "recommendation": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294047/", "reference_text": "[1] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare  (2022):", "alternatives_a": "Ibritumomab tiuxetan, Tositumomab", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248781, "ingredient1": "Phenyl salicylate", "ingredient2": "Lactic acid", "severity": "Moderate", "effect": "Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to increased urinary pH, resulting in increased renal salicylate clearance especially above urine pH of 7.  This interaction is sometimes exploited in the treatment of salicylate toxicity.", "source": "DDInter", "management_text": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294048/", "reference_text": "[1] Berg KJ \"Acute acetylsalicylic acid poisoning: treatment with forced alkaline diuresis and diuretics.\" Eur J Clin Pharmacol 12 (1977):  111-6[2] Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT \"Diuresis or urinary alkalinisation for salicylate poisoning?\" Br Med J (Clin Res Ed) 285 (1982):  1383-6[3] Balali-Mood M, Prescott LF \"Failure of alkaline diuresis to enhance diflunisal elimination.\" Br J Clin Pharmacol 10 (1980):  163-5[4] Berg KJ \"Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency.\" Eur J Clin Pharmacol 11 (1977):  111-6[5] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Mitapivat, Methazolamide, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248782, "ingredient1": "Sparfloxacin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294051/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Sildenafil, Mirabegron, Alprostadil, Yohimbine, Flavoxate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248783, "ingredient1": "Spironolactone", "ingredient2": "Phenyl salicylate", "severity": "Minor", "effect": "Some salicylates may impair the tubular secretion of canrenone, the main active metabolite of spironolactone.  This effect could inhibit the natriuretic properties of spironolactone.", "source": "DDInter", "management_text": "Some salicylates may impair the tubular secretion of canrenone, the main active metabolite of spironolactone.  This effect could inhibit the natriuretic properties of spironolactone.  Data are available for aspirin.  If diuresis is inadequate, the clinician should consider discontinuing the salicylate or increasing spironolactone dosage while paying careful attention to the patient's serum potassium concentration.", "mechanism_text": "Antagonism", "recommendation": "Some salicylates may impair the tubular secretion of canrenone, the main active metabolite of spironolactone.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294053/", "reference_text": "[1] Tweeddale MG, Ogilvie RI \"Antagonism of spironolactone-induced natriuresis by aspirin in man.\" N Engl J Med 289 (1973):  198-200[2] Favre L, Glasson P, Riondel A, Vallotton MB \"Interaction of diuretics and non-steroidal anti-inflammatory drugs in man.\" Clin Sci 64 (1983):  407-15[3] Kramer HJ, Dusing R, Stinnesbeck B, et al. \"Interaction of conventional and antikaliuretic diuretics with the renal prostaglandin system.\" Clin Sci 59 (1980):  67-70", "alternatives_a": "Amiloride, Triamterene, Finerenone", "alternatives_b": "Fesoterodine, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, Ammonium chloride, Dimethyl sulfoxide, Solifenacin", "updated_at": 1767369485}, {"id": 248784, "ingredient1": "St. John's Wort", "ingredient2": "Methylene blue", "severity": "Major", "effect": "Coadministration of methylene blue with serotonergic agents may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Current research suggests that methylene blue has structural properties similar to monoamine oxidase inhibitors (MAOIs). As such, it may enhance serotonergic effects by inhibiting serotonin metabolism.", "source": "DDInter", "management_text": "Serotonergic agents should not be used in patients receiving methylene blue intravenously.  Most serotonergic psychiatric drugs should be stopped 1 to 2 weeks (i.e., 4 to 5 half-lives) prior to treatment with methylene blue if possible, while others such as fluoxetine may require discontinuation up to 5 weeks in advance due to its prolonged half-life.  Treatment with serotonergic medications may be resumed 24 hours after the last dose of methylene blue.  In patients receiving methylene blue who require urgent treatment of a psychiatric condition, other interventions including hospitalization should be considered.  Conversely, when urgent treatment with methylene blue is required (e.g., methemoglobinemia, ifosfamide-induced encephalopathy, cyanide poisoning) in patients receiving serotonergic agents, the benefit of methylene blue treatment should be weighed against the risk of serotonin toxicity.  If a decision is made to use methylene blue, the serotonergic drug must be immediately stopped, and the patient closely monitored for emergent symptoms of CNS toxicity for two weeks (five weeks if fluoxetine was taken; three weeks if vortioxetine was taken) or until 24 hours after the last dose of methylene blue, whichever comes first.  Patients and/or their caregivers should be advised to seek medical attention if potential symptoms of serotonin syndrome develop.", "mechanism_text": "Synergism", "recommendation": "Serotonergic agents should not be used in patients receiving methylene blue intravenously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294054/", "reference_text": "[1] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Ng BK, Cameron AJ, Liang R, Rahman H \"[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review]\" Can J Anaesth 55 (2008):  36-41[4] Gillman PK \"Methylene blue is a potent monoamine oxidase inhibitor.\" Can J Anaesth 55 (2008):  311-2; author reply 312[5] Khavandi A, Whitaker J, Gonna H \"Serotonin toxicity precipitated by concomitant use of citalopram and methylene blue.\" Med J Aust 189 (2008):  534-5[6] Ng BK, Cameron AJ \"The role of methylene blue in serotonin syndrome: a systematic review.\" Psychosomatics 51 (2010):  194-200[7] Heritier Barras AC, Walder B, Seeck M \"Serotonin syndrome following Methylene Blue infusion: a rare complication of antidepressant therapy.\" J Neurol Neurosurg Psychiatry 81 (2010):  1412-3[8] Gillman PK \"Methylene blue and serotonin toxicity: definite causal link.\" Psychosomatics 51 (2010):  448-9[9] Health Canada \"Association of serotonin toxicity with methylene blue injectable in combination with serotonin reuptake inhibitors.  http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/advisories-avis/prof/2011/methylene_blue-bleu_nth-aah-eng.pdf\"   (2011):[10] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications.  http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm\"   (2011):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248785, "ingredient1": "Streptokinase", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.", "source": "DDInter", "management_text": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.  Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment.", "mechanism_text": "Synergism", "recommendation": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294055/", "reference_text": "[1] \"Product Information. Ticlid (ticlopidine).\" Syntex Laboratories Inc  (2001):[2] \"Product Information. Abbokinase (urokinase).\" Abbott Pharmaceutical  (2001):[3] \"Product Information. Activase (alteplase).\" Genentech  (2001):[4] \"Product Information. Streptase (streptokinase).\" Astra-Zeneca Pharmaceuticals  (2001):[5] \"Product Information. Retavase (reteplase).\" Boehringer Mannheim  (2001):[6] \"Product Information. TNKase (tenecteplase).\" Genentech  (2001):[7] Harder S, Klinkhardt U \"Thrombolytics: drug interactions of clinical significance.\" Drug Saf 23 (2000):  391-9[8] Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians \"The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians.\" Chest 119(1 Suppl) (2001):  1S-2S", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248786, "ingredient1": "Streptomycin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods.", "source": "DDInter", "management_text": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.  During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294056/", "reference_text": "[1] Zarfin Y, Koren G, Maresky D, et al. \"Clinical and laboratory observations: possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 106 (1985):  511-3[2] Scott CS, RetschBogart GZ, Henry MM \"Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen.\" Pediat Pulm 31 (2001):  314-6[3] Kovesi TA, Swartz R, MacDonald N \"Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.\" N Engl J Med 338 (1998):  65-6[4] Gagliardi L \"Possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 107 (1985):  991-2[5] Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S \"Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium.\" Clin Sci 91 (1996):  187-91[6] Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M \"Prostaglandins and aminoglycoside nephrotoxicity.\" Toxicol Appl Pharmacol 78 (1985):  386-94", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248787, "ingredient1": "Telmisartan", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294057/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Sacubitril, Nebivolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Papaverine, More", "updated_at": 1767369485}, {"id": 248788, "ingredient1": "Tenecteplase", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.", "source": "DDInter", "management_text": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.  Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment.", "mechanism_text": "Synergism", "recommendation": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294058/", "reference_text": "[1] \"Product Information. Ticlid (ticlopidine).\" Syntex Laboratories Inc  (2001):[2] \"Product Information. Abbokinase (urokinase).\" Abbott Pharmaceutical  (2001):[3] \"Product Information. Activase (alteplase).\" Genentech  (2001):[4] \"Product Information. Streptase (streptokinase).\" Astra-Zeneca Pharmaceuticals  (2001):[5] \"Product Information. Retavase (reteplase).\" Boehringer Mannheim  (2001):[6] \"Product Information. TNKase (tenecteplase).\" Genentech  (2001):[7] Harder S, Klinkhardt U \"Thrombolytics: drug interactions of clinical significance.\" Drug Saf 23 (2000):  391-9[8] Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians \"The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians.\" Chest 119(1 Suppl) (2001):  1S-2S", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248789, "ingredient1": "Teriflunomide", "ingredient2": "Phenyl salicylate", "severity": "Major", "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide.  The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.", "source": "DDInter", "management_text": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity.  Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter.  Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide.  Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.  Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary.  All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, light colored stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294059/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion Roussel  (2001):[2] EMEA \"EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.  Available from URL: http://www.eudra.org/emea.html\"   (2001):[3] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation  (2012):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248790, "ingredient1": "Ticagrelor", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The concomitant use of ticagrelor with other platelet inhibitors, anticoagulants, thrombolytic agents, or nonsteroidal anti-inflammatory drugs may increase the risk of bleeding.", "source": "DDInter", "management_text": "Caution is recommended when these drugs are used concomitantly with ticagrelor or within 24 hours of ticagrelor dosing.  Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when these drugs are used concomitantly with ticagrelor or within 24 hours of ticagrelor dosing.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294060/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals  (2011):", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248791, "ingredient1": "Tiludronic acid", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa.  Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.  Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools.  Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.  Serum creatinine should be assessed prior to each treatment, and treatment should be withheld in the presence of renal deterioration.  In patients treated for bone metastases, treatment should not be resumed until renal function returns to baseline.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294061/", "reference_text": "[1] \"Product Information. Didronel I.V. (etidronate).\" MGI Pharma Inc  (2022):[2] \"Product Information. Didronel (etidronate).\" Procter and Gamble Pharmaceuticals  (2022):[3] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Fosamax (alendronate).\" Merck & Co., Inc  (2001):[5] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals  (2001):[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals  (2001):[7] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001):  107-10[8] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001):  1862[9] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc  (2001):[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories  (2005):[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248792, "ingredient1": "Tinzaparin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294062/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248793, "ingredient1": "Tirofiban", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due to the additive inhibitory effects of salicylates on platelet function.  Arterial puncture sites may be most problematic.", "source": "DDInter", "management_text": "It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.  Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites.  Therapy should be discontinued immediately if serious or uncontrollable bleeding or thrombocytopenia occurs.", "mechanism_text": "Synergism", "recommendation": "It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294063/", "reference_text": "[1] \"Product Information. ReoPro (abciximab).\" Lilly, Eli and Company  (2001):[2] \"Product Information. Integrilin (eptifibatide).\" Schering Corporation  (2001):[3] Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S \"Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.\" Clin Pharmacol Ther 67 (2000):  305-13[4] Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians \"The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians.\" Chest 119(1 Suppl) (2001):  1S-2S", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248794, "ingredient1": "Tobramycin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods.", "source": "DDInter", "management_text": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.  During coadministration, plasma antibiotic concentrations and renal function should be closely monitored, and the antibiotic dosage further adjusted as necessary.", "mechanism_text": "Synergism", "recommendation": "It may be advisable to consider reducing the dosage of aminoglycoside prior to initiation of NSAID therapy in infants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294064/", "reference_text": "[1] Zarfin Y, Koren G, Maresky D, et al. \"Clinical and laboratory observations: possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 106 (1985):  511-3[2] Scott CS, RetschBogart GZ, Henry MM \"Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen.\" Pediat Pulm 31 (2001):  314-6[3] Kovesi TA, Swartz R, MacDonald N \"Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.\" N Engl J Med 338 (1998):  65-6[4] Gagliardi L \"Possible indomethacin-aminoglycoside interaction in preterm infants.\" J Pediatr 107 (1985):  991-2[5] Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S \"Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium.\" Clin Sci 91 (1996):  187-91[6] Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M \"Prostaglandins and aminoglycoside nephrotoxicity.\" Toxicol Appl Pharmacol 78 (1985):  386-94", "alternatives_a": "Rifamycin, Ampicillin, Azithromycin, Acyclovir, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Neomycin, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Trospium, More", "updated_at": 1767369485}, {"id": 248795, "ingredient1": "Tofacitinib", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294065/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248796, "ingredient1": "Tolazamide", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294066/", "reference_text": "[1] Petitpierre B, Perrin L, Rudhardt M, et al. \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972):  120-4[2] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[3] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[4] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[5] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984):  470-2[6] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[7] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[8] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[9] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967):  889-94[10] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[11] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[12] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[13] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[14] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[15] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[16] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[17] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[18] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[19] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[20] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[21] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[22] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[23] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990):  s30-4[24] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[25] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[26] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[27] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976):  58-63[28] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[29] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[30] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[31] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[32] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[33] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[34] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985):  482-5[35] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[36] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[37] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987):  245-7[38] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992):  317-9[39] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974):  344[40] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[41] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971):  1092-3[42] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[43] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977):  573-9[44] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[45] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971):  29-30[46] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[47] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[48] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[49] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn  (2002):[50] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[51] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[52] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[53] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[54] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[55] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[56] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[57] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[58] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[59] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[60] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[61] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[62] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[63] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[64] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[65] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[66] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[67] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994):  163-76[68] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994):  997-1002[69] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[70] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[71] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[72] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[73] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[74] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[75] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[76] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[77] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990):  245-52[78] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[79] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982):  123-6[80] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[81] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[82] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[83] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[84] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[85] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[86] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[87] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[88] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001):  194-200[89] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[90] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[91] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002):  1772-8[92] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[93] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997):  31-36[94] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[95] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[96] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001):  344[97] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001):  1845-6[98] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[99] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[100] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[101] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[102] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248797, "ingredient1": "Tolbutamide", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294067/", "reference_text": "[1] Petitpierre B, Perrin L, Rudhardt M, et al. \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972):  120-4[2] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[3] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[4] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[5] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984):  470-2[6] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[7] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[8] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[9] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967):  889-94[10] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[11] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[12] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[13] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[14] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[15] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[16] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[17] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[18] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[19] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[20] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[21] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[22] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[23] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990):  s30-4[24] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[25] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[26] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[27] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976):  58-63[28] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[29] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[30] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[31] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[32] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[33] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[34] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985):  482-5[35] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[36] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[37] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987):  245-7[38] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992):  317-9[39] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974):  344[40] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[41] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971):  1092-3[42] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[43] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977):  573-9[44] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[45] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971):  29-30[46] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[47] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[48] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[49] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn  (2002):[50] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[51] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[52] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[53] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[54] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[55] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[56] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[57] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[58] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[59] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[60] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[61] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[62] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[63] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[64] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[65] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[66] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[67] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994):  163-76[68] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994):  997-1002[69] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[70] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[71] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[72] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[73] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[74] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[75] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[76] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[77] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990):  245-52[78] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[79] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982):  123-6[80] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[81] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[82] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[83] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[84] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[85] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[86] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[87] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[88] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001):  194-200[89] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[90] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[91] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002):  1772-8[92] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[93] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997):  31-36[94] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[95] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[96] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001):  344[97] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001):  1845-6[98] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[99] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[100] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[101] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[102] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Methacholine, Folic acid, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248798, "ingredient1": "Torasemide", "ingredient2": "Phenyl salicylate", "severity": "Minor", "effect": "Salicylates in anti-inflammatory dosages may blunt the diuretic and natriuretic response to loop diuretics.  The interaction has been demonstrated in patients with ascites secondary to liver cirrhosis and in normal volunteers.  Investigators theorize that salicylates may inhibit the renal effects of loop diuretics that are mediated by prostaglandins, including increases in sodium excretion, renal blood flow, and plasma renin activity.", "source": "DDInter", "management_text": "Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.  No clinical interventions are generally required, but the possibility of a potential interaction should be considered in patients with ascites treated with a loop diuretic and salicylate or salicylate-related product.", "mechanism_text": "Antagonism", "recommendation": "Since renal prostaglandins are believed to play a major role in the maintenance of renal blood flow and glomerular filtration rate in cirrhotics with ascites, the interaction may be particularly important in this population.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294068/", "reference_text": "[1] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981):  663-7[2] Salerno F, Lorenzano E, Maggi A, Badalamenti S, Minuz P, Degan M, Chinea B, Scotti A \"Effects of imidazole-salicylate on renal function and the diuretic action of furosemide in cirrhotic patients with ascites.\" J Hepatol 19 (1993):  279-84[3] Bartoli E, Arras S, Faedda R, Soggia G, Satta A, Olmeo NA \"Blunting of furosemide diuresis by aspirin in man.\" J Clin Pharmacol 20 (1980):  452-8[4] Tobert MB, Ostaszewski T, Reger B, Meisinger MA, Cook TJ \"Diflunisal-furosemide interaction.\" Clin Pharmacol Ther 27 (1980):  289-90[5] Planas R, Arroyo V, Rimola A, Perez-Ayuso RM, Rodes J \"Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites.\" Gastroenterology 84 (1983):  247-52[6] Wilson TW, McCauley FA, Wells HD \"Effects of low-dose aspirin on responsses to furosemide.\" J Clin Pharmacol 26 (1986):  100-5[7] Valette H, Apoil E \"Interaction between salicylate and two loop diuretics.\" Br J Clin Pharmacol 8 (1979):  592-4", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Mitapivat, Methazolamide, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 248799, "ingredient1": "Trandolapril", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.  Some NSAIDs may also alter the pharmacokinetics of certain ACE inhibitors.", "source": "DDInter", "management_text": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294069/", "reference_text": "[1] Moore TJ, Crantz FR, Hollenberg NK \"Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.\" Hypertension 3 (1981):  168-73[2] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[3] Silberbauer K, Stanek B, Templ H \"Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.\" Br J Clin Pharmacol 14 (1982):  s87-93[4] Ahmad S \"Indomethacin-enalapril interaction: an alert.\" South Med J 84 (1991):  411-2[5] Allon M, Pasque CB, Rodriguez M \"Interaction of captopril and ibuprofen on glomerular and tubular function in humans.\" Am J Physiol 259 (1990):  f233-8[6] Seto S, Aoi W, Iwami K, et al. \"Effect of propranolol and indomethacin on the depressor action of captopril in patients with essential hypertension.\" Clin Exp Hypertens 9 (1987):  623-7[7] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[8] Abdel-Haq B, Magagna A, Favilla S, Salvetti A \"Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects.\" J Cardiovasc Pharmacol 18 (1991):  s33-6[9] Morgan T, Anderson A \"Interaction of indomethacin with felodipine and enalapril.\" J Hypertens 11 (1993):  S338-9[10] \"Product Information. Daypro (oxaprozin).\" Searle  (2001):[11] Townend JN, Doran J, Lote CJ, Davies MK \"Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril.\" Br Heart J 73 (1995):  434-41[12] Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, Nunes JP, Brandao F, Cerqueiragomes M \"Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients.\" J Hypertens 13 (1995):  925-31[13] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Indapamide, Bisoprolol", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "updated_at": 1767369485}, {"id": 248800, "ingredient1": "Treprostinil", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Prostacyclin/prostacyclin analogs (e.g., epoprostenol, iloprost, treprostinil) inhibit platelet aggregation and may theoretically potentiate the risk of bleeding in patients treated with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hemorrhagic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294070/", "reference_text": "[1] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome  (2001):[2] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corporation  (2002):[3] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc  (2005):", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Fesoterodine, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, Oxybutynin, More", "updated_at": 1767369485}, {"id": 248801, "ingredient1": "Triamcinolone", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.", "source": "DDInter", "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294071/", "reference_text": "[1] Baer PA, Shore A, Ikeman RL \"Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis.\" Arthritis Rheum 30 (1987):  345-7[2] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L \"Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis.\" Ther Drug Monit 9 (1987):  177-9[3] Edelman J, Potter JM, Hackett LP \"The effect of intra-articular steroids on plasma salicylate concentrations.\" Br J Clin Pharmacol 21 (1986):  301-7[4] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991):  735-40[5] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD \"Risk of adverse gastrointestinal events from inhaled corticosteroids.\" Pharmacotherapy 28 (2008):  1325-34", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, Mupirocin, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 248802, "ingredient1": "Triamcinolone (ophthalmic)", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates.  Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity.  This interaction has been reported in patients receiving intra-articular as well as oral corticosteroids.  One or more mechanisms may be involved, including an increase in the renal clearance and/or an induction of hepatic metabolism of salicylates caused by corticosteroids.  Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.", "source": "DDInter", "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.  Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary.  During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.  The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294072/", "reference_text": "[1] Baer PA, Shore A, Ikeman RL \"Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis.\" Arthritis Rheum 30 (1987):  345-7[2] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L \"Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis.\" Ther Drug Monit 9 (1987):  177-9[3] Edelman J, Potter JM, Hackett LP \"The effect of intra-articular steroids on plasma salicylate concentrations.\" Br J Clin Pharmacol 21 (1986):  301-7[4] Piper JM, Ray WA, Daugherty JR, Griffin MR \"Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs.\" Ann Intern Med 114 (1991):  735-40[5] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD \"Risk of adverse gastrointestinal events from inhaled corticosteroids.\" Pharmacotherapy 28 (2008):  1325-34", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, Mupirocin, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248803, "ingredient1": "Tromethamine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to increased urinary pH, resulting in increased renal salicylate clearance especially above urine pH of 7.  This interaction is sometimes exploited in the treatment of salicylate toxicity.", "source": "DDInter", "management_text": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294073/", "reference_text": "[1] Berg KJ \"Acute acetylsalicylic acid poisoning: treatment with forced alkaline diuresis and diuretics.\" Eur J Clin Pharmacol 12 (1977):  111-6[2] Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT \"Diuresis or urinary alkalinisation for salicylate poisoning?\" Br Med J (Clin Res Ed) 285 (1982):  1383-6[3] Balali-Mood M, Prescott LF \"Failure of alkaline diuresis to enhance diflunisal elimination.\" Br J Clin Pharmacol 10 (1980):  163-5[4] Berg KJ \"Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency.\" Eur J Clin Pharmacol 11 (1977):  111-6[5] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Calcium chloride, Potassium chloride, Magnesium sulfate, Zinc sulfate, Arginine, Sodium glycerophosphate, Zinc chloride, Sodium chloride, Potassium acetate, Ammonium chloride, Magnesium chloride, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248804, "ingredient1": "Trovafloxacin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use.  The interaction has been reported most often with enoxacin.  It may occur with other fluoroquinolones as well, but is poorly documented.  The exact mechanism of interaction is unknown.  Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect.  Patients with a history of seizures may be at greater risk.", "source": "DDInter", "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "mechanism_text": "Synergism", "recommendation": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294074/", "reference_text": "[1] Ball P \"Ciprofloxacin: an overview of adverse experiences.\" J Antimicrob Chemother 18 (1986):  187-93[2] Hooper DC, Wolfson JS \"The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.\" Antimicrob Agents Chemother 28 (1985):  716-21[3] \"Product Information. Cipro (ciprofloxacin).\" Bayer  (2002):[4] \"Product Information. Penetrex (enoxacin).\" Rhone Poulenc Rorer  (2002):[5] \"Product Information. Floxin (ofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[6] Domagala JM \"Structure-activity and structure-side-effect relationships for the quinolone antibacterials.\" J Antimicrob Chemother 33 (1994):  685-706[7] \"Product Information. Levaquin (levofloxacin).\" Ortho McNeil Pharmaceutical  (2001):[8] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[9] Davey PG \"Overview of drug interactions with the quinolones.\" J Antimicrob Chemother 22(suppl c) (1988):  97-107[10] Ball P, Tillotson G \"Tolerability of fluoroquinolone antibiotics: past, present and future.\" Drug Saf 13 (1996):  343-8[11] \"Product Information. Avelox (moxifloxacin).\" Bayer  (2001):[12] \"Product Information. Tequin (gatifloxacin).\" Bristol-Myers Squibb  (2001):[13] \"Product Information. Factive (gemifloxacin).\" *GeneSoft Inc  (2003):[14] Segev S. Rehavi M, Rubinstein E \"Quinolones, theophylline, and diclofenac interactions with the gamma-aminobutyric acid receptor.\" Antimicrob Agents Chemother 32 (1988):  1624-6", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248805, "ingredient1": "Upadacitinib", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294075/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248806, "ingredient1": "Urokinase", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.", "source": "DDInter", "management_text": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.  Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment.", "mechanism_text": "Synergism", "recommendation": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294076/", "reference_text": "[1] \"Product Information. Ticlid (ticlopidine).\" Syntex Laboratories Inc  (2001):[2] \"Product Information. Abbokinase (urokinase).\" Abbott Pharmaceutical  (2001):[3] \"Product Information. Activase (alteplase).\" Genentech  (2001):[4] \"Product Information. Streptase (streptokinase).\" Astra-Zeneca Pharmaceuticals  (2001):[5] \"Product Information. Retavase (reteplase).\" Boehringer Mannheim  (2001):[6] \"Product Information. TNKase (tenecteplase).\" Genentech  (2001):[7] Harder S, Klinkhardt U \"Thrombolytics: drug interactions of clinical significance.\" Drug Saf 23 (2000):  391-9[8] Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians \"The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians.\" Chest 119(1 Suppl) (2001):  1S-2S", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 248807, "ingredient1": "Valsartan", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294077/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Hydrochlorothiazide, Sacubitril, Nebivolol, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Pravastatin, Ezetimibe, Bempedoic acid, Indapamide, Fenofibrate", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Papaverine, Magnesium hydroxide, Ammonium chloride, More", "updated_at": 1767369485}, {"id": 248808, "ingredient1": "Venlafaxine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294079/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Avanafil, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248809, "ingredient1": "Verapamil", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers.  The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids.", "source": "DDInter", "management_text": "Monitoring for altered blood pressure control is recommended.", "mechanism_text": "Antagonism", "recommendation": "Monitoring for altered blood pressure control is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294080/", "reference_text": "[1] Ring ME, Corrigan JJ, Fenster PE \"Effects of oral diltiazem on platelet function: alone and in combination with \"low dose\" aspirin.\" Thromb Res 44 (1986):  391-400[2] Altman R, Scazziota A, Dujovne C \"Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation.\" Clin Pharmacol Ther 44 (1988):  320-5[3] Cremer KF, Pieper JA, Joyal M, Mehta J \"Effects of diltiazem, dipyridamole, and their combination on hemostasis.\" Clin Pharmacol Ther 36 (1984):  641-4[4] Minuz P, Pancera P, Ribul M, et al. \"Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.\" Br J Clin Pharmacol 39 (1995):  45-50[5] Houston MC, Weir M, Gray J, et al. \"The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.\" Arch Intern Med 155 (1995):  1049-54[6] Deleeuw PW \"Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective.\" Drugs 51 (1996):  179-87[7] \"Product Information. DurAct (bromfenac).\" Wyeth-Ayerst Laboratories[8] \"Product Information. Arthrotec (diclofenac-misoprostol).\" Searle  (2001):[9] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002):  1015-1022", "alternatives_a": "Hydrochlorothiazide, Indapamide, Bisoprolol", "alternatives_b": "Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 248810, "ingredient1": "Vilazodone", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294081/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248811, "ingredient1": "Vortioxetine", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294083/", "reference_text": "[1] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[7] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993):  241[9] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[13] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994):  781-2[15] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995):  132[17] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997):  110-2[23] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001):  167-76[29] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003):  59-64[32] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. \"Australian Product Information.\" O 0[35] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[36] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[37] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[38] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[39] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 248812, "ingredient1": "Warfarin", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.  Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.  The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.   Ambulatory patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.  Patients should also be counseled to avoid any other over-the-counter salicylate products.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294084/", "reference_text": "[1] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971):  547-58[3] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967):  620-4[4] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968):  2169-80[5] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970):  403-8[6] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[7] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association;  (1994):[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Apomorphine, Fesoterodine, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Avanafil, Papaverine, Magnesium hydroxide, Ammonium chloride, More", "updated_at": 1767369485}, {"id": 248813, "ingredient1": "Zoledronic acid", "ingredient2": "Phenyl salicylate", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa.  Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.  Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools.  Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.  Serum creatinine should be assessed prior to each treatment, and treatment should be withheld in the presence of renal deterioration.  In patients treated for bone metastases, treatment should not be resumed until renal function returns to baseline.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294085/", "reference_text": "[1] \"Product Information. Didronel I.V. (etidronate).\" MGI Pharma Inc  (2022):[2] \"Product Information. Didronel (etidronate).\" Procter and Gamble Pharmaceuticals  (2022):[3] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Fosamax (alendronate).\" Merck & Co., Inc  (2001):[5] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals  (2001):[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals  (2001):[7] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001):  107-10[8] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001):  1862[9] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc  (2001):[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories  (2005):[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 248814, "ingredient1": "Bupropion", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294086/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Citalopram, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248815, "ingredient1": "Bupropion", "ingredient2": "Brentuximab vedotin", "severity": "Moderate", "effect": "Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294087/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Dexfenfluramine, Ephedrine, Fenfluramine, Phentermine, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Citalopram, Sertraline, Maprotiline, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 248816, "ingredient1": "Diamorphine", "ingredient2": "Bupropion", "severity": "Major", "effect": "The use of bupropion is associated with a dose-related risk of seizures.  The risk may be further increased when coadministered with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline).  These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Extreme caution is advised if bupropion is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with a history of seizures or other risk factors for seizures (e.g., head trauma; brain tumor; severe hepatic cirrhosis; metabolic disorders; CNS infections; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; diabetes treated with oral hypoglycemic agents or insulin).  Bupropion as well as concomitant medications should be initiated at the lower end of the dosage range and titrated gradually as needed and as tolerated.  The maximum recommended dosage for the specific bupropion formulation should not be exceeded.  Bupropion should be discontinued and not restarted in patients who experience a seizure during treatment.", "mechanism_text": "Synergism", "recommendation": "Extreme caution is advised if bupropion is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with a history of seizures or other risk factors for seizures (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294088/", "reference_text": "[1] Rosenstein DL, Nelson JC, Jacobs SC \"Seizures associated with antidepressants: a review.\" J Clin Psychiatry 54 (1993):  289-99[2] James WA, Lippmann S \"Bupropion: overview and prescribing guidelines in depression.\" South Med J 84 (1991):  222-4[3] Johnston JA, Lineberry CG, Ascher JA, et al. \"A 102-center prospective study of seizure in association with bupropion.\" J Clin Psychiatry 52 (1991):  450-6[4] Gittelman DK, Kirby MG \"A seizure following bupropion overdose.\" J Clin Psychiatry 54 (1993):  162[5] Sheehan DV, Welch JB, Fishman SM \"A case of bupropion-induced seizure.\" J Nerv Ment Dis 174 (1986):  496-8[6] Dufresne RL, Weber SS, Becker RE \"Bupropion hydrochloride.\" Drug Intell Clin Pharm 18 (1984):  957-64[7] \"Product Information. Wellbutrin (bupropion).\" Glaxo Wellcome  (2001):[8] Masco HL, Kiev A, Holloman LC, Batey SR, Johnston JA, Lineberry CG \"Safety and efficacy of bupropion and nortriptyline in outpatients with depression.\" Curr Ther Res Clin Exp 55 (1994):  851-63[9] Storrow AB \"Bupropion overdose and seizure.\" Am J Emerg Med 12 (1994):  183-4[10] \"Product Information. Wellbutrin SR (bupropion).\" Glaxo Wellcome  (2001):[11] \"Product Information. Zyban (bupropion).\" Glaxo Wellcome  (2001):[12] Pisani F, Spina E, Oteri G \"Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice.\" Epilepsia 40(Suppl 10) (1999):  S48-56[13] \"Product Information. Wellbutrin XL (bupropion).\" GlaxoSmithKline  (2003):[14] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[15] \"Product Information. Aplenzin (bupropion).\" sanofi-aventis  (2009):", "alternatives_a": "Dexfenfluramine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Nalmefene, Disulfiram", "updated_at": 1767369485}, {"id": 248817, "ingredient1": "Bupropion", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294089/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Citalopram, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248818, "ingredient1": "Bupropion", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 2B6 may decrease the plasma concentrations of bupropion.  In vitro findings suggest that CYP450 2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, one of three active metabolites of bupropion.", "source": "DDInter", "management_text": "Pharmacologic response to bupropion should be monitored more closely whenever a CYP450 2B6 inducer is added to or withdrawn from therapy, and the bupropion dosage adjusted as necessary.  Concomitant use of potent and moderate CYP450 2B6 inducers such as carbamazepine, efavirenz, rifampin, ritonavir, and lopinavir-ritonavir should be avoided with fixed-dose combination products such as bupropion-naltrexone or bupropion-dextromethorphan.  For other bupropion products, increases in bupropion dosage should be guided by clinical response; however, the maximum recommended dosage should not be exceeded.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bupropion should be monitored more closely whenever a CYP450 2B6 inducer is added to or withdrawn from therapy, and the bupropion dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294090/", "reference_text": "[1] James WA, Lippmann S \"Bupropion: overview and prescribing guidelines in depression.\" South Med J 84 (1991):  222-4[2] \"Product Information. Wellbutrin (bupropion).\" Glaxo Wellcome  (2001):[3] Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS, Callahan AM, Hinton ML, Chao J, Post RM \"Carbamazepine but not valproate induces bupropion metabolism.\" J Clin Psychopharmacol 15 (1995):  327-33[4] \"Product Information. Sustiva (efavirenz).\" DuPont Pharmaceuticals  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Forfivo XL (buPROPion).\" Almatica Pharma Inc  (2022):[8] \"Product Information. Zyban (bupropion).\" GlaxoSmithKline UK Ltd  (2022):[9] \"Product Information. Auvelity (bupropion-dextromethorphan).\" Axsome Therapeutics, Inc.  (2022):[10] \"Product Information. Wellbutrin XL (bupropion).\" Bausch Health, Canada Inc.  (2022):[11] \"Product Information. Contrave (bupropion-naltrexone).\" Currax Pharmaceuticals LLC  (2021):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Maprotiline, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248819, "ingredient1": "Irbesartan", "ingredient2": "Amobarbital", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294091/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248820, "ingredient1": "Irbesartan", "ingredient2": "Chlorphenesin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294092/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Griseofulvin, Econazole, Flucytosine, Tioconazole", "alternatives_b": "Eprosartan, Eprosartan, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248821, "ingredient1": "Irbesartan", "ingredient2": "Chlorzoxazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294093/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlormezanone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248822, "ingredient1": "Irbesartan", "ingredient2": "Dimethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294094/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Amlodipine, Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 248823, "ingredient1": "Irbesartan", "ingredient2": "Diroximel fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294095/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Amlodipine, Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 248824, "ingredient1": "Irbesartan", "ingredient2": "Ethanol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294096/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248825, "ingredient1": "Irbesartan", "ingredient2": "Diamorphine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294097/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "Acamprosate, Naltrexone, Disulfiram, Levacetylmethadol, Nalmefene", "updated_at": 1767369485}, {"id": 248826, "ingredient1": "Irbesartan", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294098/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Amlodipine, Sacubitril, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248827, "ingredient1": "Irbesartan", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294099/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More", "updated_at": 1767369485}, {"id": 248828, "ingredient1": "Irbesartan", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294100/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 248829, "ingredient1": "Irbesartan", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294101/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More", "updated_at": 1767369485}, {"id": 248830, "ingredient1": "Brentuximab vedotin", "ingredient2": "Rosiglitazone", "severity": "Moderate", "effect": "Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294102/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Guar gum", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 248831, "ingredient1": "Somapacitan", "ingredient2": "Rosiglitazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294105/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Guar gum, Rosuvastatin", "alternatives_b": "Mecasermin, Mecasermin rinfabate", "updated_at": 1767369485}, {"id": 248832, "ingredient1": "Thyrotropin alfa", "ingredient2": "Rosiglitazone", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294106/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "Mecasermin, Mecasermin rinfabate", "updated_at": 1767369485}, {"id": 248833, "ingredient1": "Glimepiride", "ingredient2": "Brentuximab vedotin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294107/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Guar gum", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 248834, "ingredient1": "Glimepiride", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294109/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248835, "ingredient1": "Glimepiride", "ingredient2": "Thyrotropin alfa", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294110/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248836, "ingredient1": "Diamorphine", "ingredient2": "Azelastine (nasal)", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294112/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248837, "ingredient1": "St. John's Wort", "ingredient2": "Azelastine (nasal)", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294114/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Sertraline, Paroxetine, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248838, "ingredient1": "Aldesleukin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The concomitant administration of hypotensive agents may potentiate the hypotensive effects of aldesleukin", "source": "DDInter", "management_text": "Blood pressure should be monitored during concomitant administration.  Aldesleukin doses should be held if systolic blood pressure falls to less than 90 mmHg.", "mechanism_text": "Synergism", "recommendation": "Blood pressure should be monitored during concomitant administration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294116/", "reference_text": "[1] \"Product Information. Proleukin (aldesleukin).\" Chiron Therapeutics  (2001):", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248839, "ingredient1": "Alfentanil", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294117/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248840, "ingredient1": "Alprazolam", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294118/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248841, "ingredient1": "Amifostine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Concomitant use with antihypertensive agents or drugs with hypotensive effects may increase the risk and severity of hypotension associated with amifostine.", "source": "DDInter", "management_text": "If medically feasible, antihypertensive medications should be interrupted 24 hours prior to amifostine administration.  Blood pressure should be closely monitored during and after treatment.  In addition to hypotension, transient hypertension or exacerbation of preexisting hypertension may occur from intravenous hydration, discontinuation of antihypertensive medications, or other causes.  Patients who continue their hypotensive medication(s) during amifostine therapy should be carefully monitored for the development of hypotension.  Clinical symptoms of hypotension are usually quickly reversed by fluid infusion and postural management.", "mechanism_text": "Synergism", "recommendation": "If medically feasible, antihypertensive medications should be interrupted 24 hours prior to amifostine administration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294119/", "reference_text": "[1] \"Product Information. Ethyol (amifostine).\" Alza  (2001):[2] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248842, "ingredient1": "Amisulpride", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294120/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248843, "ingredient1": "Amobarbital", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294121/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248844, "ingredient1": "Amoxapine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294122/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248845, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Apomorphine", "severity": "Moderate", "effect": "Apomorphine may potentiate the hypotensive effect of vasodilators and antihypertensive agents.", "source": "DDInter", "management_text": "Caution and close monitoring for altered efficacy and safety are recommended if patients receive apomorphine with an antihypertensive agent or vasodilator.  Patients should be made aware of the possible side effects (e.g., dizziness, lightheadedness, orthostasis) and be cautioned about driving, operating machinery, or performing other hazardous tasks.  They should also be advised to avoid rising abruptly from a sitting or recumbent position and to contact their physician if they experience symptoms of hypotension such as dizziness, lightheadedness, or fainting.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for altered efficacy and safety are recommended if patients receive apomorphine with an antihypertensive agent or vasodilator.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294124/", "reference_text": "[1] \"Product Information. Apokyn (apomorphine).\" Mylan Pharmaceuticals Inc  (2004):", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248846, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Aripiprazole", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294125/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248847, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Asenapine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294126/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248848, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Avanafil", "severity": "Moderate", "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications.  These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.", "source": "DDInter", "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.  Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294127/", "reference_text": "[1] \"Product Information. Viagra (sildenafil).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Levitra (vardenafil).\" Bayer  (2003):[3] \"Product Information. Stendra (avanafil).\" Vivus Inc  (2012):", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248849, "ingredient1": "Baclofen", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294128/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248850, "ingredient1": "Betamethasone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention.  These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity.  Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure.  The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294129/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248851, "ingredient1": "Brexpiprazole", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294131/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248852, "ingredient1": "Brimonidine (ophthalmic)", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects such as hypotension and bradycardia.  The possibility for an additive or potentiating effect on blood pressure and heart rate should be considered when used with other medications that affect these parameters, such as ophthalmic and systemic beta blockers, vasodilators, cardiac glycosides, and antihypertensive agents.", "source": "DDInter", "management_text": "Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs.  Patients should be advised to notify their physician if they experience slow pulse, irregular heartbeat, dizziness, lightheadedness, or syncope.", "mechanism_text": "Synergism", "recommendation": "Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294132/", "reference_text": "[1] King MH, Richards DW \"Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy.\" Am J Ophthalmol 110 (1990):  308-9[2] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[3] Nordlund JR, Pasquale LR, Robin AL, Rudikoff MT, Ordman J, Chen KS, Walt J \"The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine.\" Arch Ophthalmol 113 (1995):  77-83[4] \"Product Information. Alphagan (brimonidine ophthalmic).\" Allergan Inc  (2001):[5] Walters TR \"Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.\" Surv Ophthalmol 41 ( Suppl (1996):  s19-26[6] Pekdemir M, Yanturali S, Karakus G \"More than just an ocular solution.\" Emerg Med J 22 (2005):  753-4[7] \"Product Information. Mirvaso (brimonidine topical).\" Galderma Laboratories Inc  (2013):", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248853, "ingredient1": "Brimonidine (topical)", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects such as hypotension and bradycardia.  The possibility for an additive or potentiating effect on blood pressure and heart rate should be considered when used with other medications that affect these parameters, such as ophthalmic and systemic beta blockers, vasodilators, cardiac glycosides, and antihypertensive agents.", "source": "DDInter", "management_text": "Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs.  Patients should be advised to notify their physician if they experience slow pulse, irregular heartbeat, dizziness, lightheadedness, or syncope.", "mechanism_text": "Synergism", "recommendation": "Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294133/", "reference_text": "[1] King MH, Richards DW \"Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy.\" Am J Ophthalmol 110 (1990):  308-9[2] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[3] Nordlund JR, Pasquale LR, Robin AL, Rudikoff MT, Ordman J, Chen KS, Walt J \"The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine.\" Arch Ophthalmol 113 (1995):  77-83[4] \"Product Information. Alphagan (brimonidine ophthalmic).\" Allergan Inc  (2001):[5] Walters TR \"Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.\" Surv Ophthalmol 41 ( Suppl (1996):  s19-26[6] Pekdemir M, Yanturali S, Karakus G \"More than just an ocular solution.\" Emerg Med J 22 (2005):  753-4[7] \"Product Information. Mirvaso (brimonidine topical).\" Galderma Laboratories Inc  (2013):", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248854, "ingredient1": "Bromfenac", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294134/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248855, "ingredient1": "Buprenorphine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294135/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248856, "ingredient1": "Buspirone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294136/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248857, "ingredient1": "Butabarbital", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294137/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248858, "ingredient1": "Butorphanol", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294138/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248859, "ingredient1": "Cabergoline", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294139/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole, Amantadine, Ritodrine, Bremelanotide, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248860, "ingredient1": "Canagliflozin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators.  Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.  Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary.  Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure.  If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294140/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals  (2013):[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb  (2014):[5] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim  (2014):[6] \"Product Information. Brenzavvy (bexagliflozin).\" TheracosBio, LLC  (2023):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248861, "ingredient1": "Captopril", "ingredient2": "Azilsartan medoxomil", "severity": "Major", "effect": "Coadministration of an ACE inhibitor in combination with an angiotensin II receptor antagonist may increase the risk of hyperkalemia, hypotension, syncope, and renal dysfunction due to additive or synergistic effects on the renin-angiotensin system.", "source": "DDInter", "management_text": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.  Most patients receiving the combination do not obtain any additional benefit compared to monotherapy.  However, if the combination is considered medically necessary, serum electrolytes, blood pressure, and renal function should be closely monitored.  Routine monitoring of electrolytes and renal function may be indicated in the elderly or patients with worsening heart failure or a risk for dehydration.  Potassium supplementation should generally be avoided unless it is closely monitored, and patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as weakness, listlessness, confusion, tingling of the extremities, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294141/", "reference_text": "[1] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Micardis (telmisartan).\" Boehringer-Ingelheim  (2001):[4] Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D \"Dual renin-angiotensin system blockade at optimal doses for proteinuria.\" Kidney Int 62 (2002):  1020-5[5] Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH \"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.\" Kidney Int 63 (2003):  1874-80[6] Rossing K, Jacobsen P, Pietraszek L, Parving HH \"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.\" Diabetes Care 26 (2003):  2268-74[7] Jacobsen P, Andersen S, Jensen BR, Parving HH \"Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.\" J Am Soc Nephrol 14 (2003):  992-9[8] McMurray JJ, Ostergren J, Swedberg K, et al. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.\" Lancet 362 (2003):  767-71[9] Pfeffer MA, McMurray JJ, Velazquez EJ, et al. \"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.\" N Engl J Med 349 (2003):  1893-1906[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] ONTARGET Investigators, Yusuf S, Teo KK, et al. \"Telmisartan, ramipril, or both in patients at high risk for vascular events.\" N Engl J Med 358 (2008):  1547-59[12] Mann JF, Schmieder RE, McQueen M, et al. \"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.\" Lancet 372 (2008):  547-53[13] Guthrie RM \"Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary.\" Postgrad Med 121 (2009):  202-4[14] National Kidney Foundation \"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update.\" Am J Kidney Dis 60 (2012):  850-86[15] EMA. European Medicines Agency \"PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system: recommendation will now be considered by CHMP for final opinion.  http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Renin-angiotensin_sys\"   (2014):[16] MHRA. Medicines and Healthcare Regulatory Agency \"Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function--new warnings.  http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON426905\"   (2014):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "Nebivolol", "updated_at": 1767369485}, {"id": 248862, "ingredient1": "Cariprazine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294142/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248863, "ingredient1": "Chloral hydrate", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294143/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248864, "ingredient1": "Chlormezanone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294144/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Irbesartan, Candesartan, Losartan, Eprosartan, Irbesartan, Losartan, Candesartan, Sacubitril, Aliskiren, Eprosartan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248865, "ingredient1": "Chlorphenesin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294145/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, Flucytosine, More", "alternatives_b": "Eprosartan, Eprosartan, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248866, "ingredient1": "Chlorpromazine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294146/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248867, "ingredient1": "Chlorzoxazone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294147/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248868, "ingredient1": "Choline salicylate", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294148/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Hydrochlorothiazide, Sacubitril", "updated_at": 1767369485}, {"id": 248869, "ingredient1": "Clobazam", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294149/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248870, "ingredient1": "Clomipramine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294150/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248871, "ingredient1": "Clonazepam", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294151/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248872, "ingredient1": "Clorazepic acid", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294152/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248873, "ingredient1": "Clozapine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294153/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248874, "ingredient1": "Corticotropin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention.  These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity.  Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure.  The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294155/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248875, "ingredient1": "Tetracosactide", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention.  These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity.  Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure.  The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294157/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248876, "ingredient1": "Cyclobenzaprine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294158/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Eprosartan, Eprosartan, Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248877, "ingredient1": "Cyclosporine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Coadministration of cyclosporine with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia or precipitate acute renal failure.  Cyclosporine causes afferent arteriolar vasoconstriction and decreased glomerular filtration.  These effects may be significant when combined with ACE inhibitors or angiotensin II receptor antagonists, which block the mechanism that maintains glomerular filtration rate by constricting the efferent arterioles.", "source": "DDInter", "management_text": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists.  Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.  Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294159/", "reference_text": "[1] Murray BM, Venuto RC, Kohli R, Cunningham EE \"Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine.\" Am J Kidney Dis 16 (1990):  66-9[2] \"Product Information. Neoral (cycloSPORINE).\" Sandoz Pharmaceuticals Corporation[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, More", "alternatives_b": "Nebivolol", "updated_at": 1767369485}, {"id": 248878, "ingredient1": "Dalteparin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The concomitant use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and heparin or low molecular weight heparins may increase the risk of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised if ACE inhibitors or ARBs are used with heparin or low molecular weight heparin.  Serum potassium and renal function should be checked regularly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ACE inhibitors or ARBs are used with heparin or low molecular weight heparin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294160/", "reference_text": "[1] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[3] \"Product Information. Avapro (irbesartan).\" Bristol-Myers Squibb  (2001):[4] \"Product Information. Teveten (eprosartan).\" SmithKline Beecham  (2001):[5] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[6] \"Product Information. Micardis (telmisartan).\" Boehringer-Ingelheim  (2001):[7] \"Product Information. Benicar (olmesartan).\" Sankyo Pharma  (2002):[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[10] \"Product Information. Edarbi (azilsartan).\" Takeda Pharmaceuticals America  (2011):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "updated_at": 1767369485}, {"id": 248879, "ingredient1": "Dapagliflozin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators.  Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.  Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary.  Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure.  If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294161/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals  (2013):[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb  (2014):[5] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim  (2014):[6] \"Product Information. Brenzavvy (bexagliflozin).\" TheracosBio, LLC  (2023):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248880, "ingredient1": "Deflazacort", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention.  These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity.  Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure.  The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294162/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Sacubitril", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248881, "ingredient1": "Desipramine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294163/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Irbesartan, Candesartan, Eprosartan, Irbesartan, Candesartan, Sacubitril, Aliskiren, Eprosartan", "updated_at": 1767369485}, {"id": 248882, "ingredient1": "Dexamethasone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention.  These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity.  Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure.  The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294164/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248883, "ingredient1": "Dexmedetomidine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Dexmedetomidine has been associated with hypotensive and negative chronotropic effects.  Coadministration with other agents causing these effects, especially vasodilators and alpha-2 agonists, may result in additive effects on blood pressure and heart rate.", "source": "DDInter", "management_text": "Caution and monitoring of the patient's hemodynamic status are recommended during coadministration.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring of the patient's hemodynamic status are recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294165/", "reference_text": "[1] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[4] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248884, "ingredient1": "Dexmethylphenidate", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294166/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248885, "ingredient1": "Dezocine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294167/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Irbesartan, Losartan, Olmesartan, Candesartan, Eprosartan, Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Candesartan, More", "updated_at": 1767369485}, {"id": 248886, "ingredient1": "Diazepam", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294168/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248887, "ingredient1": "Diflunisal", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294169/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248888, "ingredient1": "Dimethyl fumarate", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294170/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, More", "alternatives_b": "Amlodipine, Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 248889, "ingredient1": "Diroximel fumarate", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294171/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, More", "alternatives_b": "Amlodipine, Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 248890, "ingredient1": "Doxepin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294172/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248891, "ingredient1": "Doxepin (topical)", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294173/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248892, "ingredient1": "Dronabinol", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294174/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Granisetron, Scopolamine, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248893, "ingredient1": "Empagliflozin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators.  Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.  Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary.  Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure.  If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294175/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals  (2013):[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb  (2014):[5] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim  (2014):[6] \"Product Information. Brenzavvy (bexagliflozin).\" TheracosBio, LLC  (2023):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248894, "ingredient1": "Enalapril", "ingredient2": "Azilsartan medoxomil", "severity": "Major", "effect": "Coadministration of an ACE inhibitor in combination with an angiotensin II receptor antagonist may increase the risk of hyperkalemia, hypotension, syncope, and renal dysfunction due to additive or synergistic effects on the renin-angiotensin system.", "source": "DDInter", "management_text": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.  Most patients receiving the combination do not obtain any additional benefit compared to monotherapy.  However, if the combination is considered medically necessary, serum electrolytes, blood pressure, and renal function should be closely monitored.  Routine monitoring of electrolytes and renal function may be indicated in the elderly or patients with worsening heart failure or a risk for dehydration.  Potassium supplementation should generally be avoided unless it is closely monitored, and patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as weakness, listlessness, confusion, tingling of the extremities, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294176/", "reference_text": "[1] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Micardis (telmisartan).\" Boehringer-Ingelheim  (2001):[4] Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D \"Dual renin-angiotensin system blockade at optimal doses for proteinuria.\" Kidney Int 62 (2002):  1020-5[5] Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH \"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.\" Kidney Int 63 (2003):  1874-80[6] Rossing K, Jacobsen P, Pietraszek L, Parving HH \"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.\" Diabetes Care 26 (2003):  2268-74[7] Jacobsen P, Andersen S, Jensen BR, Parving HH \"Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.\" J Am Soc Nephrol 14 (2003):  992-9[8] McMurray JJ, Ostergren J, Swedberg K, et al. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.\" Lancet 362 (2003):  767-71[9] Pfeffer MA, McMurray JJ, Velazquez EJ, et al. \"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.\" N Engl J Med 349 (2003):  1893-1906[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] ONTARGET Investigators, Yusuf S, Teo KK, et al. \"Telmisartan, ramipril, or both in patients at high risk for vascular events.\" N Engl J Med 358 (2008):  1547-59[12] Mann JF, Schmieder RE, McQueen M, et al. \"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.\" Lancet 372 (2008):  547-53[13] Guthrie RM \"Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary.\" Postgrad Med 121 (2009):  202-4[14] National Kidney Foundation \"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update.\" Am J Kidney Dis 60 (2012):  850-86[15] EMA. European Medicines Agency \"PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system: recommendation will now be considered by CHMP for final opinion.  http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Renin-angiotensin_sys\"   (2014):[16] MHRA. Medicines and Healthcare Regulatory Agency \"Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function--new warnings.  http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON426905\"   (2014):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "Nebivolol", "updated_at": 1767369485}, {"id": 248895, "ingredient1": "Enoxaparin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The concomitant use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and heparin or low molecular weight heparins may increase the risk of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised if ACE inhibitors or ARBs are used with heparin or low molecular weight heparin.  Serum potassium and renal function should be checked regularly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ACE inhibitors or ARBs are used with heparin or low molecular weight heparin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294177/", "reference_text": "[1] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[3] \"Product Information. Avapro (irbesartan).\" Bristol-Myers Squibb  (2001):[4] \"Product Information. Teveten (eprosartan).\" SmithKline Beecham  (2001):[5] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[6] \"Product Information. Micardis (telmisartan).\" Boehringer-Ingelheim  (2001):[7] \"Product Information. Benicar (olmesartan).\" Sankyo Pharma  (2002):[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[10] \"Product Information. Edarbi (azilsartan).\" Takeda Pharmaceuticals America  (2011):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "updated_at": 1767369485}, {"id": 248896, "ingredient1": "Eplerenone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Coadministration of eplerenone with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia due to additive pharmacodynamic effects.", "source": "DDInter", "management_text": "Given the potential for serious, sometimes fatal cardiac arrhythmias associated with hyperkalemia, caution is advised if eplerenone is administered with ACE inhibitors or angiotensin II receptor antagonists.  Periodic monitoring of serum potassium levels is recommended until the effect of eplerenone is established.  In clinical trials, monitoring occurred every 2 weeks for the first 1 to 2 months, then monthly thereafter.  Particular caution is warranted in patients with renal impairment, diabetes, old age, or dehydration.  Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Given the potential for serious, sometimes fatal cardiac arrhythmias associated with hyperkalemia, caution is advised if eplerenone is administered with ACE inhibitors or angiotensin II receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294178/", "reference_text": "[1] \"Product Information. Inspra (eplerenone).\" Searle  (2002):[2] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006):  49-58", "alternatives_a": "Sacubitril, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248897, "ingredient1": "Epoprostenol", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents.", "source": "DDInter", "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.  If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.  Treatment guidelines should be consulted for the optimum management of pulmonary arterial hypertension.", "mechanism_text": "Synergism", "recommendation": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294179/", "reference_text": "[1] Buchdahl RM, Taylor P, Warner JD \"Nebulised ribavirin for adenovirus pneumonia.\" Lancet 2 (1985):  1070-1[2] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome  (2001):[3] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[4] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corporation  (2002):[5] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc  (2005):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248898, "ingredient1": "Ethanol", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294180/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248899, "ingredient1": "Ethchlorvynol", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294181/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Irbesartan, Losartan, Olmesartan, Candesartan, Eprosartan, Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Candesartan, More", "updated_at": 1767369485}, {"id": 248900, "ingredient1": "Etodolac", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294182/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248901, "ingredient1": "Everolimus", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The use of mTOR (mammalian target of rapamycin) inhibitors has been associated with the development of angioedema, and coadministration with other drugs that are also known to cause angioedema such as ACE inhibitors, angiotensin II receptor antagonists, and renin inhibitors may increase the risk.", "source": "DDInter", "management_text": "Clinicians and patients should be aware of the potential for increased risk of angioedema when mTOR inhibitors are prescribed with other drugs that are also known to cause angioedema.  Patients should be advised to promptly discontinue these medications and seek medical attention if they develop signs or symptoms suggestive of angioedema such as swelling of the face, extremities, eyes, lips, or tongue, and difficulty swallowing or breathing.", "mechanism_text": "Synergism", "recommendation": "Clinicians and patients should be aware of the potential for increased risk of angioedema when mTOR inhibitors are prescribed with other drugs that are also known to cause angioedema.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294183/", "reference_text": "[1] \"Product Information. Rapamune (sirolimus).\" Wyeth-Ayerst Laboratories  (2001):[2] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[3] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "Hydrochlorothiazide, Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 248902, "ingredient1": "Exenatide", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Drugs that affect renal function and/or hydration status may potentiate the adverse renal effects of exenatide.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for increased adverse renal effects of exenatide during coadministration with drugs that are known to affect renal function or hydration status.", "mechanism_text": "Synergism", "recommendation": "Clinicians should be aware of the potential for increased adverse renal effects of exenatide during coadministration with drugs that are known to affect renal function or hydration status.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294184/", "reference_text": "[1] \"Product Information. Byetta (exenatide).\" Amylin Pharmaceuticals Inc  (2005):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Tolbutamide, Miglitol, Glimepiride, More", "alternatives_b": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "updated_at": 1767369485}, {"id": 248903, "ingredient1": "Fenoldopam", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The use of fenoldopam with other hypotensive agents has not been studied.  However, these combinations would theoretically increase the risk of severe symptomatic hypotension.", "source": "DDInter", "management_text": "Caution is strongly advised during concurrent use.  Inpatient monitoring of the heart rate and blood pressure is recommended.  Sublingual nitroglycerin has been used safely with fenoldopam.", "mechanism_text": "Synergism", "recommendation": "Caution is strongly advised during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294185/", "reference_text": "[1] \"Product Information. Corlopam (fenoldopam).\" Neurex  (2001):[2] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Isoprenaline, Metaraminol, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248904, "ingredient1": "Fenoprofen", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294186/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248905, "ingredient1": "Fentanyl", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294187/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248906, "ingredient1": "Fludrocortisone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention.  These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity.  Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure.  The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294189/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248907, "ingredient1": "Fluphenazine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294190/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248908, "ingredient1": "Flurazepam", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294191/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248909, "ingredient1": "Flurbiprofen", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294192/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Lidocaine, Bacitracin, Chlorhexidine, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248910, "ingredient1": "Fosinopril", "ingredient2": "Azilsartan medoxomil", "severity": "Major", "effect": "Coadministration of an ACE inhibitor in combination with an angiotensin II receptor antagonist may increase the risk of hyperkalemia, hypotension, syncope, and renal dysfunction due to additive or synergistic effects on the renin-angiotensin system.", "source": "DDInter", "management_text": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.  Most patients receiving the combination do not obtain any additional benefit compared to monotherapy.  However, if the combination is considered medically necessary, serum electrolytes, blood pressure, and renal function should be closely monitored.  Routine monitoring of electrolytes and renal function may be indicated in the elderly or patients with worsening heart failure or a risk for dehydration.  Potassium supplementation should generally be avoided unless it is closely monitored, and patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as weakness, listlessness, confusion, tingling of the extremities, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294193/", "reference_text": "[1] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Micardis (telmisartan).\" Boehringer-Ingelheim  (2001):[4] Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D \"Dual renin-angiotensin system blockade at optimal doses for proteinuria.\" Kidney Int 62 (2002):  1020-5[5] Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH \"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.\" Kidney Int 63 (2003):  1874-80[6] Rossing K, Jacobsen P, Pietraszek L, Parving HH \"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.\" Diabetes Care 26 (2003):  2268-74[7] Jacobsen P, Andersen S, Jensen BR, Parving HH \"Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.\" J Am Soc Nephrol 14 (2003):  992-9[8] McMurray JJ, Ostergren J, Swedberg K, et al. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.\" Lancet 362 (2003):  767-71[9] Pfeffer MA, McMurray JJ, Velazquez EJ, et al. \"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.\" N Engl J Med 349 (2003):  1893-1906[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] ONTARGET Investigators, Yusuf S, Teo KK, et al. \"Telmisartan, ramipril, or both in patients at high risk for vascular events.\" N Engl J Med 358 (2008):  1547-59[12] Mann JF, Schmieder RE, McQueen M, et al. \"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.\" Lancet 372 (2008):  547-53[13] Guthrie RM \"Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary.\" Postgrad Med 121 (2009):  202-4[14] National Kidney Foundation \"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update.\" Am J Kidney Dis 60 (2012):  850-86[15] EMA. European Medicines Agency \"PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system: recommendation will now be considered by CHMP for final opinion.  http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Renin-angiotensin_sys\"   (2014):[16] MHRA. Medicines and Healthcare Regulatory Agency \"Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function--new warnings.  http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON426905\"   (2014):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "Nebivolol", "updated_at": 1767369485}, {"id": 248911, "ingredient1": "Garlic", "ingredient2": "Azilsartan medoxomil", "severity": "Minor", "effect": "Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents", "source": "DDInter", "management_text": "There have been no reports of clinical hypotension resulting from the simultaneous use of garlic and antihypertensive drugs. Therefore, we recommend no additional clinical intervention.", "mechanism_text": "Synergism", "recommendation": "There have been no reports of clinical hypotension resulting from the simultaneous use of garlic and antihypertensive drugs.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294195/", "reference_text": "[1] Richard CL, Jurgens TM \"Effects of natural health products on blood pressure.\" Ann Pharmacother 39 (2005):  712-20[2] Tattelman E \"Health effects of garlic.\" Am Fam Physician 72 (2005):  103-6", "alternatives_a": "Sacubitril", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248912, "ingredient1": "Guanfacine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Use of guanfacine in combination with antihypertensive agents may result in additive pharmacodynamic effects such as hypotension and syncope.", "source": "DDInter", "management_text": "Caution is advised during coadministration of these agents.  Dosage adjustments may be required and hemodynamic responses should be monitored during concomitant therapy.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294196/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Rauwolfia serpentina root, Reserpine, Methyldopa, Clonidine, Deserpidine", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248913, "ingredient1": "Halazepam", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294197/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Irbesartan, Losartan, Olmesartan, Candesartan, Eprosartan, Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Candesartan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248914, "ingredient1": "Haloperidol", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294198/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248915, "ingredient1": "Heparin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The concomitant use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and heparin or low molecular weight heparins may increase the risk of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised if ACE inhibitors or ARBs are used with heparin or low molecular weight heparin.  Serum potassium and renal function should be checked regularly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ACE inhibitors or ARBs are used with heparin or low molecular weight heparin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294199/", "reference_text": "[1] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[3] \"Product Information. Avapro (irbesartan).\" Bristol-Myers Squibb  (2001):[4] \"Product Information. Teveten (eprosartan).\" SmithKline Beecham  (2001):[5] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[6] \"Product Information. Micardis (telmisartan).\" Boehringer-Ingelheim  (2001):[7] \"Product Information. Benicar (olmesartan).\" Sankyo Pharma  (2002):[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[10] \"Product Information. Edarbi (azilsartan).\" Takeda Pharmaceuticals America  (2011):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 248916, "ingredient1": "Diamorphine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294200/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 248917, "ingredient1": "Hydralazine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Concomitant treatment with other antihypertensive agents or vasodilators, including alpha-adrenoreceptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-adrenergic blockers, calcium channel blockers, diuretics and nitrates, may potentiate the hypotensive effects of hydralazine and dihydralazine.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be closely monitored when hydralazine or dihydralazine is used with other agents that can induce hypotension.", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be closely monitored when hydralazine or dihydralazine is used with other agents that can induce hypotension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294201/", "reference_text": "[1] \"Product Information. Apresoline (hydralazine).\" Sterimax Inc  (2022):[2] \"Product Information. Hydralazine (hydralazine).\" Advanz Pharma  (2022):", "alternatives_a": "Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine", "alternatives_b": "Nebivolol, Aliskiren", "updated_at": 1767369485}, {"id": 248918, "ingredient1": "Hydrocortisone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention.  These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity.  Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure.  The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294202/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Tetracycline, Minocycline, Amphotericin B, Miconazole, Doxycycline, Metronidazole, Clotrimazole, Epinephrine, Chlorhexidine, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248919, "ingredient1": "Hydromorphone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294203/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248920, "ingredient1": "Hydroxyzine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294204/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248921, "ingredient1": "Iloperidone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294205/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248922, "ingredient1": "Iloprost", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents.", "source": "DDInter", "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.  If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.  Treatment guidelines should be consulted for the optimum management of pulmonary arterial hypertension.", "mechanism_text": "Synergism", "recommendation": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294206/", "reference_text": "[1] Buchdahl RM, Taylor P, Warner JD \"Nebulised ribavirin for adenovirus pneumonia.\" Lancet 2 (1985):  1070-1[2] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome  (2001):[3] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[4] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corporation  (2002):[5] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc  (2005):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248923, "ingredient1": "Imipramine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294207/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248924, "ingredient1": "Indomethacin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294208/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Fluocinolone acetonide, Fluorometholone, Tolazoline, Rabeprazole, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248925, "ingredient1": "Insulin human", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294209/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Amlodipine, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248926, "ingredient1": "Insulin aspart (aspart)", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294210/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248927, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294211/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248928, "ingredient1": "Insulin degludec", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294212/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Amlodipine, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248929, "ingredient1": "Insulin detemir", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294213/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Amlodipine, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248930, "ingredient1": "Insulin glargine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294214/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Amlodipine, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248931, "ingredient1": "Insulin glulisine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294215/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Amlodipine, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248932, "ingredient1": "Insulin human (inhalation, rapid acting)", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294216/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Amlodipine, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248933, "ingredient1": "Insulin lispro", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294217/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Amlodipine, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248934, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294218/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248935, "ingredient1": "Insulin human (zinc)", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294219/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Amlodipine, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248936, "ingredient1": "Insulin human (zinc extended)", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294220/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "Amlodipine, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248937, "ingredient1": "Isocarboxazid", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications.  MAOIs alone quite commonly produce orthostatic hypotension.  This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission.  The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.  Close monitoring for development of hypotension is recommended.  Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294221/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[5] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[8] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[9] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[10] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[11] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[12] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[13] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248938, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Ketoprofen", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294222/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248939, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Ketorolac", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294223/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Homatropine, Atropine, Scopolamine, Methscopolamine, Ephedrine, Tropicamide, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248940, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "The hypotensive effects of levodopa and antihypertensive agents may be additive.  Postural hypotension may occur.", "source": "DDInter", "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Dose adjustments of the antihypertensive agent may be required.  Patients should be advised to notify their physician if they experience dizziness or syncope.", "mechanism_text": "Synergism", "recommendation": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294224/", "reference_text": "[1] \"Product Information. Stalevo 150 (carbidopa/entacapone/levodopa).\" Novartis Pharmaceuticals  (2003):", "alternatives_a": "Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole, Amantadine", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248941, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294225/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Irbesartan, Losartan, Olmesartan, Candesartan, Eprosartan, Amlodipine, Irbesartan, Losartan, Olmesartan, Candesartan, Sacubitril, More", "updated_at": 1767369485}, {"id": 248942, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294226/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Irbesartan, Losartan, Olmesartan, Candesartan, Eprosartan, Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Candesartan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248943, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Licorice", "severity": "Moderate", "effect": "Licorice use has been associated with hypertension and may antagonize the effects of antihypertensive agents.  Glycyrrhizic acid, a component of licorice, is hydrolyzed in the intestine to a metabolite (glycyrrhetinic acid) that causes mineralocorticoid and renin-suppressing effects.", "source": "DDInter", "management_text": "Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products.  Even relatively moderate doses of licorice may be problematic in susceptible patients when ingested regularly for prolonged periods.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294227/", "reference_text": "[1] Ishikawa S, Kato M, Tokuda T, Momoi H, Sekijima Y, Higuchi M, Yanagisawa N \"Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa.\" Int J Eating Disorder 26 (1999):  111-4[2] Cumming AM, Boddy K, Brown JJ, et al. \"Severe hypokalaemia with paralysis induced by small doses of liquorice.\" Postgrad Med J 56 (1980):  526-9[3] Cumming A \"Severe reduction of serum potassium induced by licorice.\" Nurs Times 72 (1976):  367-70[4] Lin SH, Yang SS, Chau T, Halperin ML \"An unusual cause of hypokalemic paralysis: chronic licorice ingestion.\" Am J Med Sci 325 (2003):  153-6[5] de Klerk GJ, Nieuwenhuis MG, Beutler JJ \"Lesson of the week: hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum.\" BMJ 314 (1997):  731[6] Edwards CR \"Lessons from licorice.\" N Engl J Med 325 (1991):  1242-3[7] Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR \"Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age.\" Lancet 2 (1987):  821-4[8] Nielsen I, Pedersen RS \"Life-threatening hypokalaemia caused by liquorice ingestion.\" Lancet 1 (1984):  1305[9] Rosseel M, Schoors D \"Chewing gum and hypokalaemia.\" Lancet 341 (1993):  175[10] Clyburn EB, DiPette DJ \"Hypertension induced by drugs and other substances.\" Semin Nephrol 15 (1995):  72-86[11] Farese RV, Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R \"Licorice-induced hypermineralocorticoidism.\" N Engl J Med 325 (1991):  1223-7[12] Elinav E, Chajek-Shaul T \"Licorice consumption causing severe hypokalemic paralysis.\" Mayo Clin Proc 78 (2003):  767-8[13] Richard CL, Jurgens TM \"Effects of natural health products on blood pressure.\" Ann Pharmacother 39 (2005):  712-20[14] Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S \"Liquorice-induced rise in blood pressure: a linear dose-response relationship.\" J Hum Hypertens 15 (2001):  549-52[15] Dellow EL, Unwin RJ, Honour JW \"Pontefract cakes can be bad for you: refractory hypertension and liquorice excess.\" Nephrol Dial Transplant 14 (1999):  218-20[16] Epstein MT, Espiner EA, Donald RA, Hughes H \"Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects.\" Br Med J 1 (1977):  488-90[17] Epstein MT, Espiner EA, Donald RA, Hughes H \"Liquorice toxicity and the renin-angiotensin-aldosterone axis in man.\" Br Med J 1 (1977):  209-10[18] Cumming AM \"Metabolic effects of licorice.\" Br Med J 1 (1977):  906[19] Bannister B, Ginsburg R, Shneerson J \"Cardiac arrest due to liquorice-induced hypokalaemia.\" Br Med J 2 (1977):  738-9[20] Holmes AM, Young J, Marrott PK, Prentice E \"Pseudohyperaldosteronism induced by habitual ingestion of liquorice.\" Postgrad Med J 46 (1970):  625-9", "alternatives_a": "Sacubitril", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248944, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Linezolid", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications.  MAOIs alone quite commonly produce orthostatic hypotension.  This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission.  The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.  Close monitoring for development of hypotension is recommended.  Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294228/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[5] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[8] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[9] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[10] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[11] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[12] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[13] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Lefamulin, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248945, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Lisinopril", "severity": "Major", "effect": "Coadministration of an ACE inhibitor in combination with an angiotensin II receptor antagonist may increase the risk of hyperkalemia, hypotension, syncope, and renal dysfunction due to additive or synergistic effects on the renin-angiotensin system.", "source": "DDInter", "management_text": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.  Most patients receiving the combination do not obtain any additional benefit compared to monotherapy.  However, if the combination is considered medically necessary, serum electrolytes, blood pressure, and renal function should be closely monitored.  Routine monitoring of electrolytes and renal function may be indicated in the elderly or patients with worsening heart failure or a risk for dehydration.  Potassium supplementation should generally be avoided unless it is closely monitored, and patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as weakness, listlessness, confusion, tingling of the extremities, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294229/", "reference_text": "[1] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Micardis (telmisartan).\" Boehringer-Ingelheim  (2001):[4] Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D \"Dual renin-angiotensin system blockade at optimal doses for proteinuria.\" Kidney Int 62 (2002):  1020-5[5] Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH \"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.\" Kidney Int 63 (2003):  1874-80[6] Rossing K, Jacobsen P, Pietraszek L, Parving HH \"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.\" Diabetes Care 26 (2003):  2268-74[7] Jacobsen P, Andersen S, Jensen BR, Parving HH \"Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.\" J Am Soc Nephrol 14 (2003):  992-9[8] McMurray JJ, Ostergren J, Swedberg K, et al. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.\" Lancet 362 (2003):  767-71[9] Pfeffer MA, McMurray JJ, Velazquez EJ, et al. \"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.\" N Engl J Med 349 (2003):  1893-1906[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] ONTARGET Investigators, Yusuf S, Teo KK, et al. \"Telmisartan, ramipril, or both in patients at high risk for vascular events.\" N Engl J Med 358 (2008):  1547-59[12] Mann JF, Schmieder RE, McQueen M, et al. \"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.\" Lancet 372 (2008):  547-53[13] Guthrie RM \"Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary.\" Postgrad Med 121 (2009):  202-4[14] National Kidney Foundation \"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update.\" Am J Kidney Dis 60 (2012):  850-86[15] EMA. European Medicines Agency \"PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system: recommendation will now be considered by CHMP for final opinion.  http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Renin-angiotensin_sys\"   (2014):[16] MHRA. Medicines and Healthcare Regulatory Agency \"Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function--new warnings.  http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON426905\"   (2014):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Valsartan, Simvastatin, Atorvastatin, Lovastatin, More", "alternatives_b": "Nebivolol", "updated_at": 1767369485}, {"id": 248946, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Lithium carbonate", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor antagonists may increase the serum concentrations of lithium.  The exact mechanism of interaction is unknown, but thought to be related to the natriuresis induced by angiotensin II receptor antagonists secondary to the inhibition of aldosterone secretion.", "source": "DDInter", "management_text": "Given the narrow therapeutic index of lithium, caution is advised during coadministration with angiotensin II receptor antagonists, particularly in the elderly or patients with other risk factors (e.g., sodium restriction, renal impairment, congestive heart failure, dehydration, concomitant use of diuretics or NSAIDs).  Pharmacologic response and serum lithium levels should be monitored more closely whenever an angiotensin II receptor antagonist is added to or withdrawn from therapy, and the lithium dosage adjusted as necessary.  Empiric reductions of both drugs may be appropriate during initial therapy.  Renal function should also be monitored regularly.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of lithium toxicity such as drowsiness, dizziness, confusion, muscle weakness, vomiting, diarrhea, polydipsia, polyuria, tinnitus, tremor, ataxia, and blurred vision.", "mechanism_text": "Others", "recommendation": "Given the narrow therapeutic index of lithium, caution is advised during coadministration with angiotensin II receptor antagonists, particularly in the elderly or patients with other risk factors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294230/", "reference_text": "[1] \"Product Information. Eskalith (lithium).\" SmithKline Beecham  (2002):[2] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[3] Blanche P, Raynaud E, Kerob D, Galezowski N \"Lithium intoxication in an elderly patient after combined treatment with losartan.\" Eur J Clin Pharmacol 52 (1997):  501[4] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[5] \"Product Information. Micardis (telmisartan).\" Boehringer-Ingelheim  (2001):[6] Leung M, Remick RA \"Potential drug interaction between lithium and valsartan.\" J Clin Psychopharmacol 20 (2000):  392-3[7] \"Product Information. Benicar (olmesartan).\" Sankyo Pharma  (2002):[8] \"Product Information. Benicar HCT (hydrochlorothiazide-olmesartan).\" Sankyo Pharma  (2003):[9] Spinewine A, Schoevaerdts D, Mwenge GB, Swine C, Dive A \"Drug-induced lithium intoxication: a case report.\" J Am Geriatr Soc 53 (2005):  360-1[10] Su YP, Chang CJ, Hwang TJ \"Lithium intoxication after valsartan treatment.\" Psychiatry Clin Neurosci 61 (2007):  204", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248947, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "The hypotensive effects of lofexidine and antihypertensive agents may be additive.  Postural hypotension may occur.", "source": "DDInter", "management_text": "Hemodynamic responses should be monitored during coadministration of lofexidine with antihypertensive agents, especially during the first few weeks of therapy.", "mechanism_text": "Synergism", "recommendation": "Hemodynamic responses should be monitored during coadministration of lofexidine with antihypertensive agents, especially during the first few weeks of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294231/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Lucemyra (lofexidine).\" US WorldMeds LLC  (2018):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248948, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Lorazepam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294232/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248949, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Loxapine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294233/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248950, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294234/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248951, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294235/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248952, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294236/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248953, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Maraviroc", "severity": "Moderate", "effect": "Maraviroc may potentiate the hypotensive effect of some medications.", "source": "DDInter", "management_text": "Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure.  Close monitoring for development of hypotension is recommended.  Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294237/", "reference_text": "[1] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group  (2007):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248954, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294238/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248955, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294239/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248956, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294240/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248957, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294241/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248958, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294242/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Irbesartan, Candesartan, Eprosartan, Olmesartan, Irbesartan, Hydrochlorothiazide, Olmesartan, Candesartan, Eprosartan, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248959, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294243/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248960, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Metaxalone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294244/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Irbesartan, Losartan, Olmesartan, Candesartan, Eprosartan, Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Candesartan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248961, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Methadone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294245/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248962, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294246/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248963, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Methocarbamol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294247/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248964, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294248/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248965, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Methylphenidate", "severity": "Moderate", "effect": "Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.", "source": "DDInter", "management_text": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.", "mechanism_text": "Antagonism", "recommendation": "Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294249/", "reference_text": "[1] \"Product Information. Ritalin (methylphenidate).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Metadate CD (methylphenidate).\" Celltech Pharmaceuticals Inc  (2022):[3] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[4] \"Product Information. Metadate ER (methylphenidate).\" Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Ritalin LA (methylphenidate).\" Quality Care Products/Lake Erie Medical  (2013):[8] \"Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate).\" Corium, Inc.  (2021):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248966, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Methylprednisolone", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention.  These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity.  Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure.  The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294250/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248967, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294251/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248968, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294252/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248969, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Moexipril", "severity": "Major", "effect": "Coadministration of an ACE inhibitor in combination with an angiotensin II receptor antagonist may increase the risk of hyperkalemia, hypotension, syncope, and renal dysfunction due to additive or synergistic effects on the renin-angiotensin system.", "source": "DDInter", "management_text": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.  Most patients receiving the combination do not obtain any additional benefit compared to monotherapy.  However, if the combination is considered medically necessary, serum electrolytes, blood pressure, and renal function should be closely monitored.  Routine monitoring of electrolytes and renal function may be indicated in the elderly or patients with worsening heart failure or a risk for dehydration.  Potassium supplementation should generally be avoided unless it is closely monitored, and patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as weakness, listlessness, confusion, tingling of the extremities, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294253/", "reference_text": "[1] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Micardis (telmisartan).\" Boehringer-Ingelheim  (2001):[4] Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D \"Dual renin-angiotensin system blockade at optimal doses for proteinuria.\" Kidney Int 62 (2002):  1020-5[5] Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH \"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.\" Kidney Int 63 (2003):  1874-80[6] Rossing K, Jacobsen P, Pietraszek L, Parving HH \"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.\" Diabetes Care 26 (2003):  2268-74[7] Jacobsen P, Andersen S, Jensen BR, Parving HH \"Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.\" J Am Soc Nephrol 14 (2003):  992-9[8] McMurray JJ, Ostergren J, Swedberg K, et al. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.\" Lancet 362 (2003):  767-71[9] Pfeffer MA, McMurray JJ, Velazquez EJ, et al. \"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.\" N Engl J Med 349 (2003):  1893-1906[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] ONTARGET Investigators, Yusuf S, Teo KK, et al. \"Telmisartan, ramipril, or both in patients at high risk for vascular events.\" N Engl J Med 358 (2008):  1547-59[12] Mann JF, Schmieder RE, McQueen M, et al. \"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.\" Lancet 372 (2008):  547-53[13] Guthrie RM \"Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary.\" Postgrad Med 121 (2009):  202-4[14] National Kidney Foundation \"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update.\" Am J Kidney Dis 60 (2012):  850-86[15] EMA. European Medicines Agency \"PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system: recommendation will now be considered by CHMP for final opinion.  http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Renin-angiotensin_sys\"   (2014):[16] MHRA. Medicines and Healthcare Regulatory Agency \"Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function--new warnings.  http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON426905\"   (2014):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "Nebivolol", "updated_at": 1767369485}, {"id": 248970, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Molindone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294254/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248971, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294255/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Amlodipine, Sacubitril, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248972, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Morphine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294256/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248973, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Nabilone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294257/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Granisetron, Scopolamine, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248974, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Nabumetone", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294258/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248975, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294259/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248976, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "Nefazodone may potentiate the hypotensive effect of many drugs including vasodilators and antihypertensive agents.", "source": "DDInter", "management_text": "Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators.  Patients should be made aware of the possible side effects (e.g., dizziness, lightheadedness, orthostasis) and be cautioned about driving, operating machinery, or performing other hazardous tasks.  They should also be advised to avoid rising abruptly from a sitting or recumbent position and to contact their physician if they experience symptoms of hypotension such as dizziness, lightheadedness, or fainting.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294260/", "reference_text": "[1] \"Product Information. Serzone (nefazodone).\" Bristol-Myers Squibb  (2001):", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248977, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294261/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248978, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294262/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248979, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294263/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248980, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Opium", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294264/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248981, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Oxaprozin", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294265/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248982, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Oxazepam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294266/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248983, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294267/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Irbesartan, Losartan, Olmesartan, Candesartan, Eprosartan, Amlodipine, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Candesartan, More", "updated_at": 1767369485}, {"id": 248984, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Ozanimod", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications.  MAOIs alone quite commonly produce orthostatic hypotension.  This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission.  The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.  Close monitoring for development of hypotension is recommended.  Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294268/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[5] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[8] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[9] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[10] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[11] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[12] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[13] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248985, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294269/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248986, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294270/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248987, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Pentazocine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294271/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248988, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294272/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Irbesartan, Candesartan, Eprosartan, Olmesartan, Irbesartan, Hydrochlorothiazide, Olmesartan, Candesartan, Eprosartan, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 248989, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Pentoxifylline", "severity": "Moderate", "effect": "Pentoxifylline may potentiate the action of hypotensive agents.", "source": "DDInter", "management_text": "Caution is advised if pentoxifylline is used in combination with hypotensive agents.  Periodic systemic blood pressure monitoring is recommended.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pentoxifylline is used in combination with hypotensive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294273/", "reference_text": "[1] \"Product Information. Trental (pentoxifylline).\" Hoechst Marion Roussel  (2001):", "alternatives_a": "Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Niacin, Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248990, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications.  MAOIs alone quite commonly produce orthostatic hypotension.  This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission.  The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.  Close monitoring for development of hypotension is recommended.  Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294274/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[5] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[8] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[9] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[10] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[11] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[12] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[13] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248991, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294275/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Amlodipine, Sacubitril", "updated_at": 1767369485}, {"id": 248992, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Piroxicam", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294276/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 248993, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294277/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248994, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Potassium acetate", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.  The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks.  Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter.  Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294278/", "reference_text": "[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984):  1409-12[2] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982):  21-5[3] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974):  433-40[4] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[5] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[6] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002):  663-5[7] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003):  812[8] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[9] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995):  551-2[10] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997):  646-56[11] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984):  370-3", "alternatives_a": "Calcium chloride, Zinc sulfate, Magnesium sulfate, Sodium acetate, Arginine, Sodium glycerophosphate, Zinc chloride, Tromethamine, Sodium bicarbonate, Sodium chloride, Ammonium chloride, Magnesium chloride", "alternatives_b": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "updated_at": 1767369485}, {"id": 248995, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Monopotassium phosphate", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.  The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks.  Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter.  Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294279/", "reference_text": "[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984):  1409-12[2] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982):  21-5[3] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974):  433-40[4] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[5] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[6] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002):  663-5[7] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003):  812[8] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[9] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995):  551-2[10] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997):  646-56[11] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984):  370-3", "alternatives_a": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248996, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Potassium bicarbonate", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.  The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks.  Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter.  Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294280/", "reference_text": "[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984):  1409-12[2] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982):  21-5[3] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974):  433-40[4] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[5] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[6] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002):  663-5[7] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003):  812[8] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[9] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995):  551-2[10] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997):  646-56[11] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984):  370-3", "alternatives_a": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248997, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Potassium chloride", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.  The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks.  Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter.  Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294281/", "reference_text": "[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984):  1409-12[2] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982):  21-5[3] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974):  433-40[4] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[5] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[6] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002):  663-5[7] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003):  812[8] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[9] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995):  551-2[10] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997):  646-56[11] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984):  370-3", "alternatives_a": "Calcium chloride, Zinc sulfate, Magnesium sulfate, Sodium acetate, Arginine, Sodium glycerophosphate, Zinc chloride, Tromethamine, Sodium bicarbonate, Sodium chloride, Ammonium chloride, Magnesium chloride", "alternatives_b": "Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 248998, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.  The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks.  Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter.  Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294282/", "reference_text": "[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984):  1409-12[2] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982):  21-5[3] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974):  433-40[4] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[5] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[6] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002):  663-5[7] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003):  812[8] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[9] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995):  551-2[10] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997):  646-56[11] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984):  370-3", "alternatives_a": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 248999, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Potassium gluconate", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.  The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks.  Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter.  Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294283/", "reference_text": "[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984):  1409-12[2] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982):  21-5[3] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974):  433-40[4] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[5] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[6] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002):  663-5[7] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003):  812[8] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[9] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995):  551-2[10] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997):  646-56[11] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984):  370-3", "alternatives_a": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249000, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Potassium Iodide", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.  The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks.  Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter.  Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294284/", "reference_text": "[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984):  1409-12[2] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982):  21-5[3] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974):  433-40[4] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[5] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[6] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002):  663-5[7] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003):  812[8] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[9] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995):  551-2[10] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997):  646-56[11] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984):  370-3", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Acetylcysteine, Nandrolone, Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, More", "alternatives_b": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "updated_at": 1767369485}]